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Cover illustration
“Untitled (Trapped)” by Paul Klee (1879–
1940). Paul Klee, a prominent 20th century 
artist born in Bern (Switzerland), is probably 
the most famous person to suffer, and finally 
die from scleroderma. Scleroderma is one 
of the autoimmune diseases described in 
this thesis, and primarily affects the skin. 
“Untitled (Trapped)” is one of Klee’s last 
paintings, and represents the painter, trapped 
in the prison of his disease (visualized by the 
steel bars), which rendered him physically 
immobile.
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General introduction 9
Our environment is populated with a wide variety of micro-organisms, such as bacteria, viruses, and parasites, which can cause a broad range of diseases. 
Humans have developed a complex mechanism to fight against such pathogenic 
intruders: their immune system. Many different cells are involved in this defence, 
and each of these cells carry out specific jobs. An important step in the removal 
of pathogens is their recognition, a process in which the antibody-producing 
B cells are one of the key players. The theory of specific antibody 
formation was first introduced by Paul Ehrlich in 1900. In 1908, 
he and Ilya Mechnikov received a Nobel Prize in Physiology or 
Medicine for their work on immunity. From Ehrlich’s Nobel Lecture: 
“The relations between toxin and its antitoxin are strictly specific – tetanus 
antitoxin neutralizes exclusively tetanus toxin, diphtheria serum only diphterial 
toxin, snake serum only snake venom, to mention just a few examples out of 
hundreds.” Their specificity makes antibodies very valuable for the characterization 
of proteins. In fact, antibodies do not react with the complete pathogen, but only 
with one or more antigenic determinants (epitopes) present on the pathogen. 
In autoimmune patients, autoantibodies are directed to molecules of the body 
itself. The specificity of autoantibodies can be advantageous for research and 
diagnostics, since many autoantibodies are associated with particular diseases. 
This chapter summarizes the current knowledge on antibody applications, 
with special focus on the antibody phage display technology, and provides an 
introduction to autoimmune diseases and their autoantibodies.
Antibodies in the immune 
system
As depicted in Figure 1a, the basic antibody 
structure is composed of four chains: two 
(identical) light chains and two (identical) 
heavy chains, which are linked by covalent 
binding through disulfide bonds, and by non-
covalent bindings through hydrogen bonds 
and hydrophobic interactions (1). Similar 
interactions link one heavy- and light-chain 
pair with another (identical) pair.
A major characteristic of immunoglobulins 
is their diversity. Remarkably, it has been 
estimated that lymphocytes are capable of 
producing 1015 different antibodies, whereas 
the diversity of the human immune repertoire 
originates from around 400 genes (2). In 
humans, diversity is generated through 
somatic recombination of variable (V), 
diversity (D) and joining (J) gene segments in 
the variable region of the heavy chain, and of 
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Monoclonal hybridoma technology
In 1975, Köhler and Milstein published the 
principles for the production of monoclonal 
antibodies, which is based on the fusion of 
a mouse myeloma cell line with spleen cells 
from an immunized mouse (12). For this 
discovery they received the Nobel prize in 
medicine in 1984. Remarkably, the hybridoma 
technology was never patented, and although 
the technique is laborious (5), monoclonal 
antibodies against numerous antigens have 
been generated with this technique (13). In 
addition to their use as important research 
tools, monoclonal antibodies have been 
successfully applied in therapy (14-16). At the 
end of 2005, eighteen monoclonal hybridoma 
antibodies have been approved for therapeutic 
applications, and several others are being 
tested in phase 2 and 3 clinical studies (17,18). 
Two strategies have been used to reduce or 
prevent a human immune response to murine 
antibodies. One approach is the production of 
complete human monoclonal antibodies by 
immortalization of human B cell clones (19), 
but the establishment of this technique, and 
the production of sufficient amounts of human 
antibody from these cell lines appeared to 
be difficult (19,20). The other approach is to 
prepare chimeric antibodies by replacing the 
murine Fc region by a human sequence (21), or 
to ‘humanize’ murine antibodies by replacing 
the CDRs of a human antibody with the 
corresponding CDRs of the murine antibody 
of interest (22). Fifteen of the eighteen 
therapeutic monoclonal antibodies currently 
on the market are chimeric or humanized 
antibodies (18).
Antibody phage display technology
An alternative method to generate monoclo-
nal antibodies is offered by the antibody phage 
display technology. Bacteriophages, in this 
chapter referred to as phages, are viruses that 
infect and propagate in bacteria (23). Phage 
display was first described by George Smith in 
1985 (24), and is based on two crucial concepts 
(25). The first is that the gene encoding 
the peptide or protein that is displayed on 
the phage surface is contained within the 
phage particle, and that this linkage between 
genotype and phenotype is maintained when 
the phages replicate. The second is that large 
cDNA libraries can be cloned into the phages. 
Compared to the hybridoma technology, anti-
body phage display is easier, cheaper and 
less time-consuming (26). Due to the use of 
large naïve libraries, immunization can be 
by-passed (27). Other advantages of such large 
naïve libraries is that one library can be used 
for all antigens, and that antibodies can be 
isolated against antigens that are toxic or non-
immunogenic in laboratory animals (28).
Many variables have to be considered when 
preparing phage display libraries, including 
the display system (phage versus phagemid; 
in the phage system the encoding gene is 
inserted into the phage genome, whereas in 
the phagemid system the encoding gene is 
present on a plasmid), the coat protein that 
is used for fusion (in general either major 
coat protein VIII or minor coat protein 
III), and the (poly)peptide that is displayed 
(in case of antibody fragments scFv versus 
Fab; see Figure 1). The libraries used in the 
experiments described in this thesis are based 
on single chain variable fragment (scFv) 
Figure 1. Schematic structure of an antibody (fragment). (a) Structure of a complete immunoglobulin, which is 
composed of two heavy chain and two light chains. (b) Structure of a recombinant Fab fragment, which is composed of 
the constant domain 1 (CH1) of the heavy chain, the constant domain of the light chain (CL), and the variable domains 
of the heavy and light chains. (c) Structure of an scFv, which is composed of the variable domains of the heavy and light 
chains, also linked by a flexible linker.
V and J segments in the variable region of the 
light chain, through pairing of heavy and light 
chains and through somatic mutations (3). 
The variable regions are involved in antigen 
binding, and are composed of four framework 
regions and three hyper-variable regions, 
which are called complementarity determining 
regions (CDRs) (4). The constant regions are 
involved in secondary effector functions, such 
as complement activation and binding to 
specific cell types (1).
Antibodies in the laboratory
Biological mechanisms, in health and 
disease, will be better understood when we 
know the function of the participating proteins 
(5,6). In such studies, antibodies are important 
tools, because they can be extremely helpful in 
functional studies, protein-protein interaction 
studies and localization studies (7).
Polyclonal and monoclonal antibodies
In general, polyclonal antibodies are 
produced by immunization with proteins, 
conjugated peptides (8), or DNA expression 
vectors (9), and specific antibodies can be 
isolated from the (anti)serum by affinity 
purification (10). The fact that a polyclonal 
antiserum recognizes multiple epitopes on one 
target is advantageous, because such a serum 
can be used in a wide variety of experiments 
(11). However, a drawback of a polyclonal 
serum is that blood withdrawal, even from 
the same animal, is unique and therefore not 
completely reproducible (11). Monoclonal 
antibodies (mAbs) are produced by a single 
B cell clone derived from animals immunized 
by similar procedures, and as a consequence 
they are directed to only one epitope (1). 
The two most common methods to generate 
monoclonal antibodies are by the hybridoma 
technology and by antibody phage display.
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Figure 3. Selection procedure 
of specific phages. 
(1) The antibody phage display 
library is amplified in a suitable 
host, such as E.coli TG1. (2) The 
phage library is incubated with 
the antigen, immobilized on 
supporting material. (3) Unbound 
phages are washed off. (4) Bound 
phages are eluted, for example 
by a pH shock. (5) A suitable 
bacterial host, such as E.coli TG1 
is infected with the eluted phages, 
and plated on agar plates with 
antibiotic selection pressure. (6) 
Bacteria are scraped from the 
agar plates, stored, and phages 
are amplified to start another 
selection round.
end up with antibodies to unknown cell- or 
tissue-specific targets, which can subsequently 
be purified using the antibody as bait, and 
identified by mass spectrometry. A major 
advantage of this procedure is that when 
biomarkers are discovered, at the same time 
antibodies to these molecules are available.
Monoclonal antibodies to biomarkers 
obtained by these recombinant DNA 
technologies (recombinant antibodies) have 
been engineered for (tumour) imaging, 
chemotherapy, immunotherapy, and radio-
immunotherapy. At this moment, one 
recombinant phage display-derived antibody, 
Adalimumab (trade name Humira), is appro-
ved for therapy of psoriatic arthritis and 
rheumatoid arthritis, and many more are in 
clinical and pre-clinical trials (31).
Figure 5 provides a schematic overview 
of the most common methods for the 
identification of biomarkers using antibody 
phage display. The most straightforward 
method to discover novel (tumor) cell surface 
markers is direct selection of antibody phage 
libraries on intact cells (Figure 5a) (37-43). In 
1995, de Kruif et al. were the first to use mouse 
antibodies to known cell surface markers to 
isolate phages directed to unknown markers 
on the same cell (44). They incubated a large 
synthetic antibody library with a peripheral 
blood leukocyte preparation, in which CD3+ 
and CD20+ cells were fluorescently labelled 
with specific antibodies, and sorted the labelled 
cells by fluorescence activated cell sorting 
(FACS). The isolated phages bound to the 
CD3+ and CD20+ cells, and to a limited set of 
other cells. This approach has been effectively 
applied in a number of studies (45-50). Cell 
surface markers have also been identified 
by in vivo or ex vivo selections (Figure 5e). 
For example, scFvs binding to thymic cells 
have been successfully identified by isolating 
phages from the thymuses of mice that were 
injected intravenously with an antibody phage 
antibodies fused to minor coat protein III in 
a phagemid system. For extensive information 
on antibody phage display the reader is 
referred to a selected number of excellent 
reviews (23,26,29-31).
An scFv antibody fragment (see Figure 
1c) consists of the two variable domains of 
an immunoglobulin molecule, namely the 
variable domain of the heavy chain (VH) 
and the variable domain of the light chain 
(VL), connected by a linker sequence (32), 
that enables proper folding of the antibody 
fragment. A schematic overview of the 
preparation of a library is presented in 
Figure 2. 
Libraries can be prepared from immunized 
individuals (immune libraries) (33) and from 
naïve IgM antibody repertoires (naïve libraries) 
(28). Lymphocytes from blood, bone marrow, 
spleen, lymph nodes or tonsil can be used as 
source material to prepare immunoglobulin 
(fragment) cDNAs (25). Several synthetic 
libraries are available as well (34). In case of 
synthetic libraries, the antibodies are built 
artificially by in vitro assembly of synthesized 
V- and D-/J- gene segments. A higher diversity 
is obtained by introducing a pre-determined 
level of randomization of the CDRs. Figure 3 
illustrates a general procedure for the selection of 
antibodies from phage display libraries. After 
one or more selection rounds, monoclonal 
phages are analyzed for reactivity with the 
target antigen. Often, robotic equipment is 
used in the laborious parts of the selection 
procedure (35,36).
Target discovery by antibody phage display
Proteins or peptides that are only expressed 
on specific cells or tissues, or under certain 
(pathological) conditions, are potential targets 
for therapeutics and diagnostics. During the 
last decade, many antibody phage display 
approaches have been developed for the 
identification of such biomarkers, and most 
of these include a subtraction or competition 
step to remove phages that bind to ‘common’ 
or non-specific epitopes (31). As schematically 
shown in Figure 4, such selection strategies 
Figure 2. Preparation of an antibody phage display library. (1) mRNA is isolated from lymphocytes, and cDNA 
is synthesized by RT-PCR. (2) The V
H
 and V
L
 domains are individually amplified by PCR, and fused by an overlap PCR. 
(3) The V
H
-V
L
 PCR products are ligated into phagemid vectors as fusion products with gene III, encoding minor capsid 
protein III. The ligation products are transferred to a suitable host, such as E.coli TG1. The library is amplified by means 
of a helper phage, resulting in phage particles displaying antibody fragments on their surfaces. Note that the gene 
encoding the scFv to be displayed is contained within the phage particle.
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Antibodies in autoimmune 
diseases: autoantibodies
Autoimmune diseases, affecting approxi-
mately 2-3% of the population of the 
industrialized world (63), can be divided into 
systemic and organ-specific autoimmune 
diseases. The autoimmune diseases studied 
in this thesis are systemic autoimmune 
diseases, and include systemic sclerosis 
(SSc), systemic lupus erythematosus (SLE), 
rheumatoid arthritis (RA), polymyositis/
dermatomyositis (PM/DM), and SLE overlap 
disease (also referred to as mixed connective 
tissue disease, MCTD). An overview of the 
characteristics of these diseases is presented 
Figure 5. Overview of subtractive antibody phage display approaches to discover proteome-specific target 
epitopes, with subtraction or competition to remove binders to common epitopes. (a) Selection on cells. 
Phages are incubated with a cell population, and specific cell types are isolated by labelled antibodies and FACS. The 
phages binding these selected cells can be isolated. (b) Selection on coated cell extracts. Cell extracts with target 
epitopes are immobilized on immunotubes, and phages recognizing common epitopes are subtracted by competition 
with non-immobilized cell extract. (c) Selection on biotinylated cell extracts. Cell extracts, containing target epitopes, 
are biotinylated for capture with magnetic streptavidin-coated beads, whereas non-biotinylated proteins with common 
epitopes can be used for competition. (d) Selection on tissue sections. Antibody phage display libraries are incubated 
with tissue sections and areas containing specific cells or structures are excised by means of laser microdissection. (e) 
In vivo selections. Phage libraries are injected in laboratory animals. Phages can then be isolated from specific organs 
or parts of the body. (f) Selection on blotting membranes. Antibody phage display libraries are incubated with blotting 
membranes, containing proteins from cell extracts, optionally separated by two-dimensional gel electrophoresis.
Figure 4. Strategy for the identification of biomarkers. 
For the identification of proteome-specific targets (i.e. 
present in proteome B, but not present in proteome A), 
antibody phage libraries are first incubated with proteome 
A (subtraction). Phages that do not bind to proteome A 
are incubated with proteome B to select for phages that 
bind to proteome B-specific targets. Optionally, the 
subtractive selection round is repeated. The reactivity of 
monoclonal phages is tested, and target-specific phages 
are identified. Finally, the target can be immunoaffinity 
purified with the antibody fragment, and identified by 
mass spectrometry.
library (51). Theoretically, ex vivo selections 
should be applicable for antibody libraries, 
but so far they have only been described for 
peptide libraries (52).
An elegant method for the identification of 
both extracellular and intracellular antigens 
involves panning of phage libraries on tissue 
cryosections, followed by the isolation of 
specific cells or pieces of tissue by laser 
microdissection (Figure 5d) (53). 
Identification of intracellular markers by 
subtractive antibody phage display is mainly 
based on the use of cellular extracts (Figure 5 b, 
c, and f). Cellular extracts can be immobilized 
in many ways, for example by (i) coating 
on immunotubes or the wells of microtiter 
plates (54-56), by (ii) blotting to membranes 
after electrophoresis (57) or directly by dot 
blotting (58,59), and by (iii) biotinylation in 
combination with streptavidin-coated beads 
(60,61).
Finally, two studies describe the isolation 
of differentially expressed proteins, visualized 
by two-dimensional gel electrophoresis, 
prior to selection. Pini et al. excised specific 
protein spots from two-dimensional gels, and 
subsequently eluted the proteins from the gel 
slices. The proteins were biotinylated and used 
for selection of specific phages (60). Liu et al. 
used a similar approach, in which they excised 
differentially expressed protein spots from 
two-dimensional western blots and used these 
spots for screening of phage display antibody 
libraries (62).
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Autoantibodies are in some cases specifi-
cally associated with a certain autoimmune 
disease. For example, anti-citrullinated 
protein autoantibodies (ACPA) are almost 
exclusively found in patients suffering from 
rheumatoid arthritis (reviewed by (72)), 
and autoantibodies directed to the U1 small 
nuclear ribonucleoprotein (snRNP) complex 
are associated with SLE overlap syndrome 
(reviewed by (73)). Autoantibodies can be 
detected in patient sera with a number of 
laboratory tests, and the results are in most 
cases helpful for rheumatologists to diagnose 
patients and to provide prognoses. Auto-
antibodies to cell death-specific epitopes are 
believed to be present in the beginning of 
disease, and identification of such ‘early’ targets 
might therefore allow an earlier diagnosis and 
treatment of autoimmune diseases.
Outline of the thesis
The goals of this research project were to 
develop novel applications of the antibody 
phage display technique, and to use these 
applications to gain more insight into the 
occurrence of autoantibodies and their 
antigenic targets.
The results described in this thesis can be 
divided into two parts:
Part 1: Novel applications of the antibody 
 phage display technology
Part 2: Autoantigenicity of cell death-asso-
 ciated epitopes
In Part 1, novel antibody phage display 
applications are described. Chapter 2 illustra-
tes an approach to reduce the number of 
animals needed for antibody phage display 
experiments. Libraries were prepared from 
chickens that were simultaneously immunized 
with multiple antigens, the majority of them 
being human autoantigens, and antibodies 
recognizing the individual antigens were 
isolated from these libraries. In Chapter 3 
it is demonstrated that, by fusing constant 
domains from immunoglobulins from different 
organisms (human, mouse and chicken), the 
recombinant antibodies become attractive 
tools for double- and triple-staining of cells and 
tissues. Chapter 4 describes a novel subtractive 
phage display approach, which is applicable for 
the identification of disease-related proteins 
that are specifically present in a certain cell 
type or tissue, or specifically expressed under 
certain conditions. The approach combines 
repeated subtractive selection in solution, 
followed by selection on western blots of two-
dimensional gels. This approach allowed the 
identification of apoptosis-specific epitopes 
that are targets of autoantibodies in systemic 
autoimmune diseases. 
In Part 2, the antigenic targets, identified 
by the subtractive phage display experiments 
in Chapter 4, are further characterized. These 
apoptosis-specific epitopes are present on the 
proteins U1-70K, hnRNP C, and p54nrb/PSF. 
Chapter 5 elaborates on the involvement of 
neo-epitopes in breaking tolerance to self-
antigens. Focus is on the modifications of 
the U1 snRNP complex, a major autoantigen 
in SLE overlap syndrome (also named 
mixed connective tissue disease, MCTD). 
in Table 1. A hallmark of these diseases is 
that patients produce high titres of antibodies 
(autoantibodies) directed to specific “self” 
molecules (autoantigens). 
It is still unclear why autoimmune patients 
produce autoantibodies. The autoimmune 
response is a complex process, of which 
the underlying mechanisms are still poorly 
understood. It is believed that (a combination 
of) genetic, hormonal, and environmental 
factors are involved. A model that is increasingly 
supported by experimental data, hypothesizes 
that unusual posttranslational modifications 
play an important role in breaking tolerance 
to self-antigens (see reviews by (64-67)). It 
has been shown that dying cells represent 
an important source of such unusual protein 
modifications. During apoptosis and necrosis 
many known autoantigens are modified, as 
for example by proteolytic cleavage, hyper- or 
dephosphorylation, or citrullination (65-68). 
Furthermore, oxidative fragmentation of 
proteins has been put forward as a mechanism 
of autoantigen modification (69,70). It is 
believed that modified autoantigens contain 
neo-epitopes that, upon exposure to the 
immune system, trigger a primary immune 
response. Subsequent responses may lead to 
the generation of autoreactivity to other, not 
modified parts of the antigen via a process 
called epitope spreading. In this process, the 
secondary immune responses may spread 
intramolecularly, but also intermolecularly to 
other proteins that are stably associated with 
the primary target (71). Data supporting this 
idea mainly result from experiments on the 
U1-70K protein, a major autoantigen in SLE 
overlap disease, and will be discussed in detail 
in Chapter 5.A
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Antibody phage display is a powerful tool for the generation of monoclonal  antibodies against virtually any given antigen. Chickens are phylogenetically 
more distant from humans compared to other laboratory animals like mice and 
rats. Therefore, the use of chickens is especially beneficial when generating 
recombinant antibodies against human autoantigens, which are often highly 
conserved among mammals. Another advantage of using chickens in antibody 
phage display is that the preparation of scFv antibody libraries is faster and easier 
compared to preparing such libraries from other species, since only limited 
primer sets are needed for amplification of the chicken V
H
 and V
L
 genes. In the 
present study we explored the possibility to immunize chickens with antigen 
cocktails for the generation of recombinant antibody fragments directed to a 
range of human autoantigens. After immunization of chickens with two cocktails 
of 7 recombinant, bacterially expressed autoantigenic proteins, the polyclonal 
chicken sera reacted strongly with most of the antigens used for immunisation. 
By creating and screening single-chain variably fragment antibody phage display 
libraries, recombinant monoclonal antibody fragments were successfully isolated 
against the autoantigens annexin XI, CENP-B, HspB3, DNA topoisomerase I, 
Jo-1, Ro52, Ro60, Rpp30, and U1A. In conclusion, the immunization of only four 
chickens with two distinct pools of in total 14 autoantigenic proteins allowed the 
isolation of scFvs against 9 of these antigens.
Introduction
Autoimmune diseases are characterized 
by the presence of serum antibodies 
(autoantibodies) directed to ‘self’-
antigens (autoantigens). Characterization 
of autoantibodies and their targets will 
provide more insight into the underlying 
mechanisms of autoimmune diseases. 
However, characterization of autoantigens in 
for example tissue sections of patient biopsies 
or on western blots containing human patient 
material (such as serum) is not possible with 
patient autoantibodies, due to cross-reaction 
of the secondary antibodies with human 
immunoglobulins present in the tissue or 
serum. This problem can be circumvented by 
using antibodies from other species.
Antibody phage display has brought a 
revolution in the preparation of monoclonal 
antibodies, since it is easier, faster and less 
expensive compared to conventional hybrido-
ma technology. The phage display technique 
is based on the display of (poly)peptides, 
such as antibody fragments, on the surface of 
bacteriophages (1). Recombinant antibodies 
have been selected from immune libraries, 
naïve libraries (2) and (semi-)synthetic 
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Figure 1. Schematic overview of the selection strategy. Libraries are prepared from chickens 1 and 2, which are 
immunized with antigen mixture 1(annexin XI, CENP-B, Topo, Jo-1, Ro60, Rpp38, and U1A), and from chickens 3 and 
4, which are immunized with mixture 2 (α-fodrin, hPop1, HspB3, Ro52, Rpp30, Rrp4, and Rrp42). After immunizations, 
cDNA is prepared from isolated mRNA, and pooled, and the V
H
 and V
L
 genes are individually amplified by PCR. 
Subsequently, V
H
 and V
L
 PCR products are linked with a short linker or with a long linker, and are inserted into the 
pComb3 vector. Libraries A (mixture 1, long linker) and B (mixture 1, short linker) are pooled, and libraries C (mixture 
2, long linker) and D (mixture 2, short linker) are pooled. Finally, the pooled libraries are panned on the individual 
antigens.
libraries (3). One of the advantages of immune 
libraries is that clonal selection and affinity 
maturation in the individual generally lead to 
scFvs with higher affinities compared to scFvs 
isolated from naïve or synthetic libraries (4).
Recombinant antibodies to human auto-
antigens have been successfully isolated 
from patient-derived libraries (5-7). The 
disadvantages of using patient libraries are 
that the preparation of human libraries is 
relatively time-consuming, and furthermore 
that autoimmune patients generally 
produce autoantibodies to a small subset of 
autoantigens. This means that libraries from 
several patients have to be prepared to isolate 
antibody fragments to a range of autoantigens. 
Recombinant antibody fragments can also 
be isolated from animals immunized with 
human targets. Often mice are used for the 
preparation of immune libraries, but other 
animals have been used successfully as well, 
especially due to unique features of their 
immune systems. For example, the camelids 
produce next to complete immunoglobulins, 
homodimers of only heavy chains, which are 
devoid of light chains (8). These single domain 
llama VHH have appeared to be highly soluble 
and very stable when expressed in bacteria 
(9). Another example is the chicken immune 
system, which is particularly beneficial when 
constructing libraries. Where mammals 
diversify their immune response through 
somatic V(D)J recombination, chickens use 
only one recombination event, in combination 
with a process called ‘gene conversion’ (10). In 
this process, pseudogenes, which are located 
upstream, are translocated into the heavy and 
light chain variable regions. Consequently, 
only two primer sets (one for the amplification 
of the VH gene and one for the amplification of 
the VL gene) are needed to construct chicken 
libraries (11). As a result, construction of 
chicken antibody libraries is much easier 
and faster compared to human and murine 
libraries. The advantage of using chickens is 
furthermore attributed by the fact that non-
mammal species are more likely to evoke an 
immune response to epitopes that are highly 
conserved between mammals (12).
Here, we studied the immunization of 
chickens with two mixtures of seven distinct 
human autoantigens each, the preparation 
of scFv phage display libraries using material 
from these immunized animals, and the 
isolation of recombinant antibodies to these 
autoantigens. As a result of the selection 
procedures presented here, monoclonal scFvs 
to most of the antigens were obtained, which 
are available to be used for characterization of 
autoantigens in patient samples.
Results
Immunization and generation of libraries
A schematic overview of the library prepa-
ration and selection strategy is depicted in 
Figure 1. Four chickens were immunized with 
two distinct protein cocktails, which were 
composed of proteins that are autoantigenic 
in human (except HspB3), and which are 
in general highly conserved molecules with 
key functions in the cell. An overview of the 
characteristics of the antigens used is presented 
in Table 1. Prior to immunization, recombinant 
proteins were expressed in E.coli, and protein 
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cocktails were prepared by mixing equal 
amounts of each purified protein. Pre-immune 
and immune sera were tested in ELISA for 
reactivity with the individual antigens and 
BSA as a negative control antigen. Since 
Rpp38 and hPop1 were applied as GST fusion 
proteins, reactivity to GST was measured as 
well. Figure 2 demonstrates the reactivities of 
the pre-immune sera, and of the sera obtained 
after the final immunization. None of the pre-
immune sera showed significant reactivity 
Figure 2. Chicken serum ELISA. Chicken sera before immunization (pre-immune) and after the final immunization 
(immune) were analyzed for reactivity with the individual antigens in ELISA. Antigens were coated, incubated with the 
chicken sera at a 500-fold dilution, and bound antibodies were detected with HRP-labelled goat anti-chicken antibodies. 
After TMB conversion the absorbance was measured at 450 nm. Chicken sera were tested for reactivity with the 
antigens they were immunized with, and for reactivity with BSA as control antigen. Reactivity with GST was measured as 
well, since hPop1 and Rrp38 were GST fusion proteins. (a) Pre-immune and immune sera of chickens 1 and 2 were tested 
for reactivity with annexin XI, CENP-B, Topo, Jo-1, Ro60, Rpp38, U1A, GST and BSA. (b) Pre-immune and immune sera 
of chickens 3 and 4 were tested for binding to α-fodrin, hPop1, HspB3, Ro52, Rpp30, hRrp4, hRrp42, GST and BSA.
with any of the antigens. Immune sera from 
chickens 1 and 2 showed strong reactivity with 
annexin XI, CENP-B, Topo, Jo-1, Ro60, U1A, 
and GST, but no or hardly any reactivity with 
Rpp38. Immune sera from chickens 3 and 4 
reacted strongly with hPop1, Ro52, Rpp30, 
and GST, and did not or only very weakly react 
with α-fodrin, HspB3, Rrp4, and Rrp42.
After immunization, antibody phage 
display libraries were constructed with a short 
linker of seven amino acids (GQSSRSS), and 
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The V
H
 and V
L
 chains of underlined clones were sequenced. Anti-CENP-B clone 5D4 and anti-Ro60 clone 5H10 contained a 
long linker, all other clones contained short linkers.
* Anti-annexin XI clones A5A3 and A5E12 differ one amino acid in CDR2 of V
H
 chain (V
L
 chains are identical)
** Anti-Rpp30 clones 5C9 and 6E12 differ one amino acid in CDR2 of V
H
 chain (V
L
 chains are identical)
*** Anti-Jo-1 clones 5B6, 5B9, and 5B10 have different V
L
 chains. The V
H
 chains of 5B6 and 5B9 are identical, the V
H
 chain of 
      5B10 differs three amino acids in CDR3 compared to 5B6 and 5B9.
**** Anti-U1A clones U11B1 and U13D12 have identical V
H
 chains, and different V
L
 chains.
Antigen  Antigen-specific phages   Cross-reactive phages 
Annexin XI     A5A3*, A5E2, A5E12*, A5F6, A5G9    -
CENP-B      5D1, 5D2, 5D4      -
HspB3      6E5, 7B4, 7B9, 7B11    7C5 (cross-reactive with Ro60)
Topo      5A12, 5C2, 5C3, 5C6, 5C8, 5C9, 5D6    -
Jo-1      5B4, 5B5***, 5B6***, 5B8, 5B9, 5B10***, 5B11   -
Ro52      R3E4, R3G10, R2A11, R2E5, R2E6, R2F11  R2G8 (cross-reactive with Topo)
Ro60       -     5E2, 5H10 (both cross-reactive with U1A)
Rpp30      5C9**, 5D11, 6E12**     -
U1A      U11A8, U11B1****, U11B3, U11B5, U11B6, U11B10,  U11A3 (cross-reactive with annexin XI) 
      U11D4, U11D11, U13B4, U13B7, U13D4, U13D12****
Table 2 Overview of isolated phages with antigen-binding activity
Screening of phages
After the analysis of polyclonal phages 
in ELISA, individual colonies were isolated 
to analyze their specificity in a monoclonal 
phage ELISA. Colonies were picked from 
the first, or first two selection rounds with 
high polyclonal phage ELISA reactivity. For 
each antigen, 96 to 144 monoclonal phages 
were first screened for full-length scFv cDNA 
insert by PCR. Subsequently, DNA fingerprint 
patterns were analyzed using the restriction 
enzyme BstNI, and phages were grouped 
based on fingerprint pattern similarities. From 
each fingerprint group, several phages were 
tested in ELISA for binding to their target 
antigens, and for potential cross-reactivity 
with the other proteins used for immunization. 
As summarized in Table 2, for most of the 
antigens (annexin XI, CENP-B, HspB3, 
Topo, Jo-1, Ro52, Rpp30, and U1A) several 
monoclonal phages were reactive in ELISA. 
Phages directed to HspB3 reacted weakly, but 
exclusively with their target antigen. Some 
phages cross-reacted very specifically with one 
of the other antigens. For example, anti-U1A 
phage U11A3 cross-reacted only with annexin 
XI in ELISA. Furthermore, two phages that 
were derived from selection on Ro60, reacted 
strongly with both Ro60 and U1A in ELISA, 
but no phages were detected that reacted 
with Ro60 exclusively. None of the selected 
monoclonal phages reacted detectably with 
α-fodrin, hPop1, Rpp38, Rrp4 and Rrp42 in 
ELISA.
with a long linker of eighteen amino acids 
(GQSSRSSGGGGSSGGGGS), similar to the 
linkers described by Andris-Widhopf et al. 
(13). Subsequently, the libraries with short and 
long linkers from chickens immunized with the 
same antigen cocktail were pooled, and panned 
on the individual antigens. The complexities of 
the combined libraries were 2.1x108 for the 
library corresponding to antigen mixture 1, 
and 1.1x108 for the library corresponding to 
antigen mixture 2. Several selections were 
performed, with the main difference being 
the amount of antigen coated to the well and 
the number of selection rounds, as described 
in the Materials and Methods section. After 
selection, polyclonal phages of each selection 
round were tested in ELISA for reactivity with 
the antigen the pool was selected on. Figure 3 
demonstrates ELISA results for the phages 
of the different selection rounds, in which 
the libraries were panned on annexin XI, 
α-fodrin, hPop1, Ro52, Rpp38, Rrp4, Rrp42, 
and U1A (polyclonal phage ELISA results 
of the other selections are not shown). The 
polyclonal phages were assayed for reactivity 
with the antigen the phages were selected 
on, and for “background” reactivity with the 
unrelated protein BSA. The polyclonal phage 
pools were detectably enriched for phages 
directed to annexin XI, Ro52, and U1A from 
the third rounds onwards. After the first four 
selection rounds, the polyclonal phage pool 
panned on hPop1 did not show reactivity with 
hPop1. After the fifth selection round a strong 
reactivity to hPop1 was observed, although this 
reactivity decreased in subsequent selection 
rounds.
Figure 3. Polyclonal phage 
ELISA. Libraries were selected 
on annexin XI, α-fodrin, hPop1, 
Ro52, Rpp38, Rrp4, Rrp42, and 
U1A, and subsequently analyzed 
for reactivity with these antigens 
in ELISA. Seven selection 
rounds were carried out and 
the reactivities of polyclonal 
phages after each selection 
round are measured. Numbers 
corresponding to the selection 
rounds are on the right. Bound 
phages were detected with 
mouse anti-M13 antibodies, in 
combination with HRP-labelled 
rabbit anti-mouse antibodies, 
followed by TMB conversion. 
The absorbance was measured 
at 450 nm.
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Discussion
Chickens are, next to mice and rabbits, 
an excellent source for the generation of 
antibodies. Chickens are phylogenetically 
more distant from humans, and as a conse-
quence, conserved mammalian proteins are 
often more immunogenic in avian species 
than in mammals (12). Polyclonal antibodies 
(IgG-like antibodies termed IgY) are easily 
isolated from chicken egg yolk (14), and the 
generation of monoclonal chicken antibodies 
by the hybridoma technology has been 
described (15), although these techniques are 
not routinely used (14). In a number of studies, 
recombinant monoclonal antibodies have been 
successfully isolated from chicken libraries 
(11,13,16). The demonstration by Tsurushita et 
al. (17) that chicken antibodies can be readily 
humanized recently boosted the potential 
use of recombinant chicken antibodies for 
therapeutic applications. 
Recently, Finlay et al. isolated recombinant 
antibodies directed to two individual proteins, 
and yellow jacket venom, from a library that 
was prepared from a chicken immunized 
with a mixture of these proteins (18). Our 
study extends these observations and shows 
that chickens can be successfully immunized 
with a mixture of at least 7 distinct proteins. 
It also emphasizes the ease of using chickens 
for the generation of recombinant antibodies 
to highly conserved, human targets (such 
as autoantigens), and suggests a general 
applicability for antibody generation with a 
range of antigens. Immunization of animals 
with multiple antigens has been described 
previously for rabbits as well (19), and in this 
case scFvs against four haptens were isolated 
from a single immunized rabbit. Although 
the construction of rabbit libraries is easier 
compared to human or murine libraries, 
construction of chicken libraries is even 
more straightforward, since it involves only 
two primer sets. This makes chickens a very 
suitable alternative with respect to time and 
costs.
Phages were isolated against nine of the 
fourteen antigens used for immunization 
(annexin XI, CENP-B, HspB3, Topo, Jo-1, 
Ro52, Ro60, Rpp30, and U1A), and for most 
of the antigens more than one reactive phage 
was isolated. Phages directed to the other 
five antigens (α-fodrin, hPop1, Rpp38, Rrp4, 
and Rrp42) were not selected. This might be 
explained by the fact that the immune sera 
after the final booster reacted only weakly, or 
not at all, with these antigens, indicating that 
the chickens did not have an immune response 
towards these antigens. These findings suggest 
that the immune response was mainly directed 
to a panel of immunodominant epitopes 
present on the other antigens. The specific 
cross-reactivity of several monoclonal phages 
suggests that a similar epitope on two or 
more proteins is relatively immunogenic 
in chickens. This cross-reactivity could be 
explained by the fact that the process of gene 
conversion can occur multiple times in the life 
of a single B cell (see review by (20)). In case a 
B cell, producing antibodies to a first antigen, 
encounters a second (different) antigen during 
a subsequent immunization, it could be 
imagined that through gene conversion, the 
antibody reactivity slightly changes and that 
both antigens are targeted by this specific B cell.
Characterization of selected antibodies
After the first analysis with recombinant, 
purified antigens, we investigated the 
reactivity of the monoclonal phages with their 
eukaryotic antigens, which are present in a 
complex mixture of proteins. Therefore, the 
reactivity of a selected panel of monoclonal 
phages was analyzed on immunoblots 
containing a HeLa cell extract. As demonstrated 
in Figure 4, monoclonal phages A5A3 (anti-
annexin XI, 56 kDa), 5B5 and 5B10 (anti-
Jo-1, 50 kDa), U11B3, U13D12 and U11A3 
(anti-U1A, 38 kDa), and 5D1 (anti-CENP-B, 
80 kDa) reacted with proteins with molecular 
masses corresponding to those of their target 
antigens. Antisera with known reactivities 
towards the antigen of interest were used in 
parallel. Anti-U1A monoclonal phage U11A3, 
which was reactive with U1A and annexin XI 
in ELISA, reacted with proteins with molecular 
weights corresponding to U1A and annexin XI 
on western blot as well. Moreover, U11A3 
also reacted with U2B”, which is structurally 
similar to U1A and which is also recognized by 
the anti-U1A monoclonal mouse antibody, and 
with another (so far unidentified) protein of 
approximately 50 kDa.
To shed more light on the molecular 
identity of the antibody fragments, the cDNAs 
of 24 randomly chosen, antigen reactive 
scFvs were sequenced. The sequenced clones 
are underlined in Table 2. Several anti-Jo-1 
clones (5B6, 5B9 and 5B10) appeared to have 
(almost) identical VH chains, but different 
VL chains. The same holds true for anti-U1A 
clones U11B1 and U13D12. Furthermore, 22 
clones (92%) contained a short linker, whereas 
only 2 clones (8%) contained a long linker, and 
this finding suggests that antibody fragments 
with a short linker are more easily selected in 
this approach compared to antibody fragments 
with a long linker.
Figure 4. Phage immunoblot analysis. HeLa cell extracts were prepared by sonication and western blotted onto 
nitrocellulose membranes. Phages were immunoblotted at a concentration of 5x1011 cfu/ml, and bound phages were 
detected with HRP-labelled mouse anti-M13 antibodies, followed by ECL. Reactivities of phages and control antisera 
against annexin XI (56 kDa, lanes 1 and 2), Jo-1 (50 kDa, lanes 3-5), U1A (38 kDa, lanes 6-9), and CENP-B (80 kDa, lanes 
10 and 11) are shown. Molecular weights (kDa) of marker proteins are indicated on the left.
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antigen cocktail 1 and 2 respectively. The primary 
immunization was applied in complete Freunds 
adjuvant, whereas following boosters were given in 
incomplete Freunds adjuvant. ScFv phage display 
libraries were constructed with a short and a long 
linker as described previously (36). Shortly, VH genes 
were amplified using forward primer CSCVHo-F for 
a short linker, or forward primer CSCVHo-FL for a 
long linker, and reverse primer CSCG-B. VL genes 
were amplified with forward primer CSCVK and 
reverse primer CKJo-B. Amplified VL and VH genes 
were fused by overlap PCR using primers CSC-F and 
CSC-B. All primers used for library construction are 
listed in Table 3. Subsequently, VL-VH fragments 
were inserted in the pComb3 vector through SfiI 
digestion and ligation, and transferred into E.coli 
TG1 by electroporation.
Phage selection
Phages were amplified from bacterial libraries 
as described previously (2). Isolated phages were 
resuspended in PBS containing 1% bovine serum 
albumin (BSA). Libraries A (antigen mixture 1, long 
linker) and B (antigen mixture 1, short linker) were 
pooled, and libraries C (antigen mixture 2, long 
linker) and D (antigen mixture 2, short linker) were 
pooled. Libraries were panned on the individual 
antigens, which were immobilized on ELISA plates. 
Antigens were coated in 96-wells ELISA plates 
(Maxisorb, NUNC) in 50 mM NaHCO3, pH 9.6, 
in 50 µl per well. After overnight coating at 4oC, 
wells were washed with PBS and blocked with 5% 
non-fat dried milk powder in PBS (MPBS). Wells 
were incubated with 100 µl phages (approximately 
1x1013 cfu/ml), diluted with 100 µl MPBS containing 
0.05% Tween-20 (MPBST), during 90 minutes 
at 37oC. In case of GST fusion proteins (hPop1 
and Rpp38) as antigen, 10 µg soluble GST was 
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Materials and Methods
Immunization and library construction
The recombinant, purified proteins annexin 
XI (24), centromere protein B (CENP-B) (25), α-
fodrin (26), human Pop1 protein (hPop1) (27), DNA 
Topoisomerase I (Topo) (28), heat shock protein B3 
(HspB3) (29), histidyl tRNA synthetase (Jo-1) (30), 
Ro52 (31), Ro60 (32), Rpp30 (33), Rpp38 (33), Rrp4 
(34), Rrp42 (34), and U1A (35), were available at the 
Department of Biochemistry, Radboud University 
Nijmegen, The Netherlands. hPop1 and Rpp38 
were produced as glutathione S-transferase (GST) 
fusion proteins. Two different antigen cocktails 
were used for chicken immunization. Antigen 
cocktail 1 included annexin XI, CENP-B, Topo, 
Jo-1, Ro60, Rpp38, and U1A, whereas antigen 
cocktail 2 consisted of α-fodrin, hPop1, HspB3, 
Ro52, Rpp30, Rrp4, and Rrp42. Two couples of 
Barnevelder chickens were each immunized with 
The monoclonal phages isolated in this 
study, were shown to be reactive with their 
recombinant target antigen in ELISA, and 
several phages were also reactive with their 
counterparts expressed in a human cell. These 
phages are particularly useful for detection 
of autoantigens in human patient samples. 
We recently described a method in which 
scFvs are fused with constant domains from 
immunoglobulin light chains from different 
species, thereby enabling easy double- or 
triple-staining of antigens (21). Using these 
constant domain tags, the recombinant 
antibodies obtained in the study presented 
here can be easily used for simultaneous 
detection of the different autoantigens as 
well. The fact that some phages only reacted 
with recombinant protein, and not with the 
mammalian counterparts, may be explained 
by the difference in folding, or the presence 
of post-translational modifications that might 
lead to a change in the epitopes recognized 
by the phage antibody. In addition, the 
concentration of a particular protein in a 
HeLa cell extract, and thus the amount of this 
protein on the western blots, might be too low 
for detection. 
It has been described that recombinant 
antibody fragments with linkers of more 
than twelve amino acids are predominantly 
monomeric, whereas scFv fragments with a 
linker consisting of three to twelve amino acids 
may spontaneously associate with another 
scFv molecule to form bivalent dimers, termed 
a diabody (22,23). Reducing the linker length 
to less than three amino acids can even lead 
to the formation of trimers or tetramers (22). 
During the selections in the study described 
here, scFvs with short linkers (seven amino 
acids) were preferentially selected compared to 
scFvs with long linkers (eighteen amino acids). 
This finding might be explained by a higher 
avidity of diabodies compared to monomeric 
scFvs (23). It is thought that, during phage 
amplification, these diabodies are formed on 
the phage particle by association of the scFv 
fragment that is displayed on the phage with 
a soluble scFv fragment that is present as a 
result of proteolytic cleavage.
In conclusion, the immunization of only 
four chickens with two distinct pools of in 
total 14 autoantigenic proteins allowed the 
isolation of high avidity scFv’s against 9 of 
these antigens.
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sonication in sonication buffer (50 mM Tris-HCl pH 
7.6, 100 mM KCl, 0.05% Nonidet-P40, 1 mM EDTA, 
and 1 mM dithiothreitol), followed by centrifugation 
at 12,000g for 20 minutes. The clear lysate was 
stored at –70oC.
Immunoblot analysis
Proteins from HeLa cell extract were separated 
on polyacrylamide gels by SDS-PAGE and 
transferred to nitrocellulose membranes by semi-
dry electroblotting. All immunoblotting steps were 
carried out at room temperature on a shaking 
table. The membrane was blocked with MPBST. 
Phages were incubated with the membrane at a 
concentration of approximately 5x1011 cfu/ml in 
MPBST. After extensive washing with MPBST, the 
membrane was incubated with HRP-labelled mouse 
anti-M13 monoclonal antibody (GE Healthcare), 
5,000-fold diluted. Finally, bound HRP-labelled 
antibodies were visualized using enhanced 
chemiluminescence (ECL).
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added to the phage solution during selection. After 
panning, wells were washed several times with PBS 
containing 0.05% Tween-20 (PBST). Bound phages 
were eluted with 100 mM triethylamine or 100 mM 
glycine-HCl, pH 2, and neutralized with Tris-HCl, 
pH 7.4 prior to infection of E.coli TG1. After several 
selection rounds, polyclonal phage populations were 
analyzed in ELISA for reactivity with the antigens, as 
described below. 
In a first experiment, all antigens except Rrp4 
and Rrp42 were coated, at a concentration of 4 
µg per well for the first selection round, and at 
0.4 µg per well for following selection rounds. 
After five selection rounds, polyclonal phage 
ELISA demonstrated that the phage pools were 
not detectably enriched for phages directed to 
hPop1, HspB3, Topo, Ro60, and Rpp30. In a 
second experiment, these antigens were coated at 
a concentration of 0.5 µg per well in all selection 
rounds. In a third experiment, phages were selected 
on Rrp4, Rrp42, and again on annexin XI, α-fodrin, 
hPop1, Ro52, Rpp38, and U1A. The antigens were 
coated at a concentration of 0.5 µg per well in the 
first selection round, and at a concentration of 0.25 
µg per well in next selection rounds.
During single colony analysis, monoclonal phages 
were examined for binding activity in ELISA as 
described below, and the scFv gene was analyzed for 
full cDNA insert by PCR using primers pCOMB-F2548 
(TTCCGGCTCGTATGTTGTGTG) and pCOMB-R3010 
(GAATCAAGTTTGCCTTTAGCGTC). Subsequently, 
phages were grouped, based on similarities in finger-
print patterns using the restriction enzyme BstNI. 
From each fingerprint group, phages demonstrating 
activity in ELISA were further characterized on 
immunoblot. Finally, the cDNAs of several phages 
were sequenced using primers pComb-F2548 
(TTCCGGCTCGTATGTTGTGTG) and pComb-R3010 
(GAATCAAGTTTGCCTTTAGCGTC).
ELISA
Antigens were coated in 96-wells ELISA plates 
(Maxisorb, NUNC) in 50 mM NaHCO3, pH 9.6, in 
50 µl per well, overnight at 4oC. Antigens were 
coated at a concentration of 0.25 µg per well, 
except Rrp4 and Rrp42, which were coated at a 
concentration of 0.125 µg per well. Plates were 
blocked with MPBS for one hour. Subsequently, 
plates were incubated for one hour with the phage 
solutions, diluted in MPBST. In case of GST fusion 
proteins, competing soluble GST was added at a 
ten-fold excess. To detect bound phages, plates 
were washed with PBST and incubated with mouse 
anti-M13 monoclonal antibody (GE Healthcare), 
1,000-fold diluted in MPBST, followed by incubation 
with horse radish peroxidase (HRP)-labelled rabbit 
anti-mouse antibodies (DAKO), 1,000-fold diluted 
in MPBST. Plates were washed with PBST and PBS. 
Bound HRP-conjugated antibodies were detected by 
conversion of 3,3’,5,5’-tetramethylbenzidine (TMB). 
Reactions were stopped with 1 M H2SO4 and the 
absorbance at 450 nm was measured. Pre-immune 
and immune chicken sera were analyzed in ELISA 
as well. Bound chicken antibodies were detected 
using HRP-labelled rabbit anti-chicken antibodies 
(Jackson Immunoresearch), 1,500-fold diluted in 
MPBST, followed by TMB reaction as described 
above.
Cell culture
HeLa cells were grown in Dulbecco’s Modified 
Eagle’s Medium (DMEM) medium supplemented 
with 10% foetal calf serum, 1 mM penicillin and 
1 mM streptomycin. The cells were grown in a 
humidified incubator at 37oC in the presence of 5% 
CO2. HeLa cells were scraped in PBS, harvested by 
centrifugation at 800g for 5 minutes and washed 
twice with PBS. Cell extract was prepared by 
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Next to the already available mouse monoclonal and laboratory animal-derived polyclonal antibodies, recombinant antibodies offer an additional 
and virtually unlimited arsenal of new immunohistochemical research tools. The 
major advantages of recombinant antibodies are their rapid and easy generation 
against virtually any target. The avidity of antibody fragments can be increased 
by partial dimerisation. This can be achieved by fusion of C
L
 domains derived 
of different species to recombinant antibody domains. The V
L
-linker-V
H
-C
L
 
constructs result in significantly lower dimerisation levels compared to the 
V
H
-linker-V
L
-C
L
 antibody constructs. The most efficient dimerisation occurs 
with the Jun-tagged scFvs. The very large and rapidly expanding collection of 
recombinant antibodies already available combined with the ease of introducing 
various tag sequences allows for an almost unrestricted number of easily adjustable 
research tools. To our best knowledge we report for the first time that using 
C
L
 domains derived from different species, in combination with readily available 
commercial secondary antibodies specific for these C
L
 domains, provides an easy 
method for the application of recombinant monoclonal antibodies of various 
origins in immunohistochemical analyses eliminating the problem of co-staining 
with multiple mono- or polyclonal antibodies. Both double and triple labelling 
experiments can be performed successfully.
Introduction
The rapidly expanding repertoire of recom-
binant antibodies generated from various 
sources provides new powerful monoclonal 
antibody tools for immunological analysis 
of cells and tissues. In order to enable easy 
double- and triple-label immunostaining 
of cells and tissues with sets of such 
monoclonal antibodies we devised a set of 
vectors containing expression cassettes for 
the expression of recombinant antibodies as 
a fusion protein with the immunoglobulin 
light chain constant domain (CL) of either 
mouse, chicken or human origin (see Figure 1). 
Recombinant antibodies expressed using these 
vectors, in combination with readily available 
commercial secondary antibodies conjugated 
to different fluorophores, form a powerful 
source of tools that allow the easy setup of 
double or triple labelling immunostaining 
assays.
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Figure 2. Western blot analyses 
using non-denaturating (nonDen) 
and denaturating (Den) 
conditions for PAGE analyses. 
Monomeric antibody fragments 
(Mon) are indicated by black arrows 
and dimeric antibody fragments 
(Dim) by red arrows. Both V
L
-linker-
V
H
-tag (anti-P30) and V
H
-linker-V
L
-
Tag (Ra2) antibody fragments (scFv) 
containing: C
L
 domains derived from 
human (h), mouse (m), chicken 
(ch), Jun dimerisation (Jun), or no 
dimerisation domain were analysed. 
Note that the presence of Jun 
dimerisation domains does result 
in high percentage of dimers. The 
presence of the C
L
 domains results 
in significantly lower dimerisation 
levels when present in the V
H
-linker-
V
L
-Tag antibody fragments, and 
only in minor dimerisation levels in 
V
L
-linker-V
H
-Tag antibody fragments.
Figure 3. Schematic representation of different antibody fragment formats used for indirect immuno-
fluorescent cell staining. (a) Double labelling of HeLa cells: detection of the nucleolar protein P30 and cytoskeletal protein 
keratin. HeLa cells (methanol/acetone fixed) were labelled with a mix of recombinant chicken# derived anti-P30 antibody 
fragment containing the mouse Cκ domain, and the recombinant human derived anti-keratin antibody fragment (Ra2) 
containing the chicken Cλ domain. Primary antibodies were visualized using a mix of rabbit-anti-chicken-FITC, and sheep-
anti-mouse-Texas Red conjugated antibodies. (b) Triple labelling of HEp-2 cells: detection of nuclear U1-C, cytoplasmic 
RiboP, and nucleolar fibri-
llarin proteins.  HEp-2 
cells (methanol / acetone 
fixed) were triple-labelled 
with a human derived anti-
U1C antibody fragment 
(K36) containing the 
chicken Cλ domain, the 
human derived anti-RiboP 
antibody fragment (A4) 
containing the human 
Cκ domain, and the 
mouse monoclonal* anti-
fibrillarin antibody 72B9. 
Primary antibodies were 
visualized using a mix of 
goat anti-mouse-Alexa660, 
rabbit-anti-chicken-FITC, 
and sheep-anti-human-
Texas Red conjugated 
antibodies.
Results and discussion
Dimerisation behaviour and relative 
expression levels of the various subtypes of 
recombinant antibodies were analyzed using 
denaturing and non-denaturing western blots 
of the recombinant antibodies derived from 
different expression vectors and different 
recombinant antibody systems. We have 
compared recombinant human antibodies 
(VH-linker-VL-tag) with recombinant chicken 
(VL-linker-VH-tag) derived clones. In general 
we observed that the expression levels of 
the chicken VL-linker-VH-tag clones were 
lower compared to the human VH-linker-VL-
tag clones. Furthermore, the CL-domains in 
combination with the human recombinant 
antibodies resulted in a higher percentage 
of dimerisation compared to the chicken 
scFvs fused to identical tags. Only the Jun 
dimerisation domains resulted in efficient 
dimerisation under the conditions tested. Low 
levels of proteolytic cleavage were observed in 
all CL-tag scFv antibodies, but seemed to be 
more pronounced in the chicken derived scFv 
clones (Figure 2).
Double and triple labelling of HeLa and 
HEp-2 cells was easily achieved after initial 
titration of the concentrations of recombinant 
and mouse monoclonal antibodies. The 
individual antibodies for the double labelling 
experiments were chosen for their differential 
staining of nucleolar (Rpp30 protein (1)), and 
cytoplasmic cytoskeletal proteins (i.e. vimentin 
(2) and cytokeratin). The antibodies for the 
triple labelling stained nucleolar (fibrillarin 
protein (3)), nuclear (U1C protein (4)), and 
cytoplasmic (Ribo-P proteins (5)) proteins. 
Initially, in a sequential incubation procedure, 
every individual antibody was incubated with 
Figure 1. Schematic representation of different antibody fragment formats and available tag sequences. 
Two different antibody formats were designed: a V
H
-linker-V
L
-tag and a V
L
-linker-V
H
-tag format. The mouse Cκ-domain, 
human Cκ-domain and chicken Cλ-domain were fused as a tag to the scFv, in addition to a VSV-G-, and a 6xHis-tag.
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Materials and Methods
Introduction of CL-domain-tags in recombinant 
antibody expression vectors
The mouse Cκ-domain, the human Cκ-domain, 
and the chicken Cλ-domain were amplified from; 
cDNA derived from mouse spleen lymphocytes using 
oligos CκmForNot-I  and CκmBackBgl-II (6), from 
the vector pCOMb3-TT (7) using oligos CκhForNot-
I and CκhBackBGI-II, and from cDNA derived 
from chicken spleen lymphocytes using oligos 
CλchForNot-I and  CλchBackBgl-II, respectively. 
The resulting PCR fragments were digested with 
Not-I and Bgl-II and cloned in a Not-I and Bgl-II 
digested pUFosVH6 vector (6) resulting in pUCmκ-
VH6, pUChκ-VH6, and pUCchλ-VH6, respectively 
(Figure 1). All oligonucleotides used are listed in 
Table 1. 
Monoclonal antibodies
Recombinant monoclonal antibodies from 
various sources were cloned in the different 
expression vectors. The Ra2 human recombinant 
scFv antibody isolated from a human rheumatoid 
arthritis patient derived phage display library (8) 
recognising a filaggrin-derived peptide sequence 
and cytoskeletal intermediate filaments keratin 
8 and vimentin, was cloned in pUCchλ-VH6. The 
recombinant anti-human Rpp30 (a component of 
the nucleolar RNase-MRP and RNase-P complexes) 
(1) chicken antibody, isolated from an immunized 
chicken-derived phage display library (Raats, 
unpublished data) was cloned in pUCmκ-VH6. The 
anti-U1C human recombinant antibody K36 isolated 
from a human systemic lupus erythematosus (SLE) 
patient derived phage display library (9) was cloned 
in pUCchλ-VH6. The anti-Ribosomal P proteins 
antibody A4 isolated from a human SLE patient 
derived phage display library (10) was cloned in 
the pUChκ-VH6. Finally, the mouse monoclonal 
anti-human fibrillarin 72B9 (a component of the 
nucleolar hU3-snoRNP complex) was used in its 
original complete IgG2a format (11).  Recombinant 
antibodies were used at concentrations of 0.5 mg/
ml. Tissue culture supernatant of mouse monoclonal 
antibody 72B9 was used at a dilution of 1:10.
Western blot analysis of expressed recombinant 
antibodies
All recombinant antibody clones were expressed 
as periplasmic fractions as described previously 
(12). ScFv were induced by 1 mM IPTG for 3 hours 
at 37oC, whereas CL-domain scFvs and Jun dimers 
(6) were induced by 1 mM IPTG for 15 hours at 
20oC. Recombinant antibodies were analysed on 
10% polyacrylamide denaturing and non-denaturing 
SDS-PAGE, and semi-dry blotted onto nitrocellulose 
membranes. Blots were blocked for one hour in 
MPBST (5% non-fat milk, 0.05% Tween 20, in 
PBS). Antibodies were visualised using anti-VSV-
G P5D4 mouse monoclonal (1 μg/ml), followed 
by horseradish peroxidase (HRP)-labelled rabbit 
anti-mouse antibodies (Dako, Glostrup, Denmark), 
2,500-fold diluted. Bound antibodies were detected 
by enhanced chemiluminescence (ECL).
Indirect immunofluorescence staining
ScFvs were purified from periplasmic fractions by 
immobilised metal chelate affinity chromatography 
(IMAC), and dialysed overnight against PBS pH 
8.0 as described previously (13). HeLa and HEp-2 
cells were cultured in DMEM (Dulbecco’s modified 
Eagle’s medium) supplemented with 10% foetal calf 
serum, 1 mM penicillin and 1 mM streptomycin. 
For the indirect immunofluorescence staining 
procedure, HeLa and HEp-2 cells were grown on 
the fixed cells, followed by a wash step, after 
which the next antibody was added. This 
time-consuming method was successful, albeit 
the staining intensities of some recombinant 
antibodies were weaker compared to single-
label immunostaining experiments using the 
respective antibodies. The observed decrease 
in staining intensity is probably due to the 
relative long incubation times required for 
the sequential staining procedure. Eventually, 
all labelling experiments were performed as 
a two-step method. All primary antibodies 
were mixed and incubated with the fixed 
cells followed by a wash step. Subsequently, 
all secondary antibodies were mixed and 
incubated with the cells, again followed 
by a wash step. Cells were embedded in 
mowiol, and directly analysed with either an 
epifluorescence microscope (Figure 3a) or a 
confocal microscope (Figure 3b). Both fixation 
methods used gave similar staining patterns.
CκmForNot-I   5’GAGTCATTCTCGACTTGCGGCCGCGGCTGATGCTGCACCAACTGTATC3’ 
CκmBackBgl-II   5’GAAGATCTCGCGGCTGCACACTCATTCCTGTTGAAGCTC3’
CκhForNot-I   5’GAGTCATTCTCGACTTGCGGCCGCTACTGTGGCTGCACCATCTGTCTTC3’
CκhBackBgl-II   5’GAAGATCTCGCGGCTGCACACTCTCCCCTGTTGAAGCTCTTTGTGAC3’ 
CλchForNot-I   5’GAGTCATTCTCGACTTGCGGCCGCTCAGCCCAAGGTGGCCCCCACCATC3’ 
CλchBackBgl-II   5’GAAGATCTCGCGGCTGCGCACTCGGACCTCTTCAGGGTCTTCG3’ 
Table 1 Oligonucleotides used for assembly of scFv expression vectors
Summary
Next to the already available mouse 
monoclonal and laboratory animal-derived 
polyclonal antibodies, recombinant antibodies 
offer an additional and virtually unlimited 
arsenal of new immunohistochemical research 
tools. The major advantages of recombinant 
antibodies are their rapid and easy generation 
against virtually any target. The avidity of 
antibody fragments can be increased by partial 
dimerisation. This can be achieved by fusion 
of CL domains derived of different species to 
recombinant antibody domains. The VL-linker-
VH-CL constructs result in significantly lower 
dimerisation levels compared to the VH-linker-
VL-CL antibody constructs. The most efficient 
dimerisation occurs with the Jun-tagged 
scFvs. The very large and rapidly expanding 
collection of recombinant antibodies already 
available combined with the ease of introducing 
various tag sequences allows for an almost 
unrestricted number of easily adjustable 
research tools. To our best knowledge we 
report for the first time that using CL domains 
derived from different species, in combination 
with readily available commercial secondary 
antibodies specific for these CL domains, 
provides an easy method for the application of 
recombinant monoclonal antibodies of various 
origins in immunohistochemical analyses 
eliminating the problem of co-staining with 
multiple mono- or polyclonal antibodies. Both 
double and triple labelling experiments can be 
performed successfully.
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Target discovery by antibody phage display 55
Today’s research demands fast identification of potential diagnostic and therapeutic targets. We describe a novel phage display strategy to identify 
disease-related proteins that are specifically expressed in a certain (diseased) tissue 
or cells. Phages displaying antibody fragments are selected on complex protein 
mixtures in a two-step manner, combining subtractive selection in solution with 
further enrichment of specific phages on two-dimensional western blots. Targets 
recognized by the resulting recombinant antibodies are immunoaffinity purified 
and identified by mass spectrometry. We used antibody fragment libraries from 
autoimmune patients to discover apoptosis-specific and disease-related targets. 
One of the three identified targets is the U1-70K protein, a marker for SLE 
overlap disease. Interestingly, the epitope on U1-70K, recognized by the selected 
recombinant antibody, is shown to be apoptosis-dependent, and such epitopes 
are believed to be involved in breaking tolerance to self-antigens. The other two 
proteins are identified as PSF/p54nrb and hnRNP C.
Introduction
In the post-genomics era, where the human 
genome is completely sequenced and available 
in databases, it became clear that having the 
complete genome sequence is not enough 
to reveal biological function. For example, 
mRNA levels do not necessarily correlate with 
the expression levels of the corresponding 
proteins, and the relative levels of protein 
variants resulting from either alternative 
splicing or posttranslational modifications 
cannot be predicted from the gene sequence. 
‘Proteomics’ defines a broad area of interest 
and is aimed at protein identification, 
studying protein function, posttranslational 
modifications, protein-protein interactions 
and finding molecular drug targets (1). Such 
molecular drug targets can be proteins that 
are specifically present in a diseased tissue 
or cell. One approach to discover ‘proteome-
specific’ proteins is to compare the proteome 
of a diseased cell or tissue with the proteome 
of the same cell or tissue in a normal (non-
diseased) state. This is commonly done by 
two-dimensional gel electrophoresis and mass 
spectrometry. Such an approach generally 
leads to an (extensive) list of proteins that are 
up- or down-regulated or modified in various 
ways. To subsequently find the proteins that 
are actually relevant for disease is a difficult 
and laborious task. Phage display, first 
described by George Smith in 1985 (2), is a 
powerful technique based on the display of 
proteins or peptides on the surface of phage 
particles that carry the corresponding gene. 
In proteomics, phage display offers an elegant 
approach in the search for disease markers. 
Subtractive antibody selections have been 
successfully performed on whole cells (3-10), 
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selected on a two-dimensional western blot 
of the proteome of interest (Figure 1c). After 
identification of proteome-specific phages, 
their targets are immunoaffinity purified using 
these recombinant antibodies, and identified 
by means of mass spectrometry. The use 
of immune libraries (for example libraries 
from autoimmune patients) will enhance 
the chances of discovering disease-related 
epitopes, since these libraries will contain high 
affinity antibodies against disease markers. In 
systemic autoimmune diseases, it still remains 
poorly understood why patients produce 
antibodies to self-antigens. One (more 
and more supported) theory points at the 
involvement of aberrant protein modifications, 
for example those occurring during apoptosis. 
Such modifications are believed to reveal 
‘cryptic’ epitopes on autoantigens and as such 
play a role in breaking tolerance to self-antigens 
(20-22). In the current study, the subtractive 
phage display selection method was applied, 
using autoimmune patient antibody libraries, 
to identify apoptosis-specific epitopes relevant 
for systemic autoimmune diseases. Three 
epitopes were identified that are exclusively 
present in the apoptotic cell extract. One of 
these epitopes is associated with the U1-70K 
protein, which is cleaved during apoptosis 
and which is an important marker for systemic 
lupus erythematosus (SLE) overlap disease 
(also named mixed connective tissue disease, 
MCTD). Finally, we demonstrate that the 
recognition of this epitope by the selected 
antibody is dependent on the apoptotic 
modification. 
Results
Test selections on biotinylated cytoplasmic 
HeLa cell extracts
Successful selections against complex 
mixtures of antigens, such as a cellular 
extracts, depend on many factors (23), 
including the amount and concentration 
of antigen, and the affinity of the antibody 
fragments. Selection conditions were 
tested by means of mock selections. 
A semi-synthetic antibody phage library was 
simultaneously spiked with phages displaying 
monoclonal antibody fragments recognizing 
the autoantigens La and Ro52, previously 
selected from SLE derived libraries ((24), 
unpublished results), at various ratios. The 
1:109 ratio approximated the complexity of 
the libraries used in subsequent experiments. 
After selection on biotinylated cytoplasmic 
HeLa cell extract, the polyclonal phage pools 
were tested in enzyme-linked immunosorbent 
assay (ELISA) for reactivity against La and 
Ro52, and against bovine serum albumin 
(BSA) as a control antigen. As shown in 
Figure 2, at a 1:106 ratio anti-La phages were 
detectably enriched after just one selection 
round, whereas at a 1:109 ratio anti-La phages 
were detected after two rounds of panning. At 
a 1:106 ratio the polyclonal phage stock showed 
slight reactivity with Ro52, whereas at a 1:109 
ratio no reactivity against Ro52 was observed 
after two selection rounds. After three selection 
rounds, 96 monoclonal phages were analyzed 
for reactivity in ELISA, and 27% of the phages 
reacted with La, whereas 10% was positive 
tissue sections (11), biomaterials ex vivo (12), 
and cell extracts (13-19). A major advantage 
of subtractive phage display technology is 
the simultaneous generation of recombinant 
monoclonal antibodies recognizing potential 
disease markers. Such antigen-antibody pairs 
could be directly applicable in therapeutics or 
diagnostics.
Here, we present a novel subtractive anti-
body phage display method that enables the 
identification of proteome-specific, intra-
cellular epitopes. As schematically represented 
in Figure 1, the selection method comprises 
two steps. In the first step, phages are selected 
in solution on the proteome of interest with 
prior subtraction on a comparable ‘normal’ 
proteome (Figure 1a and 1b). Biotinylation 
of the proteomes allows their immobilization 
on magnetic streptavidin-coated beads. In 
the second phase, specific phages from the 
phage pool, enriched for phages to proteome-
specific epitopes in the first step, are further 
Figure 1. Schematic representation of the selection strategy. The selection strategy is a combination of several 
subtractive selection rounds on proteomes in solution, followed by an enrichment step on immunoblot. Phages 
are selected on biotinylated proteomes, with subsequent capture by magnetic streptavidin-coated beads. Phages 
recognizing common epitopes are first removed by a subtractive selection on the comparable ‘normal’ proteome (a), 
and subsequently remaining phages are selected on epitopes that are specifically present in the proteome of interest 
(b). These selection rounds are repeated several times. Subsequently, western blots containing both proteomes are 
incubated with the selected phage pool, enriched for antibodies to proteome-specific epitopes (c). Spots are excised 
from the membrane, bound phages are eluted and used to infect bacterial cultures to isolate monoclonal phages. Finally, 
these phages are screened for recognition of proteome-specific epitopes.
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were examined as detection methods. Where 
TMB staining is more accurate (due to a direct 
precipitate on the membrane), ECL detection 
resulted in a higher sensitivity. The amount 
of phages eluted from ECL-detected spots was 
approximately equal to the amount of phages 
eluted from TMB-stained spots, and no negative 
effect on phage infectivity was observed for 
both staining methods. In average, 100 phages 
eluted per spot. Phages were selected, based 
on full-length cDNA insert and expression 
of soluble single chain variable fragments 
(scFv). Fingerprint analysis of phages with 
full-length cDNA and good scFv expression 
resulted in a number of groups, and randomly, 
one clone per group was analyzed for reactivity 
on immunoblot containing both extracts. All 
scFvs were derived from their original spots.
Immunoblot analysis, as shown in 
Figure 4, demonstrated that scFvs B1H11, 
G1G10 and R3A4 recognized antigens that 
are modified during apoptosis. ScFv B1H11 
recognized protein bands of 100, 55 and 45 
kDa in non-apoptotic cell extract, and two 
additional protein bands of 50 and 42 kDa 
in apoptotic cell extract. Another additional 
protein band, that runs slightly faster than 
the 100 kDa protein band, is relatively weakly 
recognized. ScFv G1G10 reacted with a protein 
of approximately 38 kDa that migrated at a 
slightly lower molecular weight in apoptotic 
cell extract compared to non-apoptotic cell 
extract. ScFv R3A4 recognized a protein band 
of approximately 70 kDa in non-apoptotic cell 
extract, and a protein band of about 40 kDa in 
apoptotic cell extract.
Figure 3. Selection of isolated phages by 2D western blotting. Apoptosis was induced in HeLa cells by incubation 
in the presence of anisomycin for eight hours, and apoptotic cell extract was prepared by repeated freeze-thawing. 
Approximately 40 µg of non-apoptotic cytoplasmic HeLa cell extract (a) and apoptotic HeLa cell extract (b) was 
separated by two-dimensional electrophoresis. In the first dimension, proteins were separated by isoelectric focusing 
on immobilized pH gradients with a pH range from 3 to 10, and in the second dimension by SDS-PAGE on a 12.5% 
polyacrylamide gel. Molecular weights of marker proteins (kDa) are indicated on the left. After two-dimensional 
electrophoresis, proteins were transferred to a nitrocellulose membrane and the membrane was blocked with MPBST. 
Prior to the immunoblot analysis, phages were selected during three consecutive subtractive selection rounds on 
biotinylated apoptotic cell extract. Phages were incubated with the pre-blocked membrane at a concentration of 
5x1011 cfu/ml, and detected with HRP-labelled anti-M13 mAb and ECL. Between antibody incubations, the membrane 
was washed extensively with MPBST to reduce background on the film. A similar (TMB-stained) membrane was used 
for excision of apoptosis-specific spots.
for Ro52. It has been estimated that, in HeLa 
cells, the number of Ro52 molecules is about 
100-fold smaller than the number of La 
molecules (25), which might explain why 
the anti-La phages were more easily isolated 
than the anti-Ro52 phages. These results 
demonstrate that it is possible to select 
phage antibodies from libraries derived 
of autoimmune patients using only small 
amounts of biotinylated cell extract.
Subtractive selection of recombinant anti-
bodies against apoptosis-specific epitopes
To induce apoptosis, HeLa and Jurkat 
cells were incubated with anisomycin for eight 
hours. As a biochemical marker for apoptosis 
the cleavage of the U1-70K protein to a 
40 kDa apoptosis-specific fragment, an early 
event during apoptosis (26), was monitored. 
Eight hours after induction with anisomycin, 
the apoptotic 40 kDa fragment was detected 
by immunoblotting, whereas the full-length 
70 kDa protein was reduced to undetectable 
levels (data not shown), indicating that the 
cells had entered the apoptotic pathway.
Libraries of rheumatoid arthritis (RA), 
systemic sclerosis (SSc) and SLE patients 
(24,27,28) were mixed using equal amounts 
of phages from each library, and phages were 
selected for reactivity with apoptosis-specific 
epitopes by subtractive selection as detailed 
in the Materials and Methods section. After 
three selection rounds, phage populations of 
each selection round were analyzed on small 
two-dimensional western blots containing 
non-apoptotic and apoptotic cell extracts. 
The polyclonal phage stock obtained after the 
third selection round showed the strongest 
reactivity on western blot, and was chosen 
for further analysis (Figure 3). Several of the 
apoptosis-specific spots were excised and 
bound phages were eluted. Both enhanced 
chemiluminescence (ECL) detection and 
3,3’,5,5’-tetramethylbenzidine (TMB) staining 
Figure 2. Test selections of polyclonal phages using biotinylated cytoplasmic HeLa cell extract. In the test 
selections, anti-La and anti-Ro52 phages were simultaneously added to a semi-synthetic library at a 1:109 ratio (a) and at 
a 1:106 ratio (b), and selected on 1.5 µg biotinylated cytoplasmic HeLa cell extract, captured using magnetic streptavidin-
coated beads. The phage populations resulting from the selection rounds were tested for binding to La and Ro52. BSA 
was used as a negative control. Selection rounds are numbered (0, 1, and 2). Per well 0.1 µg recombinant protein was 
coated. Polyclonal phage pools were diluted to a concentration of 1011 cfu/ml and detected using HRP-labelled anti-M13 
mAb. The ELISA plates were developed with TMB as a substrate, and after the addition of H
2
SO
4
, the absorption at 
450 nm was measured.
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Identification of target antigens
The recombinant antibodies, isolated during 
the selection procedure, can serve as tools to 
identify and characterize the corresponding 
target antigens. ScFvs were C-terminally 
tagged with a 6xHis-tag, immobilized on 
nickel beads, and target proteins were then 
isolated from cell extracts and separated on 
SDS-PAGE gels. As shown in Figure 4d, scFv 
B1H11 efficiently immunoprecipitated proteins 
with molecular weights corresponding to 
those detected by immunoblotting, whereas 
immunoaffinity purification of the target 
recognized by scFv G1G10 appeared to be less 
efficient. These protein bands were excised 
from the gel and the proteins in the gel slices 
identified by mass spectrometry. An overview 
of the selected targets and their characteristics 
is presented in Table 1.
The proteins recognized by scFv B1H11 
were identified as polypyrimidine-tract binding 
protein (PTB)-associated splicing factor (PSF, 
100 kDa) and p54 nuclear RNA binding protein 
(p54nrb, 54 kDa). The scFv recognizes both PSF 
and p54nrb on immunoblot, indicating that the 
epitope recognized by this scFv is present on 
both proteins. In agreement with this, the two 
proteins are approximately 70% identical on 
the level of amino acids over a region of 328 
residues, strongly suggesting that the epitope 
is located in this region of these molecules. 
Interestingly, it has been reported that PSF is 
hyperphosphorylated (29) and p54nrb is cleaved 
(30) during apoptosis. Cleavage of p54nrb leads 
to a size reduction of approximately 4 kDa, 
which agrees well with the apoptosis-specific 
protein band of 50 kDa (Figure 4a). The 
45 kDa protein band in non-apoptotic cell 
extract is presumably either a splicing variant 
or degradation product of p54nrb. Also this 
variant seems to be cleaved in apoptotic cells 
leading to the appearance of the 42 kDa species, 
which is also recognized by scFv B1H11. In 
agreement with the nuclear localization of 
PSF and p54nrb, immunofluorescence analysis 
of scFv B1H11 demonstrated a nucleoplasmic 
staining (Figure 4e).
The protein recognized by scFv G1G10 was 
identified by mass spectrometric analysis as 
heterogeneous nuclear ribonucleoprotein C 
(hnRNP C). As a result of alternative splicing, 
two variants of hnRNP C can be detected in 
most cells, designated C1 and C2, which differ 
approximately 3 kDa in size (31). The identity 
of the G1G10 target protein was confirmed by 
the reactivity of scFv G1G10 with hnRNP C, 
immunoprecipitated from Jurkat cells using 
an anti-hnRNP C-specific patient serum 
(32). During apoptosis, hnRNP C1 and C2 
are known to be cleaved, resulting in a size 
reduction of approximately 2 kDa (33), which 
is consistent with the finding that the protein 
recognized by scFv G1G10 in apoptotic cell 
extract migrates slightly faster in SDS-PAGE 
than the antigen present in non-apoptotic cell 
extract (Figure 4b). ScFv G1G10 resulted in a 
nucleoplasmic staining (Figure 4f), consistent 
with the localization of hnRNP C (33). 
Immunoblot analysis showed that scFv 
R3A4 recognized a protein band of 70 kDa 
in non-apoptotic cell extract, and a 40 kDa 
protein band in apoptotic cell extract (Figure 
4c), which is reminiscent of the U1-70K protein 
and its apoptotic cleavage product (26). The 
U1-70K protein is a well-known autoantigen 
in SLE overlap syndrome and recognition 
Figure 4. Characterization of the reactivities of the selected monoclonal recombinant antibodies. 
(a-c) Immunoblotting. Apoptosis was induced in Jurkat cells by incubation with anisomycin for eight hours. Cell extracts 
were prepared by sonication. Approximately 10 µg of apoptotic (a) and non-apoptotic (n) Jurkat cell extract was 
separated by SDS-PAGE on a 12.5% polyacrylamide gel and electroblotted onto nitrocellulose membranes. Molecular 
weights of marker proteins (kDa) are indicated on the left. ScFvs were isolated from the periplasm. ScFvs B1H11 and 
R3A4 were incubated with the membrane at a 10-fold dilution, and scFv G1G10 at a 20-fold dilution. ScFv B1H11 (a) 
recognizes protein bands of 100, 55 and 45 kDa in non-apoptotic cell extract, and additional strong protein bands of 
50 and 42 kDa in apoptotic cell extract. Another additional protein band, running slightly faster than the 100 kDa band, 
is recognized relatively weaker. ScFv G1G10 (b) reacts with a protein band of approximately 38 kDa in non-apoptotic 
cell extract and with a protein band of approximately 37 kDa in apoptotic cell extract. ScFv R3A4 (c) recognizes a 
protein band of 70 kDa in non-apoptotic cell extract, and a 40 kDa protein band in apoptotic cell extract. Note that 
the reactivity with the apoptotic form of this protein is stronger than the reactivity with the non-apoptotic form. (e-g) 
Immunofluorescence. HeLa monolayer cells were fixed and incubated with purified scFvs. Bound scFvs were detected 
by anti-VSV-G mAb and FITC-labelled rabbit anti-mouse antibodies. ScFv B1H11 (e), G1G10 (f) and R3A4 (g) all give a 
nucleoplasmic staining. (d) Immunoaffinity purification. ScFvs G1G10 (lane 1) and B1H11 (lane 2), recloned in a pUC119-
vector for C-terminal fusion with a 6xHis-tag, were isolated from E.coli periplasm. ScFvs were coupled to nickel-NTA 
agarose beads and incubated with non-apoptotic total cell extracts, and bound antigens were eluted by a pH shock. The 
proteins were concentrated by acetone precipitation, separated on a small 12.5% polyacrylamide gel and visualized 
by silver staining. Molecular weights of marker proteins (kDa) are indicated on the left. The strong protein bands with 
an approximate molecular weight of 30 kDa are the scFvs. A similar gel, stained with colloidal Coomassie was used to 
excise and identify the protein bands of interest. Arrows indicate the excised protein bands.
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particles from apoptotic and non-apoptotic cell 
extracts. The U1 snRNP complex consists of the 
U1 snRNA molecule, three U1-specific proteins 
(U1A, U1C and U1-70K) and a ring of seven 
distinct Sm proteins. The 40 kDa apoptotic 
fragment of the U1-70K protein remains 
associated with the U1 snRNP complex (36). 
The amount of immunoprecipitated U1 snRNP 
particles was measured by quantification of 
the amount of co-precipitated U1 snRNA on 
northern blots. An anti-BSA scFv selected from 
an SLE derived library, which lacks reactivity 
with any of the U1 snRNP components, served 
as a negative control. The results in Figure 5 
show that in an immunoprecipitation assay 
scFvs R3A4, scFv-4 and scFv-6 react much 
stronger with apoptotic U1-70K than with non-
apoptotic U1-70K, which strongly suggests 
that the epitope recognized by these scFvs is 
specifically present on the apoptotic fragment. 
ScFv-7 displayed similar reactivities to the 
apoptotic and non-apoptotic U1-70K proteins. 
Mouse monoclonal antibody 2.73 reacted 
much stronger with non-apoptotic U1-70K 
than with apoptotic U1-70K, which agrees with 
its preferential recognition of the full-length 
U1-70K in immunoblotting (21). 
Discussion
Here, we describe a novel antibody 
phage display method to identify proteome-
specific epitopes that are relevant for disease. 
Recombinant autoantibodies from patient 
libraries were selected on apoptotic cell extract, 
Figure 5. U1 snRNP immunoprecipitation by anti-U1-70K scFvs. Several monoclonal antibodies to U1-70K were 
used to immunoprecipitate U1 snRNP complexes from apoptotic (a) and non-apoptotic (n) Jurkat cell extract. Apoptosis 
was induced by incubating the Jurkat cells with anisomycin for eight hours. Cell extracts were prepared by lysis in NP40 
lysis buffer, for 30 minutes at 0oC. U1 snRNP was immunoprecipitated from these extracts by anti-U1-70K scFvs R3A4, 
4, 6, and 7, an anti-BSA scFv, and an anti-U1-70K mouse monoclonal antibody (mAb 2.73). Co-immunoprecipitated RNA 
was analyzed by northern blot hybridization with a 32P-labelled U1 snRNA-specific anti-sense probe. As a control RNA 
was also isolated directly from cell extracts. The signals on the northern blots were quantified, and the percentage of 
precipitated U1 snRNA was determined.
of the cleavage product by autoantisera (21) 
suggested that scFv R3A4, which was isolated 
from a patient-derived antibody library, might 
be targeting the U1-70K protein. A number of 
experiments demonstrated that this indeed 
was the case. First, the scFv R3A4 reacted with 
recombinant U1-70K (a truncation mutant 
consisting of the first 195 amino acids of U1-
70K) in ELISA (data not shown). Second, 
immunofluorescence analysis, as shown in 
Figure 4g, revealed that the cellular localization 
of the target antigen was nucleoplasmic 
(speckled pattern), corresponding to the 
localization of the U1-70K protein. Finally, the 
sequence of scFv R3A4 cDNA appeared to be 
almost identical to the VH and VL sequences of 
scFvs directed to the U1-70K protein, which 
were previously selected from SLE libraries in 
our laboratory (34).
Identification of an apoptosis-dependent 
epitope on the U1-70K protein
Interestingly, scFv R3A4 appeared to 
react stronger with apoptotic than with non-
apoptotic U1-70K on immunoblots (Figure 4c). 
Similar observations were previously reported 
by Degen et al. for other anti-U1-70K scFvs 
(34). We hypothesized that the efficiency by 
which the epitope is recognized by these scFvs 
is dependent on the apoptotic modification. 
To study the in vitro reactivity of anti-U1-70K 
antibodies with apoptotic and non-apoptotic 
U1-70K, anti-U1-70K antibodies (i.e. scFv 
R3A4, three scFvs previously selected from 
SLE libraries and designated scFv-4, -6 and 
-7 (34), and mouse monoclonal antibody 2.73 
(35)) were used to immunoprecipitate U1 
small nuclear ribonucleoprotein (U1 snRNP) 
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If a higher diversity is preferred, one might 
continue with the phages that are selected 
during the first or second selection rounds. On 
the other hand, a less diverse phage population 
(such as obtained after three or more selection 
rounds) might give a better representation of 
the important targets in the antigen mixtures. 
Moreover, after the first and second selection 
rounds, the concentrations of individual 
phages might be too low for detection of the 
antigens on two-dimensional immunoblots, 
the second selection step in the procedure 
described here.
Individual phages, selected on two-
dimensional immunoblots, were screened on 
one-dimensional immunoblots to validate their 
reactivities. We then focused on three targets 
that were differentially detected in apoptotic 
cell extracts compared to non-apoptotic cell 
extracts. Obviously, an automated high-
throughput screening system would greatly 
facilitate the simultaneous isolation of more 
possible targets. Besides, by screening on 
immunoblots of SDS-PAGE gels, the screening 
was now restricted to differences between 
proteomes with regard to molecular weight. 
Combining this screening with other assays, 
such as immunoblots of one-dimensional 
isoelectric focusing gels, a capture ELISA, or 
a filter lift assay (39), would also augment the 
number of possible disease markers.
In general, the affinity of scFvs for antigen-
binding is lower compared to complete 
immunoglobulins, and immunoaffinity purifi-
cation may therefore be less efficient. So far, 
a few studies have successfully used scFvs to 
isolate the unknown target antigen and to 
determine its identity by mass spectrometry 
(5,6). We demonstrate that scFvs, isolated 
during the subtractive selection strategy 
presented here, can be applied successfully 
to immunoaffinity purify target proteins for 
identification by mass spectrometry. A critical 
parameter is the amount of cell extract needed. 
However, the development of more sensitive 
mass spectrometry equipment will allow the 
identification of target proteins with smaller 
amounts of protein, and thus with less cell 
extract. 
The post-genomics era demands innovative 
methods for fast target identification for 
a number of applications. The method 
described here offers an attractive platform 
for the discovery of potential therapeutic and 
diagnostic targets, especially in combination 
with a high-throughput screening system.
Materials and methods
Phage display libraries and patient sera
Patients were classified in accordance with 
standard criteria for each autoimmune disease. 
Autoimmune patient libraries of SLE (patients D5, D18, 
D181, O11 and Z5), SSc (patients B92, H248, J70, S185 
and T5) and RA (patients Du, He and Wy) patients were 
available in pHenIX-VSV vector format (24,27,28). The 
synthetic library made by Nissim (40) was used for test 
selections. To reduce the background of phages that 
do not express a functional antibody-gene III fusion 
protein, and to reduce the number of selection rounds 
needed, a trypsin sensitive helper phage (41) was used 
for phage amplification. Serum samples were provided 
by patients seen at the Department of Rheumatology 
and Internal Medicine of the Radboud University 
Nijmegen Medical Centre (The Netherlands). 
after subtraction on non-apoptotic cell extract, 
to identify disease-related targets that are 
specifically present in the apoptotic material. 
All target antigens isolated as a result of this 
selection strategy are proteins that are modified 
during apoptosis. Moreover, two of the three 
targets are well-documented autoantigens, 
with the U1-70K protein being an important 
marker for SLE overlap disease. HnRNP C is 
autoantigenic as well, although autoantibodies 
to this protein have been reported in a few 
patients only (32,33). So far, PSF and p54nrb 
have not been described as autoantigens, 
but one of the patients from the libraries was 
found to possess (low titres of) antibodies to 
recombinant p54nrb by immunoblotting. The 
autoantigenic U1-70K protein is of particular 
interest, since it was recently demonstrated 
that this protein contains an apoptosis-specific 
B-cell epitope, which is believed to be involved 
in breaking immunological tolerance to the 
U1-70K protein (20,21,37). We demonstrated 
that the anti-U1-70K scFv R3A4 reacts in 
vitro with an apoptosis-specific epitope on 
U1-70K as well. The recognition of intact 
U1-70K on immunoblots is believed to result 
from unfolding of the protein due to the 
electrophoresis procedure. 
Using large naïve libraries, the selection 
strategy presented here is generally applicable 
for the discovery of proteome-specific epitopes, 
as for example proteins that are exclusively 
present on tumour cells, or proteins that are 
specifically expressed during different life 
stages of the malaria parasite. The technique 
is especially suitable for the discovery of 
markers that are related to diseases in which 
the immune system is involved, such as 
autoimmune diseases. Since libraries of such 
patients contain high-affinity antibodies, the 
use of these libraries will bias towards the 
selection of (the most important) disease-
related epitopes.
So far, selections on complex mixtures 
of intracellular antigens have been mainly 
performed using immobilization on immuno-
tubes (13,15) or blotting membranes (16,18, 
19). The advantage of biotinylation (in 
combination with magnetic streptavidin-
coated beads) is that panning on antigens 
can be performed in solution, resulting in an 
optimal accessibility of the epitopes for the 
phages (38). The test selections, performed 
with anti-Ro52 and anti-La spiked libraries, 
demonstrated that phages from autoimmune 
libraries can be selected using small amounts 
of biotinylated cell extracts, which would allow 
simultaneous competition with a large excess 
of the non-biotinylated ‘normal’ proteome. It 
is possible that epitopes are changed due to 
the attachment of biotin groups to the protein, 
but this potential problem was minimized 
by choosing a relatively low biotin:protein 
ratio. Another advantage of our approach is 
the combinatorial approach of selection in 
solution and selection on two-dimensional 
western blots, which decreases the amount of 
individual monoclonal phages to be analyzed. 
To our knowledge, we are the first to report 
such a combinatorial approach.
In the current study, phages were 
selected on proteins in solution during three 
subtractive selection rounds prior to selection 
on immunoblots. It is generally accepted that 
in such procedures diversity decreases with 
the progression of the selection procedure. 
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washing, bound phages were detected with HRP-
conjugated anti-M13 mouse monoclonal antibody 
(GE Healthcare), followed by TMB (NEOGEN) 
staining (44) or ECL.
Phage selection
Test selections on biotinylated HeLa cytoplasmic 
cell extract
To test whether selection against biotinylated 
cell extract was promising, anti-La and anti-Ro52 
phages, previously selected from human autoimmune 
patient derived libraries ((24), unpublished results), 
were diluted in a semi-synthetic (Nissim) phagemid 
library at two different ratios, namely a 1:106 ratio 
and a 1:109 ratio. For a 1:106 ratio 107 anti-La and 
107 anti-Ro52 phages were simultaneously mixed 
with 1013 phages of the semi-synthetic library, and 
for a 1:109 ratio 104 anti-La and 104 anti-Ro52 were 
simultaneously mixed with 1013 phages of the semi-
synthetic library. All panning steps were performed 
using an end-over-end rotator at room temperature. 
First, the phages were incubated with 1 mg magnetic 
streptavidin beads, pre-blocked in PBS containing 
5% non-fat dried milk powder and 1% BSA, for 
one hour. Beads were magnetically separated from 
the solution and discarded, while the solution 
containing the remaining phages was transferred to 
a clean tube. Subsequently, phages were incubated 
with 1.5 µg biotinylated normal HeLa cytoplasmic 
cell extract for one hour, 1 mg pre-blocked magnetic 
streptavidin beads were added and the mixture was 
rotated for 15 minutes. Beads were magnetically 
harvested from the solution and washed several 
times with PBS containing 0.05% Tween-20 (PBST) 
and twice with PBS. Bound phages were eluted 
by incubating the washed beads in 1 ml trypsin 
(10 g/l in PBS, pH 7.4 and pre-warmed at 37oC) 
for 30 minutes at room temperature. Beads were 
harvested and discarded, whereas the solution 
containing the eluted phages was transferred to 
a clean tube and incubated with 1 ml of NBS for 
5 minutes to inhibit trypsin activity. Phages were 
amplified using trypsin sensitive helper phage and 
purified from the medium by polyethylene glycol 
(PEG) precipitation as described (45).
Polyclonal phage ELISA
Polyclonal phage pools of each round were 
screened in ELISA for reactivity with La and Ro52, 
and against BSA as a control. Antigens were coated 
on 96 wells maxisorb microtitre plates (NUNC) 
at a concentration of 0.1 µg per well in 100 µl 
50 mM NaHCO3 pH 9.3, overnight at 4oC. Plates 
were blocked with 400 µl MPBS, containing 0.05% 
Tween-20 (MPBST) per well at room temperature 
for two hours. Phages were diluted in MPBST at a 
concentration of 1011 cfu/ml, and 100 µl was added 
at room temperature for one hour. The plates were 
washed eight times with PBST, and subsequently 
HRP-conjugated anti-M13 monoclonal antibody 
(mAb) (Pharmacia) was added at a 5,000-fold 
dilution in MPBST at room temperature for one 
hour. Plates were washed eight times with PBST and 
twice with PBS. Bound HRP-conjugated antibodies 
were detected by TMB conversion. Reactions were 
stopped with 1 M H2SO4 and the absorbance at 
450 nm was measured.
Subtractive selection against biotinylated 
apoptotic cell extract
Libraries of RA, SLE and SSc patients were equally 
mixed and used for selection. All panning steps were 
performed using an end-over-end rotator at room 
temperature. First, the phages were incubated with 
1 mg magnetic streptavidin beads, pre-blocked with 
protease inhibitor cocktail (Roche)).  After cell 
lysis, extracts were centrifuged at 12,000g and 4oC 
for 30 minutes, and clear lysates were stored at 
–70oC. Three mg cell extract (soluble proteins) was 
biotinylated with 150 µg NHS-LC-biotin (Pierce) 
in 50 mM NaHCO3 pH 8.3, and dialyzed against 
0.5 mM DTE and 20% glycerol in PBS. The protein 
concentration of the biotinylated cell extract was 
measured using a bicinchoninic acid (BCA) protein 
assay (Pierce) with bovine serum albumin BSA as a 
standard, and the amount of magnetic streptavidin 
beads (DYNAL Biotech) needed to completely 
capture a given amount of biotinylated cell extract 
was established empirically.
Protein electrophoresis and immunoblotting
Proteins were separated by one- or two-
dimensional electrophoresis. For isoelectric 
focusing immobilized pH gradient strips were 
used (Pharmacia). Proteins were stained with 
colloïdal Coomassie (SERVA) or by silver staining. 
Alternatively, proteins were transferred to a 
nitrocellulose (Schleicher&Schuell) or polyvinylidene 
fluoride (PVDF; Millipore) membrane by 
electroblotting. For immunoblotting, all incubation 
steps were carried out at room temperature on a 
shaking table. Blocking solutions consisted of PBS, 
0.05% Tween-20, and either 5% non-fat dried milk 
powder, or 1% gelatine. Gelatine was only applied 
when phages were used for detection. ScFv were 
isolated from E.coli periplasm (43), and used at a 
5- to 100-fold dilution. Bound scFv were detected 
using a mouse anti-VSV-G monoclonal antibody, 
in combination with horseradish peroxidase (HRP)-
labelled rabbit anti-mouse antibodies followed by 
enhanced chemiluminescence (ECL). Phages were 
incubated with the membrane at a concentration of 
1011 colony forming units (cfu)/ml. After extensive 
Cell lines, induction of cell death and preparation 
of cell extracts
Jurkat (human T cell leukemia) suspension 
cells were grown in RPMI 1640 medium (Gibco-
BRL), supplemented with 1 mM sodium pyruvate, 
1 mM penicillin, 1 mM streptomycin and 10% heat-
inactivated fetal calf serum (FCS; Gibco-BRL), in 
a humidified 37oC incubator containing 5% CO2. 
Jurkat cells were maintained at a concentration of 
1x106 cells/ml. HeLa cells were either purchased 
from Computer Cell Culture Centre (Mons, 
Belgium), or HeLa suspension cells were grown in 
S-MEM medium with Joklik modification (Oxoid), 
supplemented with non-essential amino acids 
(Gibco-BRL), 5% newborn serum (NBS, Gibco-
BRL), 2 mM L-glutamine (Gibco-BRL), 1 mM 
penicillin and 1 mM streptomycin. Apoptosis was 
induced in Jurkat and HeLa cells by addition of 
10 µg/ml anisomycin. Eight hours after induction, 
cells were harvested by centrifugation at 800g for 5 
minutes and washed with PBS. Prior to the washing 
procedure, HeLa cells attached to the culture flask 
were scraped in PBS and pooled with the HeLa 
cells that are released from the flask into the 
culture medium due to the apoptotic process. Non-
apoptotic HeLa cytoplasmic extract was prepared 
as described (42). Cell extracts were prepared by 
three different methods: i) cells were resuspended 
in PBS and lysed by freezing-thawing, ii) cells were 
resuspended in lysis buffer (50 mM Tris-HCl pH 7.6, 
100 mM KCl, 0.05% Nonidet-P40 (NP40), 1 mM 
EDTA, and 1 mM dithioerythritol (DTE)) and lysed 
by sonication, or iii) cells were resuspended in NP40 
lysis buffer (25 mM Tris-HCl pH 7.6, 100 mM KCl, 
1% NP40, 10 mM MgCl2, 0.25 mM DTE) and lysed 
on ice for 30 minutes. Cell lysates were prepared, at 
a concentration of 0.5 – 1 x 108 cells/ml, on ice, and 
in the presence of protease inhibitors (CompleteTM 
    Chapter 468 Target discovery by antibody phage display 69
extracts. Phages were detected with HRP-labelled 
anti-M13 monoclonal antibody as described above. 
Several phages recognized proteins that were 
differentially present between non-apoptotic and 
apoptotic cell extracts. Three clones were chosen for 
further analysis, and their cDNAs were sequenced as 
described (46).
Immunoaffinity purification and identification 
of target antigens
ScFvs were C-terminally tagged with a 6xHis-
tag by cloning the cDNA in a pUC119 vector (45) via 
compatible NcoI and NotI digestion. Recombinant 
scFv antibody fragments were isolated from 80 ml 
E.coli periplasm as previously described (43) and 
dialyzed against p-IPP500 buffer (50 mM phosphate 
buffer, pH 8.0, 500 mM NaCl). All steps were 
performed at 4oC using an end-over-end rotator. 
The scFv solution was incubated with 50 µl Ni-NTA 
agarose beads (50% slurry, QIAGEN) for 2 hours. 
Subsequently, beads were washed three times with 
15 ml IPP500 and three times with 15 ml p-IPP150 
(50 mM phosphate buffer, pH 8.0, 150 mM NaCl). 
Beads were incubated with cell extract of 5x107 
cells, prepared by sonication, at a concentration of 
5x107 cells/ml for 2 hours. Beads were washed three 
times with p-IPP150. To remove non-specifically 
bound proteins, beads were incubated with 10 ml 
5 mM imidazole for 10 minutes and the supernatant 
was discarded. Beads were transferred to a clean 
tube and incubated with 30 µl 100 mM TEA for 
10 minutes. The supernatant was transferred to 
a clean tube, and elution was repeated with 30 µl 
100 mM TEA. The supernatant was pooled with 
the first supernatant and neutralized with 20 µl 
1M Tris-HCl pH 7.4. The proteins were concentrated 
by acetone precipitation and separated on a poly-
acrylamide gel. The gel was stained with colloïdal 
Coomassie (SERVA). Protein bands were cut out, 
and digested in-gel with trypsin. Peptides were 
then eluted from the gel slice and subjected to 
matrix-assisted desorption/ionization time-of-flight 
(MALDI-ToF) mass spectrometric analysis.
Immunofluorescence
HeLa cells were grown directly on glass 
slides. Cells were fixed using methanol/acetone 
or p-formaldehyde (47). ScFvs were purified and 
concentrated from periplasmic fractions using the 
6x-His-tag, as described (24), and incubated with 
the cells. Bound scFvs were detected via their VSV-
G-tag using anti-VSV-G mouse monoclonal antibody, 
(500-fold diluted in PBS) followed by FITC-labelled 
rabbit anti-mouse antibody (DAKO; 50-fold diluted 
in PBS). Finally, cells were embedded in Mowiol and 
analyzed using a fluorescence microscope.
U1 snRNP immunoprecipitation
All incubations were performed in t-IPP150 
(10 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.1% 
NP40) at 4oC using an end-over-end rotator. 
Between incubations, beads were washed three 
times with t-IPP150. Protein A-agarose beads 
(20 µl of 50% slurry, Kem-En-Tec) were pre-coated 
with 12.5 µl rabbit anti-mouse IgG (Dako) for 
2 hours and subsequently coated with 50 µl mouse 
anti-VSV-G mAb for 2 hours. Then, beads were 
incubated with 5 ml concentrated solution of VSV-
G-tagged recombinant scFv antibody fragments, 
isolated from E.coli periplasm as described 
above. Finally, beads were incubated with 60 µl of 
1x108 cells/ml Jurkat apoptotic or non-apoptotic 
cell extract, prepared by lysis in NP40 lysis buffer 
as described above, for 2 hours. Mouse mAb 2.73, 
directed against U1-70K protein was used as a 
positive control. Anti-BSA scFv, previously selected 
5% non-fat dried milk powder and 1% BSA in PBS, 
for one hour. Beads were magnetically separated 
from the solution and discarded, while the solution 
containing the remaining phages was transferred to 
a clean tube. To subtract phages recognizing normal 
cell extract components, phages were incubated with 
1.5 µg biotinylated non-apoptotic HeLa cytoplasmic 
cell extract for one hour, 1 mg pre-blocked magnetic 
streptavidin beads were added and the mixture was 
rotated for 15 minutes. Beads were harvested and 
discarded, and the remaining phage solution was 
transferred to a clean tube. This subtraction step 
was repeated with another 1.5 µg of biotinylated 
non-apoptotic HeLa cytoplasmic cell extract and 
1 mg pre-blocked beads. Remaining phages were 
again transferred to a clean tube. Subsequently, 
phages specifically recognizing apoptotic cell extract 
components were selected by panning against 
1.5 µg biotinylated apoptotic HeLa cell extract for 
one hour. 1 mg pre-blocked magnetic streptavidin 
beads were added and the mixture was rotated for 
15 minutes. Beads were harvested, washed several 
times with PBST and twice with PBS, and bound 
phages were eluted by incubating the beads in 1 ml 
trypsin (10 mg/ml in PBS, pH 7.4) for 30 minutes. 
Beads were discarded and eluted phages were 
incubated with 1 ml NBS, and immediately used to 
infect exponentially growing E.coli TG1. Phages were 
then amplified and purified as described above.
Selection of enriched phage populations on 
2D western blots
After three subtractive selection rounds on 
biotinylated apoptotic cell extract as described 
above, polyclonal phage pools of each round were 
analyzed on western blots of two-dimensional gels 
containing apoptotic and non-apoptotic cell extracts, 
as described above. The phage stock from the third 
round showed highest signals and most differences 
between apoptotic and non-apoptotic extracts. 
To specifically select phages recognizing a protein 
spot that was differentially recognized in apoptotic 
versus non-apoptotic cell extracts, western blot 
membranes of two-dimensional gels were incubated 
with the phage stock from the third selection round 
as described above. Directly after visualization of 
bound phages, the membrane was covered with PBS 
and membrane spots of interest were accurately 
excised, using a clean razor blade for each spot. 
TMB staining resulted in a blue precipitate on the 
membrane, allowing highly accurate excision of 
spots. For ECL detection, the film was placed on a 
light box and exactly overlaid with the membrane. 
Bound phages were eluted from the excised spots by 
incubating the blot piece in 100 mM triethylamine 
(TEA), transferred to a clean tube and neutralized 
with 1 M Tris-HCl pH 7.4. The eluted phages were 
subsequently treated with trypsin, as described 
above, to reduce background. Finally, phages were 
used to infect exponentially growing E.coli TG1 and 
plated on square (12 cm x 12 cm) 2xTY agar plates 
containing 100 µg/ml ampicillin and 2% glucose.
Screening of single colonies
Single colonies were analyzed for VSV-
G-expression by a dot blot assay, and for full 
length DNA by PCR, using primers LMB3 
(CAGGAAACAGCTATGACCATG) and FdSeq1 
(GTAACGATCTAAAGTTTTGTCG). Full-length clo-
nes with good expression levels were fingerprinted 
with the restriction enzyme BstNI. From all unique 
finger print clones with good expression, phages 
were produced in 2 ml-deepwell microtiter plates. 
Undiluted culture supernatants, containing phage, 
were screened on western blots of SDS-PAGE 
gels containing non-apoptotic and apoptotic cell 
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from an SLE patient library (unpublished results), 
was used as a negative control. Finally, beads 
were resuspended in 100 µl t-IPP150, containing 
0.5% SDS, and co-immunoprecipitated RNA was 
isolated by addition of TRIzol reagent (Gibco-BRL) 
according to the manufacturer’s protocol. Isolated 
RNA was subsequently size-fractionated on 6% 
polyacrylamide/8M urea gels and transferred to a 
nylon membrane (HybondTM-N, GE Healthcare) 
by northern blotting. Finally, U1 RNA was detected 
using a 32P-labelled U1 RNA specific anti-sense 
probe and analyzed by autoradiography. The 
signals were quantified using a ScanMaker 8700 
(MICROTEK). The U1 snRNA was isolated from the 
apoptotic and non-apoptotic Jurkat cells as well, and 
size-fractionated on the same gel (10% of the input 
material).
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A hallmark of systemic autoimmune diseases is the presence of high titers of serum autoantibodies targeting a diversity of autoantigens. Most components 
of the U1 snRNP complex are autoantigenic in systemic lupus erythematosus and 
systemic lupus erythematosus overlap syndrome, which is also called mixed 
connective tissue disease. It is hypothesized that posttranslational modifications, 
in particular cell death-specific modifications, play an important role in breaking 
tolerance to self-antigens. Recently, it became clear that the U1 snRNP particle, 
more specifically its U1-70K protein component, displays a new epitope during 
apoptosis. This chapter intends to give an overview of the modifications that 
occur on the U1 snRNP autoantigens, especially those arising during cell death, 
as an introduction to cell death-specific epitopes on autoantigens.
The U1 snRNP particle
Pre-mRNA splicing, the removal of non-
coding introns from mRNA precursors to 
obtain functional mRNA, which then serves as 
a template for protein synthesis, is one of the 
many essential processes in the eukaryotic cell. 
The main player in splicing is the spliceosome, 
a complex macromolecular machinery that 
consists of several uridine-rich small nuclear 
ribonucleoproteins (U snRNPs), and many 
non-RNP splicing factors (1). An important 
constituent of the spliceosome is the U1 snRNP 
particle, which is the first of the U snRNPs to 
bind to the pre-mRNA (1). It associates with 
the 5’-splice site through base pairing of the 
single-stranded 5’ terminal sequence element 
of the U1 snRNA molecule with conserved 
residues at the 5’ splice site of the pre-mRNA, 
which subsequently leads to functional pairing 
of the intronic 5’ and 3’ splice sites (2). 
Additionally, the U1 snRNP has been reported 
to be involved in the regulation of poly(A) tail 
synthesis (3). The U1 snRNP complex consists 
of the 165 nucleotide U1 snRNA molecule, the 
U1-specific proteins U1A, U1C, and U1-70K, 
and a doughnut-shaped structure consisting 
of seven proteins, called Sm proteins (B/B’, 
D1, D2, D3, E, F and G), which are core 
components contained in all U snRNPs (U1, 
U2, U4/U6 and U5) (4). Recently, the structure 
of the U1 snRNP complex has been determined 
by cryo-electron microscopy (2). It is believed 
that the seven relatively small Sm proteins 
form a core with the snRNA, and that the 
larger U1 snRNP-specific proteins determine 
the specific structure of the snRNP particle. 
The U1 snRNP autoantigen
Originally, autoreactivity in patient sera 
against the U1 snRNP particle was termed anti-
RNP. This reactivity was found to be related 
though not identical to anti-Sm reactivity (5). 
The elucidation of the molecular composition 
of the U snRNPs clarified that anti-RNP sera 
contained autoantibodies targeting at least 
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Different isoforms of U1 
snRNP components
The molecular diversity of the products from 
a single gene can be generated in different ways. 
A major mechanism leading to the synthesis 
of different isoforms in higher eukaryotes is 
alternative splicing of pre-mRNAs. Another 
important process that increases the molecular 
heterogeneity of products from a single gene 
is posttranslational modification. The relative 
expression levels of different protein isoforms 
may differ between different cell types and / or 
tissues and may also be affected by the state of 
the cell (e.g. phase of the cell cycle). Most of the 
current knowledge on the different isoforms of 
U1 snRNP components has been obtained by 
the analysis of material from cultured cell lines.
Isoforms of the U1-70K protein
Database analysis revealed that at least 
four alternative splice variants of the U1-70K 
protein exist in humans. Isoforms 1 and 2 differ 
only by the presence or absence of 9 amino 
acids in the centre of the sequence (aa 223-231 
in isoform 1) as a result of an alternative splice 
site. Experimental evidence to support the 
physiological relevance of isoform 3 (containing 
the N-terminal 159 amino acids of isoform 1 
and 7 other amino acids at its C-terminus) and 
isoform 4 (in which the N-terminal 159 amino 
acids of isoform 1 are replaced by 63 other 
amino acids) is still very poor.
In 1990, Woppmann et al. analyzed human 
snRNP particles isolated from HeLa cells 
by two-dimensional gel electrophoresis and 
observed at least thirteen U1-70K isoforms 
in a pI range of 6.7 to 8.8 (19). It was shown 
that the U1-70K variants have four major 
phosphopeptides in common, suggesting that 
U1-70K is constitutively phosphorylated at four 
serine residues. Additionally, they found three 
other serine residues that were differentially 
phosphorylated in the various U1-70K isoforms. 
However, phosphorylation alone could not 
explain the existence of so many isoforms, and 
it was proposed that other (yet unidentified) 
posttranslational modifications are present in 
U1-70K as well (19). Recently, Monneaux et al. 
demonstrated the importance for antigenicity 
of phosphorylation on a specific serine residue 
of U1-70K in MRL/lpr mice (lupus-prone 
mice) (20). Previously these investigators 
identified an epitope at residues 131 – 150 
of the U1-70K protein that was recognized 
by antibodies as well as CD4+ T cells in two 
strains of lupus mice (21). They subsequently 
synthesized two peptides, one with a phosphate 
group on serine residue 137, and one with a 
phosphate group on serine residue 140. It was 
demonstrated that the peptide with Ser140P, but 
not the peptide with Ser137P, was recognized by 
antibodies and CD4+ T cells from MRL/lrp 
mice. Interestingly, the Ser140P peptide, when 
administered intravenously in saline solution, 
appeared to significantly decrease both 
proteinuria and the production of anti-DNA 
antibodies in MRL/lpr mice. Furthermore, 
9 out of 15 lupus patients reacted with the 
non-phosphorylated peptide, whereas 12 of the 
same 15 lupus patients recognized the peptide 
with phosphorylated Ser140P (20), indicating 
that this phosphorylation site is important for 
autoantibody recognition as well, and might 
play a role in the autoimmune response to 
U1-70K. 
one of the U1 snRNP-specific proteins U1A, 
U1C and U1-70K, whereas anti-Sm sera are 
directed to at least one of the Sm proteins 
and as a consequence are directed to the other 
U snRNPs in addition to the U1 snRNP (6). 
Anti-RNP sera may also contain autoantibodies 
directed to the RNA component of this particle, 
the U1 snRNA (7). Later, it was demonstrated 
that some patient sera contain autoreactivity 
to both the U1 and the U2 snRNPs, but not 
to the other U snRNPs. These autoantibodies 
appeared to be directed to epitopes shared by 
the structurally related U1A and U2B” proteins 
(8). 
Autoantibodies targeting the U1A, U1C and 
U1-70K proteins and the U1 snRNA molecule 
are mainly found in patients suffering from 
systemic lupus erythematosus (SLE) overlap 
syndrome, whereas autoantibodies directed 
to Sm-D, Sm-B/B’, and the E-F-G complex are 
more specifically associated with SLE (9,10).
Hypothesis of cell death-specific epitopes 
involved in breaking tolerance to self-
antigens
The autoimmune response is a complex 
process, of which the underlying molecular 
mechanisms are still only poorly understood, 
and in which (a combination of) genetic, 
hormonal and environmental factors are 
believed to be involved. For the autoimmune 
response to Sm-B/B’ the molecular mimicry 
model, in which it is hypothesized that 
for example a viral infection can elicit an 
immune response to self-antigens through 
cross-reactivity with a viral epitope, is favored 
(11,12). This model is illustrated by the fact 
that the Sm-B/B’ protein contains a three-fold 
repeat of a proline rich sequence element, 
which constitutes a major Sm epitope in anti-
Sm sera, and which is similar to a proline 
rich sequence found in the Epstein-Barr 
virus nuclear antigen 1 (EBNA-1). Another 
model, which is increasingly supported by 
experimental data obtained during the last 
decade, hypothesizes as mentioned before that 
uncommon posttranslational modifications 
play an important role in breaking tolerance 
to (certain) self-antigens (11,13,14). In this 
context, dying cells represent an interesting 
source of modified antigens. During apoptosis 
and necrosis many known autoantigens 
are modified, as for example by proteolytic 
cleavage, by hyper- or dephosphorylation, 
and by citrullination (11,13-15). Also oxidative 
fragmentation of proteins has been put forward 
as a cause of autoantigen modification (16,17). 
It is believed that such modified autoantigens 
reveal novel ‘cryptic’ epitopes that trigger 
the primary immune response, which is 
subsequently followed by the generation of 
autoreactivity to other, non-modification-
dependent epitopes by epitope spreading. In 
this process, the secondary immune responses 
may spread intramolecularly, but also 
intermolecularly to stably associated proteins 
(18). The recent data on the immune responses 
to the U1 snRNP particle and in particular the 
studies performed on the U1-70K protein, 
which will be discussed here, strongly support 
this theory. Figure 1 depicts the U1 snRNP 
particle and summarizes the modifications of 
its individual components.
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(sDMAs) in normal cells (23). The sDMA-
modified C-terminus of Sm-D1 was shown to 
constitute a major linear epitope for anti-Sm 
autoantibodies, which suggested that also 
non-apoptotic posttranslational modifications 
of Sm proteins may play a role in the aetiology 
of autoantibody formation in SLE (23). For the 
relatively small Sm proteins, E, F and G, so far 
no variants have been reported.
Cell death-associated 
modifications of the U1 snRNP
Apoptotic modifications of U1 snRNP 
components have been studied extensively, 
and modifications occurring during cell 
death have been identified and characterized 
for the U1 snRNA molecule, and for the 
U1-70K and Sm-F proteins. Additionally, 
hyperphosphorylated splicing factors associate 
with the U1 snRNP particle during apoptosis. 
To date, no apoptotic or necrotic modifications 
of the autoantigenic proteins U1A, U1C, and 
the other Sm proteins have been reported.
Apoptotic cleavage of U1 snRNA
The U1 snRNA molecule is modified during 
apoptosis by the specific removal of 5 or 6 
nucleotides from the 5’ end, which includes the 
2,2,7-trimethylguanosine cap (24). Recently, 
Hoffman et al. revealed that the U1 snRNA 
molecule was able to stimulate the toll-like 
receptor 3 (TLR-3) at similar efficiencies as 
the known TLR-3 agonist poly(IC) (25). This 
results in the secretion of type 1 interferons, 
and these molecules have been associated 
with the development of autoimttmunity. The 
results of this study suggest that the U1 snRNA 
molecule itself is capable to elicit an immune 
response (25). Interestingly, anti-U1 snRNA 
autoantibody levels have been described to 
correlate with disease activity in patients 
suffering from SLE overlap syndrome and are 
believed to have predictive value for disease 
flares (26). It is currently unknown whether 
the apoptotic cleavage close to the 5’ end of the 
U1 snRNA affects its antigenicity.
Cleavage of the U1-70K protein during 
cell death
Since Casciola-Rosen et al. demonstrated 
in 1994 that the specific cleavage of the U1-70K 
protein early during apoptosis is a biochemical 
hallmark of apoptosis (27), U1-70K cleavage 
is often used as a marker for apoptosis. The 
U1-70K protein was found to be cleaved at 
the C-terminal side of D341 (338DGPD341) by 
caspase-3, resulting in an N-terminal 40 
kDa (aa 1-341) and a C-terminal 22 kDa (aa 
342-437) protein fragment (28). Degen et 
al. demonstrated that the U1-70K protein is 
cleaved while it is associated with the intact 
U1 snRNP particle in apoptotic cells, and 
that the N-terminal 40 kDa fragment remains 
associated with the U1 snRNP complex (24). 
In addition, Casciola-Rosen et al. observed 
that during apoptosis, autoantigens become 
clustered in two distinct populations of blebs 
at the cell surface (29). Using affinity-purified 
anti-U1-70K antibodies, it was revealed that 
U1-70K was localized in the nucleus early in 
the apoptotic process (stained as a rim around 
the condensed nucleus), and that U1-70K 
epitopes accumulated in the apoptotic bodies 
in the later phases of apoptosis (29). It is 
Isoforms of the U1A and U1C protein
Except for the removal of the N-terminal 
methionine and subsequent acetylation 
of the N-terminus, no heterogeneity has 
been reported for the U1A protein. Also the 
U1C protein does not seem to be expressed 
in various isoforms, although there are 
some indications that this protein may be 
posttranslationally modified based upon its 
electrophoretic behavior in SDS-PAGE gels 
(22).
Isoforms of the Sm proteins
Sm-B and Sm-B’ are produced from 
the same gene by alternative splicing 
and as a result they contain slightly 
different sequences at their C-termini. The 
Sm-D1, -D2 and -D3 proteins are each encoded 
by a distinct gene, although their sequences do 
share similarities. It has been demonstrated 
that the C-terminal arginine-glycine (RG) 
repeats of the human Sm-D1, Sm-D3 and 
Sm-B/B’ contain symmetric dimethylarginines 
Figure 1. Schematic representation of the U1 snRNP molecule. The secondary structure of the U1 snRNA 
molecule with the associated ring of Sm proteins, and the U1-specific proteins U1-70K, U1A and U1C are shown. 
RNA nucleotides are numbered. Modifications occurring on the U1 snRNP particle are outlined for each component 
in boxes. These modifications include alternative splicing and posttranslational modifications, which occur in normal 
cells and lead to different isoforms of the protein, and modifications that arise during different types of cell death. The 
apparent molecular masses of fragments resulting from cleavage (kDa) and the enzyme(s) responsible for the generation 
of these fragments are listed. The association of phosphorylated SR proteins with the U1 snRNP during apoptosis is not 
illustrated in this figure.
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The immune response to the 
U1 snRNP
In 2001, it was shown that the appearance 
of autoantibodies to components of the 
U1 snRNP particle follows a characteristic 
order, with U1-70K and Sm-B/B’ as 
important early immunogens (35). At the 
start of this study, a large cohort of patients 
was analyzed, on clinical grounds, for the 
presence of autoantibodies to RNP proteins. 
The presence of such antibodies was 
detected using immunoblots of Jurkat lysates 
containing the U1 polypeptides. Within this 
panel, 109 patients did not have detectable 
levels of autoantibodies directed to any of the 
U1 snRNP polypeptides in the first serum 
sample. However, these patients developed 
such anti-RNP autoantibodies in time (this 
patient group was defined as ‘monospecific 
seroconverters’). An additional group of 54 
patients was selected, consisting of patients 
that initially tested negative for autoantibodies 
to at least one of the RNP polypeptides, and 
subsequently developed autoantibodies to this 
polypeptide (so-called ‘late seroconverters’). 
Subsequently, serial serum samples of these 
patients were tested for the presence and first 
appearance of autoantibodies to the individual 
U1 polypeptides on immunoblot. It was 
observed that autoantibodies to the U1-70K and 
Sm-B/B’ proteins more frequently appeared 
early in the anti-RNP response than antibodies 
to other U1 snRNP polypeptides. Moreover, it 
was demonstrated that autoantibodies directed 
to U1A and U1C in general developed after the 
appearance of other anti-RNP autoantibodies, 
and that autoantibodies targeting Sm-D 
were detected only after the appearance of 
several autoantibodies to other U1 snRNP 
polypeptides. Autoantibodies directed to the 
U1 snRNA molecule were not included in 
this study. The finding that U1-70K is a major 
early immunogen, taken together with the fact 
that U1-70K is modified during apoptosis, is 
consistent with the hypothesis that apoptotic 
modifications on U1-70K protein might 
be important for triggering of the immune 
response to the U1 snRNP particle (35).
An apoptosis-specific epitope on the U1-70K 
protein
In 2000, Degen et al. isolated a panel 
of monoclonal recombinant autoantibodies 
directed to U1-70K from phage display 
libraries derived from SLE patients. 
Interestingly, several of these single chain 
variable fragments preferentially recognized 
apoptotic U1-70K (i.e. the 40 kDa fragment) on 
immunoblot (36). This not only indicated that 
the apoptotically cleaved U1-70K polypeptide 
contains an epitope that is not exposed by the 
full-length protein, but also suggested that 
autoimmune patients may produce antibodies 
that specifically target this epitope. The 
existence of such autoantibodies in patient 
sera was substantiated by the observation that 
a subgroup of SLE patients displays increased 
reactivity with caspase-cleaved U1-70K in 
comparison with oxidatively fragmented 
U1-70K (17). More recently, Greidinger et al. 
confirmed the presence of autoantibodies to 
caspase-cleaved U1-70K by screening a cohort 
of anti-RNP positive sera by immunoblotting 
for the occurrence of autoantibodies recogni-
zing apoptotic U1-70K in the presence of 
thought that the translocation of autoantigens 
to the fragile apoptotic vesicles enhances the 
chance that they are exposed to the immune 
system. 
The fate of the U1-70K protein during 
other forms of cell death has been studied 
as well. The U1-70K protein appeared to be 
degraded into untraceable fragments during 
primary (mercury-induced) necrosis (30) and 
secondary necrosis (prolonged exposure to an 
apoptosis-inducing agent such as etoposide) 
(15). During CTL-induced apoptosis, the 
U1-70K protein is cleaved by granzyme B 
into a 60 kDa fragment (31). Furthermore, 
the U1-70K protein can be fragmented by 
metal-catalyzed oxidation, which generates 
several fragments between 33 and 38 kDa (16). 
Interestingly, Greidinger et al. showed that 
the preferential recognition of apoptotically 
and oxidatively modified forms of the 
U1-70K autoantigen was associated with 
distinct clinical rheumatic disease manifesta-
tions (17). SLE patients with lupus skin 
disease showed increased reactivity with 
caspase-cleaved U1-70K, whereas sera from 
SLE patients with Raynaud’s phenomenon 
preferentially reacted with oxidatively modi-
fied U1-70K.
Cleavage of the Sm-F protein during 
apoptosis
Anti-Sm autoantibodies are almost 
exclusively found in SLE patients (4), and the 
fate of the Sm proteins during cell death has 
therefore been studied extensively. The only 
modification occurring on the Sm proteins 
during cell death that has been identified 
so far is the apoptotic cleavage of the Sm-F 
protein (32), a component of the autoantigenic 
E-F-G complex. Cleavage of the 11 kDa 
Sm-F protein results in a 9 kDa apoptotic 
fragment that remains associated with the 
U snRNP complexes in apoptotic cells (32). 
This finding suggests a possible role for the 
apoptotic modification of the Sm-F protein in 
triggering the autoimmune response against 
the Sm proteins, and consequently anti-Sm 
autoantibody formation in patients.
Association of phosphorylated splicing 
factors with the U1 snRNP during apoptosis
In 1998, Utz et al. noticed that 
phosphorylated serine/arginine (SR) splicing 
factors specifically associated with the 
U1 snRNP particle during apoptosis (33). It was 
shown that monospecific sera and monoclonal 
antibodies recognizing the U1 snRNP com-
plex specifically immunoprecipitated a 
phosphoprotein complex from apoptotic 
32P-labelled Jurkat cell lysates. The phospho-
protein complex appeared to consist of the 
four proteins pp54, pp42, pp34, and pp23. 
In 2000, Neugebauer et al. analyzed a 
cohort of autoimmune patients by ELISA for 
reactivity with phosphorylated SR proteins, 
purified from HeLa cells, and showed that 
SR proteins are targets of autoantibodies 
in approximately 50% of patients suffering 
from SLE (34). Interestingly, they showed 
that sera containing high reactivities against 
SR proteins were only weakly reactive 
with dsDNA, and vice versa. Furthermore, 
it was tested whether phosphorylation 
directly influenced the recognition of the SR 
proteins by autoantibodies. Remarkably, some 
patient sera showed decreased reactivity with 
dephosphorylated SR proteins, whereas other 
patient sera displayed the opposite behaviour (34).
    Chapter 586 Introduction to cell death-specific epitopes 87
Concluding remarks
As described above and summarized in 
Figure 1, a number of posttranslational and 
cell death-associated modifications occur 
on components of the U1 snRNP particle. 
One of the remaining questions is why, upon 
exposure of apoptotically modified U1 snRNP 
to the immune system, some patients develop 
antibodies to Sm-F (and the E-F-G complex), 
whereas other patients generate an immune 
response to U1-70K (and subsequently U1A 
and U1C).
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soluble U1-70K to block other autoantibodies 
to this protein. It was shown that 15 of 29 sera 
with antibodies directed to U1-70K contained 
apoptosis-specific anti-U1-70K antibodies. In 
addition, antibodies to apoptotic U1-70K were 
found in 2 of 25 sera without detectable levels 
of anti-U1-70K antibodies (37). This finding 
was recently confirmed by a study performed 
in our laboratory. We analyzed a cohort of 
patients suffering from SLE overlap syndrome, 
SLE and non-SLE autoimmune diseases (such 
as rheumatoid arthritis or systemic sclerosis) 
for the presence of antibodies to apoptotic and 
intact U1-70K protein by immunoblotting. 
We showed that the majority of patients 
suffering from SLE overlap syndrome (54%) 
had higher reactivities to apoptotic U1-70K 
than to intact U1-70K, whereas in only a few 
patients intact U1-70K was more efficiently 
recognized than apoptotic U1-70K (38). In the 
same study, a longitudinal analysis of twelve 
anti-RNP positive patients demonstrated 
that several early sera are relatively enriched 
for autoantibodies recognizing an apoptosis-
specific epitope on U1-70K (38), supporting 
the hypothesis that apoptotic U1-70K is 
involved in the triggering of the primary 
immune response to the U1-70K protein and 
the U1 snRNP particle.
Repeatedly, it has been hypothesized 
that novel ‘cryptic’ epitopes might be created 
due to posttranslational modifications, 
but only recently such an epitope has been 
characterized for the first time. Greidinger et 
al. demonstrated that the apoptotic U1-70K 
protein displays a B-cell epitope that is not 
found on the intact protein, the formation of 
which is dependent on residues 180 – 205 (39). 
In this study, seven patient sera were used 
that recognized apoptotic U1-70K much more 
efficiently than the intact form. These sera 
were analyzed for reactivity with recombinant, 
C-terminally truncated U1-70K mutants 
on immunoblot and in ELISA. All seven 
sera strongly recognized the apoptotic form 
consisting of aa 1 – 341 (the caspase-3 cleavage 
site is positioned between aa 341 and 342), as 
well as C-terminally truncated forms down to 
aa 205. Five of the seven sera did not recognize 
a further C-terminally truncated form consis-
ting of aa 1 – 180, and none of the seven sera 
recognized a C-terminally truncated form of 
aa 1 – 150. None of the sera reacted with a 
synthetic peptide comprising aa 180 – 205 in 
ELISA. Additionally, this 25-mer was neither 
able to block recognition of the 1 – 205 mutant 
in ELISA, nor to block recognition of apoptotic 
U1-70K in immunoblotting. The apoptosis-
specific epitope is therefore believed to be 
dependent on conformational constraints, and 
it is thought that the presence of other residues 
than those between 180 and 205 contributes to 
the formation of the epitope (39). Interestingly, 
the apoptosis-specific epitope on the U1-70K 
protein appeared to overlap partially with the 
most common T-cell epitope, within residues 
92 – 202, which is located in the RNA binding 
domain (RBD) (40). In the same study, human 
leukocyte antigen (HLA)-DR4 transgenic 
mouse strain of C57BL/6 was immunized 
with the recombinant 1 – 205 polypeptide. 
This resulted in the production of antibodies 
targeting the apoptotic form of U1-70K by 13 
out of 15 mice. Ten of these mice also reacted 
with intact U1-70K protein.
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Modifications occurring on autoantigens during cell death have been hypo-thesized to play a role in the initiation of autoimmune diseases. Patients 
suffering from mixed connective tissue disease produce autoantibodies directed 
to U1 snRNP, and antibodies against a 70 kDa protein component, the U1-70K 
protein, are the most prominent. During apoptosis, U1-70K is cleaved by 
caspase-3 to a 40 kDa product, which remains associated with the complex. 
Autoantibodies preferentially recognizing the apoptotic form of U1-70K have 
been described previously, and an apoptosis-specific epitope on U1-70K has 
been identified. This study shows that 29 of 53 (54%) mixed connective tissue 
disease sera preferentially recognize the apoptotic form of U1-70K over intact 
U1-70K. Moreover, we show that antibodies directed to an apoptosis-specific 
epitope on U1-70K are more specifically associated with MCTD than other anti-
U1-70K antibodies, suggesting that apoptotic U1-70K is a better antigen for the 
detection of these antibodies in MCTD patients. Longitudinal analysis of twelve 
MCTD patients demonstrated in several patients that early sera are relatively 
enriched with antibodies recognizing an apoptosis-specific epitope, and that the 
levels of these apoptosis-specific antibodies decrease in time. These findings indi-
cate that the early detection of apoptotic U1-70K is of considerable interest for 
anti-U1 snRNP positive patients. 
Introduction
Patients suffering from autoimmune 
diseases are characterized by the presence 
of autoantibodies directed to a wide range 
of autoantigens. Mixed connective tissue 
disease (MCTD) is a relatively rare systemic 
autoimmune disease, and includes a group of 
patients with overlapping clinical symptoms of 
systemic lupus erythematosus (SLE), systemic 
sclerosis (SSc), rheumatoid arthritis (RA) 
and polymyositis/dermatomyositis (PM/
DM). Sharp et al. were the first to describe 
MCTD as a distinct rheumatic disease (1), but 
whether MCTD can be regarded as a distinct 
disorder has been subject of discussion (2). 
A characteristic serological feature that dis-
tinguishes MCTD patients from patients with 
other connective tissue diseases are high levels 
of autoantibodies directed against the U1 small 
nuclear ribonucleoprotein (snRNP) particle 
(1,3). The U1 snRNP is a highly conserved 
RNA-protein complex, located in the nucleus, 
where it is involved in the processing of pre-
mRNA (4,5). It consists of the U1 snRNA 
molecule and several proteins: the U1A, 
U1C and U1-70K proteins are components 
specific for the U1 snRNP, whereas the eight 
Sm proteins (B/B’, D1, D2, D3, E, F and G) 
are shared with other U snRNPs (6). Most 
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Results
In this study, patient sera were analyzed 
for the presence of autoantibodies against 
U1-70K (70K) and its apoptotic product 
(70Kapop), on western blots containing extracts 
of non-apoptotic and apoptotic Jurkat cells. 
Two positive controls for the detection of 70K 
and 70Kapop were included in each experiment: 
anti-U1-70K mouse monoclonal antibody 2.73 
(21), which displays higher reactivities with 
70K than with 70Kapop, and patient serum 
B16, which reacts with both 70K and 70Kapop. 
The position of 70Kapop on western blots was 
confirmed by a recombinant monoclonal 
antibody, recognizing both 70K and 70Kapop 
(Figure 1a) (22). The results demonstrate 
that in these apoptotic cells U1-70K is almost 
completely converted into 70Kapop.  Besides 
positive controls for 70K and 70Kapop, mouse 
monoclonal antibody ANA125 directed 
against Sm-B/B’ (Figure 1a), and anti-U1A/
U2-B” mouse monoclonal antibody 9A9 (not 
shown) were used as well. To be able to detect 
autoantibody reactivities to the intact U1-70K 
and its apoptotic 40K fragment simultaneously 
and to facilitate a direct comparison of these 
reactivities, a mixture of apoptotic and non-
apoptotic cell extracts was used to prepare 
western blots. An additional advantage of this 
approach was that inter-blot differences could 
be excluded, thereby allowing a more accurate 
comparison of reactivities with 70K and 70Kapop 
in a single patient serum. Serum antibody 
reactivities against 70K and 70K
apop
 were 
scored ranging from 0 to 5. Figure 1b shows a 
western blot containing such a mixture of non-
apoptotic and apoptotic Jurkat cell extracts, 
probed with a serial dilution of MCTD patient 
serum B16. It is shown that the signals for 70K 
and 70Kapop increase when the serum is applied 
at a lower dilution, indicating that the western 
blot assay can be used for semi-quantitative 
interpretation.
Autoantibodies against U1-70K are more 
easily detected using apoptotic U1-70K
The presence of high levels of auto-
antibodies directed against components of the 
U1 snRNP, such as 70K, is one of the criteria 
for the diagnosis of MCTD (2). However, 
anti-70K antibodies are also found in some 
SLE and SSc patients (3). To compare the 
disease-specificity of anti-70Kapop and anti-70K 
autoantibodies, sera from a group of MCTD 
patients and from a group of patients suffering 
from a variety of autoimmune disorders were 
analyzed. As shown in Table 1, we observed 
that the majority of MCTD patients (54%), 
displayed antibody reactivities preferentially 
recognizing the apoptotic form of U1-70K, 
compared to the intact U1-70K protein. Seven 
patients (13%) reacted with 70K and 70Kapop 
with similar efficiencies, and only 6% of the 
MCTD patients preferentially reacted with 
the intact 70K protein. Fourteen sera (27%) 
did not react detectably with either U1-70K 
polypeptide, although the sera were anti-
RNP positive by several techniques. These 
results indicate that apoptotic 70K is a better 
antigen for the detection of anti-U1-70K 
autoantibodies than the intact U1-70K protein. 
Antibody reactivity with 70Kapop was found in 
only 2% of sera from control groups, whereas 
antibody reactivity with 70K was found in 5% 
of patient sera from control groups.
U1 snRNP components are autoantigenic 
in MCTD and SLE. Autoantibodies directed 
against U1A, U1C, U1-70K and the U1 snRNA 
molecule are mainly found in MCTD patients, 
whereas autoantibodies targeting Sm-D, 
Sm-B/B’ and the E-F-G complex are more 
specifically associated with SLE (7,8).  
The mechanisms through which such 
auto-antigens, generally highly conserved 
and ubiquitously expressed molecules, 
escape tolerance and are recognized by 
the immune system as non-self remain 
unclear, but it is hypothesized that cell death 
plays an important role in the initiation of 
autoimmune responses (9,10). Recently, also 
secondary necrosis has been put forward as 
a source of proteolytically modified auto-
antigens (11), but the modifications that 
occur on autoantigens during apoptosis 
were studied most extensively. Apoptotic 
modifications on autoantigens include 
specific cleavage by caspases or granzyme 
B, (hyper)phosphorylation, dephosphoryla-
tion, citrullination, methylation and trans-
glutaminase cross-linking (10,12,13), and it 
is thought that these modifications might be 
seen by the immune system as novel ‘cryptic’ 
epitopes. It is believed that these novel 
epitopes induce the primary immune response, 
and that secondary immune responses and 
epitope spreading result in autoantibodies that 
are directed against unmodified regions of the 
autoantigens and antigens that are associated 
with the initially modified autoantigen (9).
One of the apoptotic modifications oc-
curring on the U1 snRNP is cleavage of 
U1-70K at residue 341 by caspase-3 (14,15). 
Antibodies against U1-70K are in general 
the first autoantibodies to appear in anti-
U1 snRNP (often referred to as anti-RNP) 
positive patients, indicating that U1-70K is 
important as an initial autoantigen (16). The 
molecular and immunological characteristics 
of the major apoptotic isoform of U1-70K, 
a 40 kDa cleavage product which remains 
associated with the U1 snRNP complex (17), 
and its role in the triggering of the primary and 
possibly secondary autoimmune response, are 
therefore intriguing. 
Recently it was shown that sera of some anti-
U1 snRNP positive patients contain antibodies 
that specifically bind to the apoptotic form of 
U1-70K, which displays an epitope that is not 
present on the intact form (18,19). This epitope 
is dependent on the region between amino 
acids 180 and 205, partially overlapping with 
the RNA binding domain and overlapping 
with the most common T-cell epitope (20). 
In this study we analyzed a cohort of MCTD 
and control patients for the presence of 
autoantibodies against intact and apoptotic 
U1-70K. Moreover, we longitudinally analyzed 
sera from another group of MCTD patients. 
Our results show that early in disease, 
autoantibodies directed against the apoptotic 
form of U1-70K (70Kapop) are more strongly 
represented than autoantibodies against the 
intact form. Longitudinal studies also show 
that autoantibodies against 70Kapop do not sig-
nificantly correlate with disease flares.
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Autoantibodies against apoptotic U1-70K 
do not correlate with disease activity
It has been described that in some patients 
with MCTD, antibody titres against the U1 
snRNA molecule correlate with disease activi-
ty, and could even possess prognostic value 
(23). In contrast, most studies did not find 
a correlation between disease activity and 
antibody responses to 70K, either by serum 
analysis using recombinant protein as antigen 
in ELISA (23,24), or by analysis on western 
blots using native protein from cell extracts 
(25). Only one study, using ELISA with recom-
binant U1-70K as technique, has reported 
decreasing disease activity concomitant with 
decreasing anti-U1-70K antibody levels (26). 
Since apoptotic modifications on autoantigens, 
such as the cleavage of 70K, are believed to be 
involved in the primary autoimmune response, 
we hypothesized that immune complexes 
containing anti-70Kapop antibodies might also 
be important for triggering disease flares. 
Serum samples were longitudinally collected 
from twelve MCTD patients by a follow-up 
during variable time intervals (4 – 15 years; 
average 10 years). All samples were analyzed 
for the presence of autoantibodies against 70K 
and 70Kapop on western blots containing non-
apoptotic and apoptotic Jurkat cell extracts 
and the presence of these autoantibodies 
was compared with the disease activity of 
each patient. The overall conclusion of this 
longitudinal study was that no significant 
correlations between antibody titres against 
either 70Kapop or 70K and disease exacerbations 
could be observed.
Autoantibodies against apoptotic U1-70K 
are more prevalent early in disease
As mentioned above, it has been hypo-
thesized that apoptotic modifications trigger 
the primary immune response towards 
self-proteins, and that, through secondary 
immune responses and epitope spreading, 
autoantibodies directed against unmodified 
regions on the autoantigen appear at later 
stages of the disease. To investigate this 
possibility for the U1-70K autoantigen, the 
longitudinal serum collection (23) of twelve 
MCTD patients was re-examined, now for 
Patient  Nr of 70Kapop 70Kapop  70Kapop  70K    70K
group  patients  > 70K = 70K > 70Kapop 
(disease)     
* The control group of non-SLE patients consists of patients suffering from 
PM/DM (n=26), pSjS (n=18), SSc (n=10), RA (n=3), RP (n=3) and UCTD 
(n=1).
MCTD 53 15 (28%)   14 (26%)   7 (13%)   1 (2%)   2 (4%)
SLE 48 0   1 (2%)    1 (2%)     0   1 (2%)
non-SLE * 61 0    0    0  0    2 (3%)
Table 1 Recognition of U1-70K and 70Kapop by patients with different  
 autoimmune disorders
Figure 1. Anti-U1-70K and anti-70Kapop detection by western blotting. Apoptosis was induced in Jurkat cells by 
incubation with anisomycin for 8 hours. Western blots were prepared with the resulting cell extracts and the positions of 
relevant polypeptides were visualized with patient sera and monoclonal antibodies using a chemiluminescent detection 
procedure. The positions of the various proteins are indicated on the left, and molecular weight marker positions on the 
right. (a) U1-70K detected with a serum from MCTD patient B16 (lanes 1, 5), anti-U1-70K monoclonal antibody 2.73 
(lanes 2, 6) and an anti-U1-70K single-chain recombinant antibody (scFv; lanes 3, 7) (70K); lanes 4, 8: Sm-B/B’ detected 
with a monoclonal anti-Sm-B/B’ antibody (ANA125); the position of U1A, which is also recognized by patient serum B16 
(lanes 1, 5) was determined by a U1A-specific monoclonal antibody (not shown). In apoptotic cells (lanes 5-8), U1-70K 
is present as a 40 kD species (70Kapop). (b) A serum sample of MCTD patient B16 was applied at 5,000- (lane 1), 10,000- 
(lane 2) and 20,000-fold (lane 3) dilution on a western blot containing a mixture of non-apoptotic and apoptotic Jurkat 
cell extracts. In lane 4, the U1-70K protein was detected with mouse monoclonal antibody 2.73, which reacts much 
more efficiently with U1-70K than with 70Kapop. 
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epitopes on U1-70K have not been described 
so far. In our recent studies, monoclonal 
recombinant human antibodies against U1-70K 
were isolated from phage display libraries 
derived from SLE patients, and several of 
these monoclonal antibodies preferentially 
recognized apoptotic U1-70K on western blot 
and in immunoprecipitation experiments 
(22, and D.Hof , unpublished results). It is 
believed that the apoptotic cleavage of U1-
70K leads to the exposure of a neo-epitope, 
which, if presented to the immune system, 
triggers the autoimmune response. Greidinger 
et al. showed that a mutant, consisting of the 
N-terminal 205 amino acids, indeed was able 
to induce an anti-70Kapop antibody response 
in mice, with subsequent epitope spreading. 
Interestingly, some of the immunized mice 
developed pulmonary lesions comparable 
to lesions found in lungs of MCTD patients. 
This finding supports the hypothesis that 
apoptosis-specific epitopes, and antibodies 
directed to them, may play a pathological 
role in the triggering and maintenance of the 
human autoimmune response to U1-70K (19).
In our study, a minority of MCTD sera (4%) 
contained autoantibodies exclusively reacting 
with intact 70K. We suggest that these sera 
derive from patients in a relatively late disease 
phase and primarily contain antibodies resul-
ting from expanded epitope spreading. The 
majority of epitopes recognized by these sera 
might therefore be dependent on the C-termi-
nal part of the protein, which is cleaved off 
during apoptosis and is not present on 70Kapop. 
Patients that tested negative in our western 
blot experiments may either have low levels of 
anti-70K antibodies, or may not at all produce 
such antibodies. Instead, other components of 
the U1 snRNP, such as the U1 RNA molecule, 
U1A or U1C, may be targeted by these sera and 
may explain their anti-U1 snRNP reactivity.
We demonstrate here that the majority of 
U1 snRNP positive patient sera preferentially 
recognize the apoptotic form of U1-70K, 
which is most likely explained by the presence 
of antibodies targeting an apoptotic U1-70K 
epitope. These results are in line with reports by 
Greidinger et al., who found that approximately 
50% of their RNP positive sera contained 
apoptotic U1-70K autoantibodies (18,19).
How disease flares are induced is not 
completely understood. Correlations between 
serum levels of certain autoantibodies and 
disease activity have been reported for MCTD 
and SLE (23,27), but it can be disputed 
whether these antibodies contribute to the 
disease flares or are merely epiphenomena. 
Our data show that antibodies against the 
apoptotic form of U1-70K do not significantly 
correlate with disease activity, suggesting that 
there is no important role for apoptotic U1-70K 
in the initiation of disease flares. However, 
it is possible that the variations in antibody 
levels against the apoptosis-specific epitope 
are masked by the presence of antibodies 
against other epitopes on U1-70K and U1-
70Kapop. Furthermore, a polyspecific secondary 
antibody was used to detect bound serum 
antibodies, and as a consequence variations 
in isotype-specific antibody levels might have 
remained undetected.
It has been reported that the first auto-
antibodies to appear in anti-RNP positive 
patients are generally antibodies against 
U1-70K (16,26). Our results suggest that the 
Figure 2. Longitudinal anti-70K analysis of patient T2. Eighteen serum samples taken over a period of 7 years with 
approximately equal time intervals were analyzed on western blots containing non-apoptotic and apoptotic Jurkat cell 
extracts. The positions of U1-70K, of which two isoforms are visible, and 70Kapop, are indicated on the left. In lane 19, 
U1-70K was detected with mouse monoclonal 2.73, which reacts much stronger with U1-70K than with 70Kapop.
antibodies to U1-70K and for antibodies to 
70Kapop. Three patients produced antibodies 
reacting strongly with 70Kapop, whereas no or 
only weak reactivity against 70K was observed. 
In one of these three patients autoantibodies 
against 70Kapop were more prevalent in early 
serum samples and the level decreased in time. 
Eight patients were found to have high titres 
of antibodies with reactivities to both 70K and 
70Kapop. Interestingly, in three of these patients 
early serum samples demonstrated a higher 
reactivity with 70Kapop than with 70K, whereas 
later samples showed comparable reactivities 
with both antigens, or higher reactivities with 
70K. An example of this type of reactivity 
profile is shown in Figure 2. One of the 
twelve patient sera did not detectably contain 
antibodies directed to 70K or 70Kapop. These 
results thus support the idea that antibodies 
to 70Kapop appear earlier in the disease than 
antibodies to the complete 70K protein.  
Discussion
Greidinger et al. recently showed that 
antibodies to the U1-70K protein in RNP 
positive patients are often accompanied by 
antibodies directed to the apoptotic cleavage 
product of this autoantigen, and that the 
B cell epitopes recognized on the apoptotic 
product are antigenically different from those 
contained in the intact form of the U1-70K 
protein (18,19).  This study is the first to con-
firm and extend these findings and strongly 
suggests that the reactivity of a patient serum 
with anti-U1-70K antibodies depends on the 
presence of antibodies against epitopes shared 
by 70K and 70Kapop, and antibodies against 
epitopes exclusively present on 70Kapop. The 
major apoptosis-specific epitope on U1-
70K has been shown to be located in the 
region containing the RNA binding domain, 
and its formation depends on amino acids 
180 - 205, overlapping with the most common 
T-cell epitope (20). Other apoptosis-specific 
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Materials and Methods
Patient sera
All patients were seen at the Department of 
Rheumatology of the University Medical Centre 
Nijmegen or the St. Maartenskliniek Nijmegen 
(the Netherlands), and were classified according 
to standard criteria for each disease. All MCTD 
patients (n=53) tested positive for anti-U1 snRNP 
autoantibodies by counterimmuno-electrophoresis, 
and for antibodies to one or more components of the 
U1 snRNP complex by immunoblotting. Most of the 
sera (91%) were also RNP positive as demonstrated 
by U1 snRNA co-immunoprecipitation. Longitudinal 
serum collections were obtained from 12 MCTD 
patients and have been described before (23). 
From each patient, over a period of 4 to 15 years 
(average 10 years) 8 to 33 serum samples (average 
18 samples) were available and analyzed. During 
the follow-up study, the patients were regularly 
monitored for clinical and serological parameters. 
At each visit, the disease activity was measured 
according to a validated SLE disease activity index 
described by ter Borg et al. (27). Medication was 
given as indicated by the clinical status. Additionally, 
patient sera were collected from SLE (n=48), PM/
DM (n=26), primary Sjögren’s syndrome (pSjS) 
(n=18), SSc (n=10), RA (n=3), Raynaud’s phenome-
non (RP) (n=3) and undefined connective tissue 
disease (UCTD) (n=1). Informed consent was obtai-
ned from all participants according to the medical 
ethical regulations of the local ethics committee. 
Sera were stored at –70oC until use.
Cell lines, induction of cell death and 
preparation of cell extracts
Jurkat (human T cell leukemia) suspension 
cells were grown in RPMI 1640 medium (Gibco-
BRL), supplemented with 1 mM sodium pyruvate, 
1 mM penicillin, 1 mM streptomycin and 10% heat-
inactivated foetal calf serum (Gibco-BRL), in a 
humidified 37oC incubator containing 5% CO2. Cells 
were maintained at a concentration of 1x106 cells/ml 
and were induced to undergo apoptosis by addition 
of 10 µg/ml anisomycin. Eight hours after induction, 
apoptotic cells were harvested by centrifugation at 
800g for 10 minutes and washed with PBS. Apoptotic 
and non-apoptotic Jurkat cells were resuspended 
in Nonidet-P40 (NP40) containing lysis buffer 
(25 mM Tris-HCl, pH 7.6, 100 mM KCl, 10 mM 
MgCl2, 0.25 mM dithioerythritol (DTE), 1% NP40, 
CompleteTM protease inhibitor cocktail (Roche)) at a 
concentration of 1x108 cells/ml. Cells were lysed on 
ice for 30 minutes and subsequently centrifuged for 
30 min at 12,000g and 4oC. Supernatants were used 
immediately or stored at -70oC.
SDS-polyacrylamide gel electrophoresis and 
western blotting
Cell extracts of 1,3x107 non-apoptotic Jurkat cells 
and 1,3x107 apoptotic Jurkat cells, either separately 
or mixed, were separated by SDS-PAGE. Directly 
after gel electrophoresis, proteins were transferred 
to a nitrocellulose membrane (Schleicher&Schuell) 
by semi-dry electroblotting. Ponceau S (Sigma) 
staining of the membrane was used to verify protein 
transfer.
Probing western blots with patient sera
All incubation steps were carried out at room 
temperature on a shaking table. Western blots 
containing non-apoptotic and apoptotic Jurkat cell 
extracts were pre-blocked with 5% non-fat dried 
milk in PBS containing 0.1% Nonidet-P40 (MPBS/
NP40) for two hours. Subsequently, membranes 
were incubated with patient serum, 1,000- to 
apoptotic form of U1-70K drives the primary 
autoimmune response to U1-70K, because 
in several patients antibodies against an epi-
tope associated with the apoptotic form of 
U1-70K precede the appearance of reactivity 
with intact U1-70K. The fact that the first 
serum samples from relatively few patients 
exclusively contain anti-70Kapop antibodies 
may be due to the stage of disease development 
at which the patient enters the rheumatologic 
clinic. It is likely that the first symptoms, later 
followed by the diagnosis of the disease, had 
been established years before the start of the 
longitudinal study. Moreover, it is possible 
that autoantibodies, especially those that are 
generated by the primary immune response, 
were already present before the manifestation 
of clinical symptoms, and that subsequent 
epitope spreading might have occurred before 
the patient entered the rheumatology clinic. 
For example, anti-cyclic citrullinated peptide 
(anti-CCP) autoantibody is a very specific 
marker for rheumatoid arthritis, and such 
antibodies can be detected in patients up to 10 
years before the occurrence of the first clinical 
symptoms (16,28,29). In our opinion this may 
explain why a relative enrichment of anti-
70Kapop antibodies could not be detected in the 
early sera of all patients.
During apoptosis, the U1 snRNP complex 
is modified in several ways. In addition 
to cleavage of U1-70K, U1 snRNA and the 
Sm-F protein are cleaved, and phosphorylated 
serine-arginine proteins associate with the 
complex (30). Apoptotic modifications of the 
U1A and U1C proteins have not been described 
so far. U1-70K can be cleaved by caspase-3 and 
granzyme B, and it can be oxidatively frag-
mented in the presence of metals, resulting in 
products of 40, 60 and 55 kDa, respectively. 
Correlations between recognition of specific 
U1-70K fragments and disease manifestations 
are interesting. For example, patients suffering 
from Raynaud’s phenomenon preferentially 
recognize the oxidatively modified 55 kDa 
fragment of U1-70K (31). The findings that early 
MCTD sera are enriched for antibodies against 
the 40 kDa apoptotic fragment (70Kapop) and 
that most sera show a higher reactivity with 
this fragment, suggest that caspase-3 cleaved 
U1-70K plays a role in breaking tolerance 
in these patients. Although granzyme B is 
postulated to play a role in breaking tolerance 
(32) to U1-70K, it is unknown whether specific 
patient groups preferentially recognize the 
60 kDa cleavage product generated by gran-
zyme B, which would be interesting to study 
in more detail.
Summary
Analysis of a group of MCTD patient 
sera by western blotting demonstrated that 
the majority of patient sera recognized the 
apoptotic form of U1-70K more efficiently than 
the intact form of the U1-70K protein. The fact 
that the presence of these antibodies in most 
patients precedes the occurrence of other 
anti-U1-70K antibodies suggests that 70Kapop is 
particularly important for the early detection 
of this disease in patients.
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Recently, we isolated recombinant antibodies directed to the nuclear  proteins hnRNP C, p54nrb and PSF from autoimmune libraries by subtractive 
selection on apoptotic cell extracts. In the study presented here, the apoptotic 
modifications on these proteins were studied by two-dimensional IEF/SDS-
PAGE immunoblotting and indirect immunofluorescence. It was demonstrated 
that p54nrb was not only cleaved during apoptosis, as described before, but that 
the isoelectric point changed from pI 6-7 in normal cells to pI 8-9 in apoptotic 
cells. Also the hnRNP C1 protein demonstrated modifications in addition to 
the previously reported apoptotic cleavage. Five isoforms of hnRNP C1 were 
present in the normal cell extract, whereas only three isoforms were detected in 
the apoptotic cell extract. PSF and hnRNP C were demonstrated to translocate 
to apoptotic bodies on the cell surface, as has been shown previously for several 
other autoantigens. In addition, we analyzed the presence of autoantibodies 
directed to recombinant p54nrb in sera from patients suffering from systemic 
lupus erythematosus (n=65), systemic sclerosis (n=79), polymyositis/dermato-
myositis (n=24), polymyositis/scleroderma overlap syndrome (n=24), and 
mixed connective tissue disease (n=12). Autoantibody reactivity to p54nrb was 
detected in 8% (2/24) of the PM/Scl patients, and none of the other sera. Our 
results corroborate the idea that apoptotic modifications create neo-epitopes 
on autoantigens as PSF, p54nrb and hnRNP C1, which consequently can break 
tolerance to these self-proteins.
Introduction
Heterogeneous nuclear ribonucleoprotein 
C (hnRNP C) is a protein abundantly expressed 
in all eukaryotic cells. Two variants of hnRNP 
C (C1 and C2) polypeptides exist, resulting 
from alternative splicing leading to a 13 amino 
acid insertion after position 107 in hnRNP 
C2 (1). The protein is located in the nucleus, 
excluding the nucleoli (2), and is one of the 
most abundant nuclear proteins (3,4). In vivo 
and in vitro, hnRNP C forms heterotetramers 
of three C1 molecules and one C2 molecule 
(5). Recently, the oligomerization has been 
visualized using nuclear magnetic resonance 
(6). Three heterotetramers form a 19S tri-
angular complex that binds approximately 
700 nucleotides of RNA (7), and these 19S 
complexes are part of a larger 40S complex 
containing other hnRNPs (8). As schematically 
depicted in Figure 1, four distinct domains can 
be identified in hnRNP C1 and C2, namely 
an RNA recognition motif (RRM), a basic 
domain involved in binding pre-mRNA, a 
leucine zipper mediating monomer-monomer 
interactions, and an acidic carboxyterminal 
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tract-binding protein (PTB) (22). Both proteins 
bind the polypyrimidine tract, which is a 
region within introns that is important for the 
definition of the 3’-splice site. Later it became 
clear that the majority of PSF molecules in the 
cell is bound to the nuclear matrix and that 
only a minority is bound to PTB (23). PSF is 
distributed in the nucleoplasm, both diffuse 
and in punctuate patterns. As schematically 
illustrated in Figure 2, the p54nrb protein is 
highly homologous to the C-terminus of PSF 
(24). PSF and p54nrb were identified as a p100/
p52 DNA-binding heteromer (25), and indeed 
both proteins bind dsDNA, ssDNA, and RNA, 
and are involved in a wide variety of cellular 
processes such as nuclear RNA splicing, 
regulation of transcription, DNA unwinding 
and DNA pairing, and nuclear retention of 
defective RNAs (see review by (26)). So far, 
autoantibodies directed to neither p54nrb nor 
PSF have been described to occur in patient 
sera.
It is still not understood why autoimmune 
patients produce antibodies to self-antigens 
(autoantigens), but an increasingly recognized 
hypothesis focuses on the role of autoantigen 
modifications, especially those occurring 
during cell death, in breaking immunological 
tolerance to self-antigens (see reviews by (27-
30)). It is believed that these modifications, 
as for example cleavage, phosphorylation 
and citrullination, create neo-epitopes on 
autoantigens that are not recognized by the 
immune system as ‘self’ and therefore initiate a 
primary immune response. Secondary immune 
responses subsequently lead to autoantibodies 
that recognize other (non-modified) epitopes 
on the same molecule or complex. This process 
is called epitope spreading (31,32). HnRNP C, 
p54nrb and PSF have been described to be 
modified during apoptosis. HnRNP C1 and C2 
are cleaved by caspase-3, leading to the removal 
of a peptide of approximately 2 kDa (33). The 
p54nrb protein is also cleaved, resulting in 
a fragment of approximately 50 kDa (34). 
PSF is known to be hyper-phosphorylated 
during apoptosis (35), and this modification 
is thought to occur on serine, and to a lesser 
extent threonine, residues residing in its 
N-terminal part. In this study the apoptotic 
modifications of hnRNP C, p54nrb and PSF 
were further studied by immunoblotting of 
Figure 2. Schematic structure of PSF and p54nrb. The nuclear proteins PSF (707 amino acids) and p54nrb (471 amino 
acids) contain regions that are rich in proline (P), glutamine (Q), and histidine (H). The domains shared by the two 
proteins are the two RNA recognition motifs (RRM1 and RRM2), and a basic/acidic region (+/-). PSF contains an RGG 
element, which is not present in p54nrb. On the other hand, p54nrb contains a region predicted to form a helix-turn-helix 
(HTH) and a C-terminal proline-rich region, which are not present in PSF.
domain. HnRNP C is involved in pre-mRNA 
packaging, spliceosome assembly and nuclear 
retention of unspliced hnRNA (9). It functions 
in actively packaging and chaperoning nascent 
pre-mRNA transcripts in 40S hnRNP particles. 
In addition to the known involvement of 
hnRNP C in mRNA binding, new functions 
of the protein recently became apparent: 
hnRNP C has been described to have a role in 
viral RNA replication (10-13), repair of DNA 
damage (14), cell-cycle control (15,16) and 
telomere function (17).
The hnRNP A1, A2, B1, B2, C1 and C2 
proteins are the so-called core proteins of 
hnRNP complexes, and these six proteins 
are highly related, with molecular weights 
ranging from 34 to 43 kDa (see review by 
(18)). Autoantibodies directed to hnRNP A1 
and hnRNP A2/B (also named anti-Ra33 
autoantibodies) are found in a large number 
of patients suffering from systemic lupus 
erythematosus (SLE) , rheumatoid arthritis 
(RA), and mixed connective tissue disease 
(MCTD) (see review by (18)). Autoantibody 
reactivity with hnRNP C, however, has been 
described in only a few patients suffering from 
various autoimmune diseases. In 1997, Stanek 
et al. were the first to describe the presence 
of autoantibodies directed to hnRNP C, and 
they found this reactivity in one patient with 
the atypical coexistence of systemic sclerosis 
(SSc, also referred to as scleroderma) and 
psoriatic arthritis (19). In 2000, Heegaard 
et al. described three patients, which they 
selected based upon an unusual anti-nuclear 
antibodies staining pattern, with anti-hnRNP C 
autoantibody reactivity. One patient suffered 
from arthralgias and oligoarthritis, one patient 
had complaints of muscle tenderness, and one 
patient suffered from polymyositis in addition 
to psoriasis (20). Recently, we isolated a 
recombinant antibody (single chain variable 
fragment, scFv) from autoimmune libraries 
derived from SLE, SSc, and RA patients by 
subtractive selection on apoptotic cell extract 
(21). In the same subtractive selection, an 
additional scFv was obtained directed to 
both nuclear RNA-binding protein of 54 kDa 
(p54nrb) and polypyrimidine tract-binding 
protein-associated splicing factor (PSF) (21).
PSF was first identified as a 100 kDa protein 
that formed a complex with the polypyrimidine 
Figure 1. Schematic structure of hnRNP C1. The RNA recognition motif (RRM) is found from residues 8 to 84, the 
basic domain is located at residues 140 to 179, the leucine zipper domain is located at residues 179 to 207, and the acidic 
carboxyterminal domain is found from residues 214 to 290. Serine residues at positions 225 or 228, 240, 247 and 286 
are phosphorylated (P). Putative caspase cleavage sites are illustrated with arrows. HnRNP C2 is identical to hnRNP C1, 
except for a 13 amino acid insertion after residue 107 in hnRNP C1.
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Figure 3. Detection of p54nrb and PSF, and hnRNP C on two-dimensional IEF/SDS-PAGE western blots 
containing apoptotic and non-apoptotic cell extracts. To induce apoptosis, Jurkat cells were incubated with 10 
µg/ml anisomycin for 8 hours. Proteins in cell extracts from approximately 5·106 cells were separated by isoelectric 
focussing in the first dimension, followed by separation by SDS-PAGE in the second dimension as described in the 
Materials and Methods section, and subsequently transferred to nitrocellulose membranes by semi-dry electroblotting. 
The pH gradient and molecular weight markers are indicated above and at the left, respectively, of each blot. Antigens 
were detected by specific scFvs, in combination with anti-VSV-G mouse monoclonal antibody, HRP-labelled rabbit 
anti-mouse antibodies, and ECL. The position of the antigens is indicated with an arrow at the right of each blot. (a) 
Detection of p54nrb (54 kDa) and PSF (100 kDa) in normal (at the left) and apoptotic (at the right) cell extract using 
scFv B1H11. In apoptotic cell extract, prominent protein spots are observed at pH8-9/50 kDa (marked with an open 
arrow head), as well as some smaller fragments at the same pH, which are not detected in the normal cell extract. 
(b) Detection of hnRNP C in normal (at the left) and apoptotic (at the right) cell extract using scFv G1G10. The splice 
variants C1 and C2 are detected in both cell extracts.
fragment of approximately 2 kDa in apoptotic 
cells (33). On the 2D western blot with normal 
cell extract five hnRNP C1 and three hnRNP 
C2 spots were detected. The corresponding 
blot containing apoptotic cell extract showed 
three spots for both hnRNP C1 and hnRNP C2, 
indicating that during apoptosis hnRNP C1 
undergoes additional modifications besides 
cleavage. Moreover, the intensity of the three 
spots in the apoptotic material is very similar, 
whereas in the normal cell extract two spots 
are far more intense than the other spots (both 
for hnRNP C1 and hnRNP C2).
two-dimensional isoelectric focusing/SDS-
PAGE (2D) gels using specific scFvs, and their 
localization in apoptotic cells was examined 
by indirect immunofluorescence. We also 
addressed the question whether p54nrb and PSF 
are autoantibody targets by analyzing patient 
sera from different autoimmune diseases.
Results
Apoptotic modifications of hnRNP C, p54nrb 
and PSF 
To induce apoptosis, Jurkat cells were 
incubated with anisomycin for eight hours, 
as described previously (36), and cell extracts 
were prepared by sonication followed by 
centrifugation. Cleavage of the U1-70K 
protein, a component of the U1 small nuclear 
ribonucleoprotein (U1 snRNP) complex, is 
regarded as a biochemical marker for apop-
tosis (37). In the apoptotic Jurkat cell extract 
the U1-70K protein (70 kDa) was completely 
cleaved to the characteristic 40 kDa apoptosis-
specific fragment, (data not shown), confirming 
the efficient induction of apoptosis by this 
procedure. The proteins in the apoptotic and 
non-apoptotic cell extracts were separated by 
isoelectric focusing (IEF) in the first dimension 
and by SDS-PAGE in the second dimension. 
After western blotting, p54nrb and PSF were 
detected with scFv B1H11, and hnRNP C1 and 
C2 were detected using scFv G1G10 (21). As 
shown in Figure 3a, many isoelectric isoforms 
of the 100 kDa protein PSF were observed with 
isoelectric points ranging from approximately 
pH 4 to pH 10. The most intense signals were 
observed in the basic region of this pH range. 
No significant differences were observed when 
the patterns of PSF isoforms in the normal and 
apoptotic cell extracts were compared. 
On the western blot with normal cell extract, 
p54nrb was detected in six spots at 54 kDa in the 
pH range 6 to 7. The four additional spots that 
were detected at approximately 52 kDa in the 
pH range 5 to 6 probably represent splicing 
variants of p54nrb, although the possibility that 
these isoforms result from posttranslational 
modifications cannot be excluded. On the 
western blot containing apoptotic cell extract 
only four spots were detected at the 54kDa/pH 
6-7 location. Because the relative intensity 
of these spots was significantly reduced 
compared to the non-apoptotic material, 
the amount of these isoforms seems to be 
reduced during apoptosis, which may be due 
to proteolytic cleavage. Simultaneously, at 
least five new p54nrb spots were detected at 
approximately 50 kDa and at a pH range 8 
to 9, as well as a number of faster migrating 
isoforms in the same pH range. These spots are 
most likely generated via apoptotic cleavage 
of p54nrb, as has been described before (34). 
These data indicate that besides cleavage also 
the isoelectric nature of p54nrb shows marked 
changes in apoptotic cells.
By running an 8% polyacrylamide gel in the 
second dimension, it was possible to separate 
hnRNP C1 from hnRNP C2 (Figure 3b). The 
stronger signal of the smaller isoform C1 is 
consistent with the composition of hnRNP 
C heterotetramers, containing three hnRNP 
C1 molecules and one hnRNP C2 molecule. 
The apoptotic forms of hnRNP C1 and C2 
run slightly faster than those in normal cell 
extracts, which is caused by the removal of a 
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patients (21). Serum autoantibody reactivity 
directed to PSF or p54nrb, on the other hand, has 
not been described so far. However, the apop-
totic modifications of p54nrb and PSF described 
here, the translocation of PSF to apoptotic 
bodies, and the isolation of the anti-p54nrb/
PSF recombinant antibody from autoimmune 
antibody libraries, suggest that p54nrb and/or 
PSF are also genuine autoantigens. To detect 
this autoantibody reactivity in patient sera, 
we analyzed groups of patients with different 
autoimmune diseases for autoantibody reacti-
vity with p54nrb by immunoblotting. 
Because the anti-PSF/p54nrb scFv B1H11 
was isolated from a mixture of autoimmune 
libraries, including libraries from SLE 
(n=5) and SSc (n=5) patients, autoantibody 
reactivity with these proteins was expected 
to be present in sera from these diseases, 
or in sera from the related autoimmune 
diseases polymyositis/scleroderma overlap 
disease (PM/Scl) and MCTD. PM/Scl patients 
demonstrate symptoms from polymyositis/
dermatomyositis (PM/DM) and scleroderma, 
and MCTD patients show a combination of 
symptoms that are typically associated with 
SLE, SSc, RA, and PM/DM (40). Because of 
the PM/DM symptoms in these two patient 
groups, a group of PM/DM patients was 
analyzed as well. 
To develop a specific assay for anti-
PSF/p54nrb detection, cDNAs encoding both 
proteins were expressed in E.coli. Since only 
p54nrb was expressed to high levels in this 
system, PSF was not included in the screening 
for autoantibody reactivities. The recombinant 
p54nrb was purified by ammonium sulphate 
precipitation, followed by anion exchange 
chromatography and cation exchange chro-
matography. The purity of recombinant p54nrb 
was at least 90%, as demonstrated by silver-
staining of SDS-PAGE gels (data not shown). 
Sera from patients suffering from SLE (n=65), 
SSc (n=79), PM/DM (n=24), PM/Scl (n=24), 
and MCTD (n=12), were analyzed for reactivity 
with recombinant p54nrb. As demonstrated in 
Figure 5, two PM/Scl sera (Day5 and Myo36), 
but none of the other patient sera reacted with 
p54nrb. This finding shows that p54nrb indeed is 
an autoantigen in PM/Scl patients, although 
the frequency by which these autoantibodies 
occur in such patients seems to be low 
(about 8%).
Figure 5. Antibody reactivity of patient sera Day5 
and Myo36 with recombinant p54nrb on immunoblot. 
The position of recombinant p54nrb on the western blots 
(indicated with an arrow at the right) was visualized by 
Ponceau S staining. The blots were incubated with patient 
sera and bound antibodies were detected with HRP-
labelled goat anti-human IgA/G/M antibodies and ECL. 
In total 24 PM/Scl sera were analysed, but only the data 
for 11 sera are shown. Patients Myo36 (lane 1) and Day5 
(lane 9) reacted with a protein at the position of p54nrb. 
The positions of molecular mass markers are indicated 
on the left.
HnRNP C and PSF translocate to apoptotic 
bodies on the cell surface 
During apoptosis, several autoantigens 
translocate from their normal cellular location 
to apoptotic blebs and apoptotic bodies on the 
cell surface (38,39). Due to this translocation 
(modified) autoantigens may be more easily 
exposed to the immune system. To study 
the localization of hnRNP C and PSF during 
apoptosis, monolayer HEp-2 cells were exposed 
to anisomycin for six hours. Subsequently, the 
cells were fixed and antigens were detected 
in the cell by indirect immunofluorescence. 
Figure 4 demonstrates the localization of the 
U1 snRNP complex, hnRNP C, and PSF in 
apoptotic cells. The U1 snRNP complex was 
detected with patient serum D18, which is 
reactive with the U1-70K and U1A proteins. 
The U1-70K protein has been reported to 
localize in a rim around the nucleus relatively 
early during apoptosis, and later in apoptotic 
bodies on the cell surface (38). Both the rim 
and the bodies at the cell surface were indeed 
observed with patient serum D18 (Figure 
4a). The recombinant scFv antibodies to 
hnRNP C, and to p54nrb and PSF did not give a 
clear signal in the immunofluorescence assay, 
which may be either due to sensitivity problems 
or to inaccessibility of the epitopes recognised 
by these monoclonal antibodies. Therefore, 
other antibodies to these proteins were used in 
this experiment: hnRNP C was detected with 
patient serum BH, which contains antibodies 
with high specificity and affinity for hnRNP C 
(19); PSF was detected using monoclonal 
antibody B92; and for p54nrb no alternative 
antibody was available. As a negative control, 
cells were incubated only with the secondary 
antibody conjugates. With the BH and B92 
antibodies, both hnRNP C and PSF were found 
to be translocated to the apoptotic bodies 
(Figure 4b and 4c, respectively).
The p54nrb protein is recognized by poly-
myositis/scleroderma overlap patients
As mentioned above, autoantibody reacti-
vity directed to hnRNP C has been described 
in a few patients (19,20), and scFvs directed to 
hnRNP C could be isolated from antibody phage 
display libraries derived from autoimmune 
Figure 4. Immunofluorescence detection of antigens 
in apoptotic HEp-2 cells. HEp-2 cells were incubated 
with 10 µg/ml anisomycin for 6 hours, and cells were 
fixed with methanol (a and b) or p-formaldehyde (c). 
Fluorescence images (at the left) and phase-contrast (a 
and b) or bright-field (c) images (at the right) are shown 
for each experiment. (a) Detection of the U1 snRNP 
complex with patient serum D18. (b) Localization of 
hnRNP C using patient serum BH. (c) Detection of PSF 
using monoclonal antibody B92.
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A detailed characterization of the hnRNP C 
isoforms is required to investigate whether the 
different spots are due to a different number of 
phosphate groups on the protein, or whether 
other modifications are involved.
PSF has been previously reported to localize 
to apoptotic bodies using a GFP-PSF fusion 
construct (35). The immunofluorescence data 
presented in this study, using a monoclonal 
antibody to monitor the subcellular localization 
of PSF, are clearly in line with this report. 
The redistribution of hnRNP C to apoptotic 
bodies has not been previously described, and 
suggests that also this nuclear protein can be 
more easily exposed to the immune system as 
a result of apoptosis.
We report here for the first time the 
detection of autoantibodies directed to p54nrb 
in patient sera. Upon screening diffe-rent 
groups of autoimmune patients, it was found 
that 8% (2/24) of patients with PM/Scl 
contain this autoreactivity. To demonstrate 
that autoantibody reactivity with p54nrb is 
specific for PM/Scl, and can thus be regarded 
as a (minor) disease marker, it would be 
valuable to analyze a larger cohort of PM/Scl 
patients, in addition to more control groups of 
autoimmune diseases, inflammatory diseases 
and healthy individuals. Importantly, the scFv 
reactive with this protein was isolated from a 
mixture of libraries not including a PM/Scl 
patient, substantiating the need for analyses 
with larger cohorts of sera. Serum reactivity 
with PSF could not be determined, due to 
limitations in the expression of this relatively 
large protein in E. coli. Patient sera with 
autoantibodies to p54nrb might be expected to 
react with PSF as well, since p54nrb is highly 
homologous to the C-terminus of PSF (24). 
The fact that the scFv antibody B1H11 reacts 
with an epitope that is present on both PSF 
and p54nrb suggests that such autoantibodies 
indeed exist in autoimmune patients.
We hypothesize that the apoptotic modi-
fications on hnRNP C, p54nrb and PSF lead to 
the generation of neo-epitopes. Upon their 
translocation to the surface of apoptotic 
cells, these neo-epitopes are more easily 
exposed to the immune system, and are thus 
more likely to trigger a primary autoimmune 
reaction. Experimental data that would 
strongly support a role for neo-epitopes in the 
autoantibody formation would be the detection 
of autoantibodies that only react with the 
apoptotic variants of p54nrb, PSF and hnRNP C. 
Such apoptosis-specific autoantibodies are for 
example described for the MCTD autoantigen 
U1-70K (36,45,46), and the La protein, which 
is an autoantigen in Sjögren’s syndrome 
(47). Autoantibodies to the apoptotic form 
U1-70K (the 40 kDa fragment that results 
from cleavage by caspase-3) have been 
demonstrated to be present especially during 
the early phases of the disease (36). Evidence 
for the early presence of apoptosis-specific 
autoantibodies may be difficult to obtain in 
view of the small number of sera reactive with 
hnRNP C and p54nrb and the fact that patient 
sera are generally collected in later stages of 
the disease.
Discussion
The nuclear protein hnRNP C has been 
described before as an autoantigen in several 
patients with different autoimmune diseases, 
and we demonstrate here that p54nrb, another 
protein that was identified as a target of 
autoimmune patient derived scFv antibodies, 
indeed is also recognized by autoantibodies 
in patient sera. Furthermore, the additional 
experimental data on the modifications and 
translocations of p54nrb, PSF and hnRNP 
C during apoptosis support the hypothesis 
that apoptotic modifications are involved in 
breaking of immunological tolerance to these 
autoantigens in susceptible individuals.
In 2001, Shav-Tal et al. reported that PSF 
is hyperphosphorylated during apoptosis 
(35). However, the 2D immunoblots that 
we presented here did not demonstrate 
significant changes in the isoelectric point of 
the 100 kDa PSF isoforms, which would be 
expected as a result of hyperphosphorylation. 
These different observations might be due 
to differences in cell lines: Shav-Tal et al. 
used HeLa cells, whereas Jurkat T cells were 
used in the study presented here. Similarly, a 
dependence of autoantigen modification on 
the type of tissue or cell has been described 
previously for the scleroderma autoantigen 
B23 (41). In contrast, marked differences were 
observed between the pI values of the apoptotic 
fragments of p54nrb (several spots at pI 8 to 9) 
and those of the intact forms (several spots at 
pI 6 to 7). These differences might result from 
losing the part of the protein that is cleaved 
off, although this is unlikely since neither 
the N-terminal nor the C-terminal ends of 
p54nrb contain clusters of negatively charged 
amino acids. The change in pI could also be 
caused by other apoptotic modifications, but 
more experiments are needed to investigate 
this possibility. An equivalent change in pI 
was not observed in a proteomics study by 
Thiede et al., where the apoptotic cleavage of 
p54nrb was first described (34). Since this study 
was not aimed at the detection of apoptotic 
variants of p54nrb, the 2D spots representing 
these apoptotic fragments of p54nrb may have 
escaped the attention of these investigators.
HnRNP C1 and C2 are known to be 
cleaved by interleukin 1β-converting enzyme-
like proteases during apoptosis (33), but 
the finding presented here that apoptosis 
also leads to changes in the isoelectric 
isoforms indicates that additional apoptotic 
modifications occur on hnRNP C. The five 
spots obtained with material from normal cells 
probably represent the four phosphorylation 
states that are described for hnRNP C and its 
non-phosphorylated state (42,43). On the 2D 
blot containing apoptotic cell extract, hnRNP 
C1 was separated in three different spots. 
As depicted in Figure 1, phosphorylation of 
hnRNP C1 takes place on Ser225/Ser228, Ser240, 
Ser247, and Ser286 (42,43). Putative caspase 
cleavage sites have been appointed to positions 
Asp255, Asp258, Asp261, Asp264, and Asp285 (33). 
Cleavage at one of these positions would lead 
to the removal of one phosphorylated serine 
residue (Ser286). It could be hypothesized that 
one of the remaining three phosphorylated 
serine residues of hnRNP C1 is in addition 
dephosphorylated during apoptosis. Dephos-
phorylation in apoptotic cells indeed can occur, 
as has been described for the La protein (44). 
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25 mM NaCl, 1 mM EDTA, 1 mM DTT), and sonica-
ted on ice. After centrifugation at 4,000 x g and 
4oC for 30 minutes, the supernatant contained the 
soluble p54nrb protein, which was then purified by a 
combination of chromatographic and precipitation 
steps. The protein was first separated from other 
proteins by ammonium sulphate precipitation. 
Subsequently, p54nrb, which precipitated at 20% 
ammonium sulphate, was dissolved, dialyzed and 
separated from other contaminating proteins 
by anion exchange chromatography on a DEAE 
column (GE Healthcare). SDS-PAGE analysis 
revealed that the fractions containing p54nrb still 
contained relatively high levels of other proteins. 
These fractions were pooled, and finally separated 
by cation exchange chromatography on a Source 15S 
column (GE Healthcare). The purity of p54nrb in the 
fractions of this column was approximately 90%, as 
estimated from a silver-stained SDS-PAGE gel.
Gel electrophoresis and immunoblotting
For two-dimensional gel electrophoresis, pro-
teins from apoptotic and non-apoptotic Jurkat 
cell extracts were separated by isoelectric focusing 
(IEF), followed by separation by SDS-PAGE. First, 
salts and other substances interfering with IEF were 
removed using a clean-up procedure (2D Clean-up 
Kit, GE Healthcare). Proteins were separated on 
13 cm ImmobilineTM DryStrip gel (GE Healthcare) 
with a pH range 3-10, or pH range 4-7, using 
the IPGphor II Isoelectric Focusing System (GE 
Healthcare). After IEF, the gel strips were incubated 
in equilibration buffer (50 mM Tris-HCl, pH 8.8, 6M 
urea, 30% glycerol, 2% SDS, 10 mg/ml DTT, and 
bromophenol blue). For separation on molecular 
weight in the second dimension, IEF strips were 
placed on SDS-PAGE gels. For one-dimensional 
SDS-PAGE separation, SDS-PAGE loading buffer 
was added to protein samples, and samples were 
incubated at 95oC for 5 minutes. After one- or two-
dimensional gel electrophoresis, proteins were 
transferred to nitrocellulose membranes by semi-dry 
Western blotting. Protein transfer was checked with 
a Ponceau S staining. All immunoblotting steps were 
carried out on a shaking table at room temperature. 
Membranes were blocked with 5% non-fat dried 
milk powder in PBS containing 0.05% Tween-20 
(MPBST). Recombinant antibodies were incubated 
with the membrane at a 10- to 20-fold dilution in 
MPBST, and bound antibodies were detected with 
anti-VSV-G monoclonal mouse antibodies, 5,000-
fold diluted in MPBST, and horseradish peroxidase 
(HRP)-labelled rabbit anti-mouse antibodies 
(DAKO), 2,500-fold diluted in MPBST, followed by 
enhanced chemiluminescence (ECL). Patient sera 
were incubated with the membrane at a 1,000-fold 
dilution, and bound antibodies were detected using 
HRP-labelled goat anti-human IgA/G/M antibodies 
(DAKO), 1,000-fold diluted, and ECL.
Immunofluorescence analysis on apoptotic 
HEp-2 cells
For induction of apoptosis, HEp-2 cells were 
incubated with 10 µg/ml anisomycin for 6 hours. 
Cells were fixed on glass slides by methanol fixation, 
or by p-formaldehyde fixation. For methanol 
fixation, cells were washed with PBS, and incubated 
with methanol (-20oC) for 10 minutes. After a short 
wash with acetone, glass slides were air-dried. For 
p-formaldehyde fixation, cells were washed with 
PBS, and fixed on glass slides by incubation with 
4% p-formaldehyde in 250 mM Hepes, pH 7.4 for 
30 minutes on ice. After washing, the cells were 
incubated with 300 mM glycine in PBS for 5 minutes 
at room temperature. The slides were washed 
again with PBS, and subsequently incubated with 
Materials and Methods
Cell lines
Jurkat (human T cell leukemia) suspension 
cells were grown in RPMI 1640 medium (Gibco-
BRL), supplemented with 1 mM sodium pyruvate, 
1 mM penicillin, 1 mM streptomycin and 10% heat-
inactivated fetal calf serum (Gibco-BRL). HEp-2 
cells were cultured in DMEM medium (Gibco-BRL), 
supplemented with 10% heat-inactivated FCS, 1 mM 
penicillin, and 1 mM streptomycin. Cells were grown 
in a humidified 37°C incubator containing 5% CO2.
Induction of cell death and preparation of cell 
extracts
Jurkat cells were maintained at a concentration 
of 106 cells/ml. For induction of apoptosis, cells were 
incubated in the presence of 10 µg/ml anisomycin 
for 8 hours at 37oC. Cells were harvested by 
centrifugation at 800 x g for 5 minutes, and washed 
twice with PBS. Cells were then resuspended in ice-
cold sonication buffer (50 mM Tris-HCl, pH 7.6, 100 
mM KCl, 0.05% Nonidet-P40, 1 mM ETDA, 1 mM 
DTT, and CompleteTM protease inhibitor cocktail 
(Roche)) and lysed by sonication on ice. After 
centrifugation at 12,000 x g and 4oC for 20 minutes, 
clear lysates were used immediately or stored at 
−70oC.
Patient sera and antibodies
Patient sera were present in the serum collection 
of the Department of Biochemistry, Radboud 
University Nijmegen (The Netherlands). These 
patients had been seen at the St. Maartenskliniek 
Nijmegen or at the Department of Rheumatology 
of the University Medical Centre Nijmegen 
(The Netherlands). Patients had been classified 
in accordance with standard criteria for each 
disease, and informed consent was obtained from 
all participants. Patient sera were present from 
systemic lupus erythematosus (n=65), systemic 
sclerosis (n=79), polymyositis/dermatomyositis 
(n=24), polymyositis/scleroderma overlap syndrome 
(n=24), and mixed connective tissue disease (n=12). 
Control sera from healthy individuals (n=30) were 
present as well. Sera were stored at -70°C until 
use. Patient serum BH with known reactivity with 
hnRNP C was a kind gift from J. Vencovsky (Charles 
University, Prague, Czech Republic). Recombinant 
antibodies directed to p54nrb/PSF and hnRNP C 
had been previously selected from autoimmune 
libraries in a subtractive antibody phage display 
selection procedure on apoptotic cell extract (21). 
Recombinant antibodies were C-terminally tagged 
with a VSV-G- and a 6xHis-tag, expressed in E.coli 
and isolated from the periplasm as described 
previously (48).
Protein expression and purification
Expression of p54nrb from pET-9c in E.coli 
resulted in the efficient production of mainly 
insoluble protein. In order to increase the solubility 
of recombinant p54nrb, the expression was performed 
in the presence of 3% ethanol as described (49). In 
short, LB medium containing 70 µg/ml kanamycin 
was inoculated with the bacterial stock and grown 
overnight at 37oC and 200 rpm. The overnight 
culture was diluted 100-fold in LB medium 
containing 70 µg/ml kanamycin and 3% ethanol, 
and grown for 6 hours at 30oC and 200 rpm. 
Protein expression was induced by the addition of 
1 mM IPTG, and subsequently the bacterial culture 
was grown overnight at 30oC and 200 rpm. The 
bacterial culture was centrifuged at 4,000 x g and 
4oC for 15 minutes, resuspended in one-tenth of the 
starting volume lysis buffer (25 mM Tris-HCl pH7.6, 
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0.5% Triton X-100 in PBS for 30 minutes on ice. 
Fixed cells were incubated with antibodies, diluted 
in PBS+ (PBS supplemented with 40 mM glycine, 
1% BSA, and 0.2% gelatine). Bound monoclonal 
antibodies were detected using FITC-labelled rabbit 
anti-mouse antibodies (DAKO), and bound human 
serum antibodies were detected with FITC-labelled 
rabbit anti-human antibodies (DAKO). As negative 
controls, cells were incubated with (labelled) 
secondary antibodies without incubation with 
primary antibodies. Cells were embedded in Mowiol 
and analyzed using a fluorescence microscope.
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Autoimmune diseases are characterized by the presence of high levels of  antibodies to self-antigens. Systemic sclerosis (scleroderma) is a relatively 
rare autoimmune disease, affecting approximately 0.03% of the population of 
the industrialized world. The pathogenesis of scleroderma is thought to involve 
oxidative stress and the formation of free radicals, leading to tissue injury and 
autoantigen formation. It is hypothesized that posttranslational modifications, 
especially modifications that occur during cell death, create neo-epitopes on 
autoantigens, which are consequently involved in breaking tolerance to self-
antigens. Radicals, produced during oxidative stress, have been put forward as 
a primary cause of modifications on scleroderma autoantigens. In this study, 
sera from patients with systemic sclerosis (n=72), Raynaud’s phenomenon 
(n=129), polymyositis/scleroderma overlap syndrome (n=24), systemic lupus 
erythematosus (n=5), rheumatoid arthritis (n=4), undifferentiated connective 
tissue disease (n=5), and mixed connective tissue disease (n=1) were analyzed by 
immunoblotting for differential autoantibody reactivity with antigens in oxidatively 
modified and control cell extracts. Five systemic sclerosis patients, five Raynaud’s 
phenomenon patients, and two patients with polymyositis/scleroderma overlap 
syndrome were identified that displayed differential autoantibody reactivities. 
Two of these sera were further analysed using oxidatively modified, apoptotic 
and necrotic cell extracts, and it was found that the polypeptides recognized 
by these sera in the oxidatively modified cell extracts were not created during 
apoptosis and necrosis. These findings further substantiate the idea that oxidative 
modification of autoantigens is involved in the development of autoimmunity in 
scleroderma and related disorders.
Introduction
Susceptibility to autoimmune diseases 
seems to be controlled by a number of 
factors, including the genetic background, 
environmental factors, hormonal factors, 
and viral factors (see reviews by (1-4)). A 
link has been proposed between autoimmune 
diseases and cell death, such as apoptosis 
and necrosis, or oxidative stress. It is thought 
that modifications that occur on autoantigens 
during cell death play an important role 
in breaking tolerance to autoantigens. It is 
hypothesized that such modifications create 
neo-epitopes on autoantigens, which are not 
recognized by the immune system as self, and 
as a consequence elicit an immune response 
when they are presented to the immune system. 
Apoptotic modifications of autoantigens have 
been studied extensively, and include cleavage, 
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to vasoconstriction, which leads to further 
ischemia-reperfusion (22). SSc can be divided 
into diffuse and limited forms. Diffuse SSc is 
associated with autoantibodies directed to 
DNA topoisomerase I (Topo), whereas limited 
SSc often is associated with autoantibodies to 
centromere proteins (12). Anti-centromere 
autoantibodies are associated with higher 
risk of ischemic digital loss and pulmonary 
hypertension (12,23). A form of limited SSc is 
CREST (Calcinosis, Raynaud’s phenomenon, 
Esophagus dismotility, Sclerodactyly and 
Telangiectasias). Raynaud’s phenomenon 
(RP) is characterized by numbness, tingling 
and/or colour changes in the fingers and 
toes, which are caused by recurrent episodes 
of reversible vasospastic attacks of the digital 
arteries and are triggered by exposure to 
cold or by emotional stress. Secondary RP 
is present in ~90% of patients with limited 
SSc, but RP can also exist without other 
autoimmune symptoms.  A small percentage 
of such primary RP patients (~9%) develops 
SSc (24), and these can be regarded as early 
SSc patients. 
A potential mechanism for specific 
fragmentation of scleroderma antigens has 
been proposed: metal-catalyzed oxidation 
by free radicals (25). In vitro, oxidative 
fragmen-tation is dependent on metal ions 
capable of supporting Fenton chemistry 
like copper (Cu2+) and iron (Fe2+) (Fenton 
reaction = Fe2+ + H2O2 à Fe
3+ + OH– + OH•) 
(25). A Fenton reaction produces free radicals 
that can cause fragmentation of the antigen 
near metal-binding sites (26). Greidinger 
et al. demonstrated that recognition of cell 
death-specific fragments by patient sera can 
correlate with clinical symptoms (27). They 
demonstrated that SLE patients with RP 
preferentially recognized oxidatively modified 
fragments of the U1-70K protein, whereas 
serum from patients with lupus skin disease 
preferentially reacted with caspase-cleaved 
U1-70K. These findings suggested that neo-
epitopes generated upon damage by radicals 
are linked to RP, which in some cases can be 
considered as an early phase of SSc.
In this study, we analyzed sera from SSc 
patients for differential autoantibody reactivity 
to antigens in normal and oxidatively modified 
Jurkat cell extracts by immunoblotting. 
Next to patients with SSc, patients suffering 
from the SSc-related conditions RP and 
polymyositis/scleroderma  overlap syndrome 
(PM/Scl), and patients suffering from other 
autoimmune diseases like systemic lupus 
erythematosus (SLE), rheumatoid arthritis 
(RA), undifferentiated connective tissue 
disease (UCTD), and mixed connective tissue 
disease (MCTD) were analyzed as well.
Results
Oxidative modification of Jurkat cell extracts
Apoptotic pathways have been well 
characterized in Jurkat T cells, and this 
cell line has been extensively used for the 
characterization of apoptotic and necrotic 
modifications of autoantigens (18,28). To 
compare autoantibody reactivity directed 
to polypeptides in oxidatively modified cell 
extracts with reactivities to autoantigens 
present in extracts from apoptotic and 
necrotic cells, the same Jurkat T cell line 
phosphorylation, hyperphosphorylation, trans-
glutamination, and citrullination (5,6). Fur-
thermore, during apoptosis, the (modified) 
proteins translocate to apoptotic blebs at the 
cell surface (7,8), and it is believed that in 
such a way they are more easily exposed to 
the immune system. During necrosis, proteins 
are modified as well (6,9,10), and modified 
autoantigens may leak out of the cell due to 
the loss of membrane integrity of the necrotic 
cell. In a situation of massive cell death and/or 
a deficiency in the clearance system, the dying 
cells are not efficiently removed and elevated 
levels of modified self-molecules, displaying 
neo-epitopes, are presented to the immune 
system (11).
Some autoantibodies specifically occur 
in a particular autoimmune disease, and 
therefore have clinical relevance (12). For 
example, autoantibodies directed to the 
U1 small nuclear ribonucleoprotein complex 
(U1 snRNP) are associated with systemic lupus 
erythematosus (SLE) overlap disease (also 
referred to as mixed connective tissue disease, 
MCTD) (13). Recently, it was demonstrated 
that during apoptosis a neo-epitope is formed 
on the U1 snRNP, more specifically on its 
U1-70K protein component, and that patient 
sera (14,15) as well as antibody phage display 
libraries derived from such patients (16,17) 
contain autoantibodies that specifically react 
with this neo-epitope. Furthermore, we 
recently demonstrated that autoantibodies 
directed to apoptosis-specific epitopes on 
U1-70K are predominantly present early in 
the disease (18). This suggests that two steps 
can be distinguished in the anti-U1 snRNP 
autoimmune response: first autoantibodies 
arise against a specific neo-epitope on this 
U1-70K protein, which is created as a result 
of apoptotic modifications and is not present 
on the normal U1-70K. Subsequently, a 
secondary immune response is generated 
with autoantibodies directed to other epitopes 
on U1-70K that are present on both the 
apoptotic and the non-modified U1-70K, in a 
process called epitope spreading. Recently, a 
neo-epitope was also described to be created 
on the La protein upon treatment with 
granzyme B, which is involved in cytotoxic T 
lymphocyte (CTL)-induced cell death, and it 
was demonstrated that patient sera contain 
autoantibodies that specifically recognize 
granzyme B-cleaved La protein (19).
Much less is known about an association 
between the other forms of cell death (necrosis 
and oxidative stress) and autoimmune disea-
ses. Systemic sclerosis (SSc, and also referred 
to as scleroderma) is an autoimmune disease 
that affects approximately 0.03% of the 
population of the industrialized world (20). 
SSc is characterized by excessive production of 
collagen, which not only occurs in the skin, but 
also in tissues surrounding organs like lungs, 
heart, kidneys and gut. The tissue damage in 
SSc is thought to be caused by free radicals 
(oxidative stress) (21), which are produced 
upon ischemia-reperfusion. After a short 
period of ischemia (O2-depletion), reperfusion 
of the tissue takes place, and it is thought 
that in some cases re-oxygenation of the 
tissue is too rapid, leading to the production 
of free radicals that cannot be efficiently 
removed by the tissue. Free radicals stimulate 
fibroblast proliferation and fibrosis, and cause 
endothelial injury of micro-vessels leading 
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Figure 2. Patient sera that 
differentially react with oxidati-
vely modified and control cell 
extracts on immunoblot. Patient 
sera were analyzed for autoantibody 
reactivity with oxidatively modified 
(+) and control (-) cell extract. 
Patient sera were diluted 1,000-fold, 
and bound human antibodies were 
detected using HRP-labelled rabbit 
anti-human IgA,IgG,IgM antibodies 
and ECL. Patient sera are grouped 
by disease: SSc patients F14 (lanes 1 
and 2), Ks (lanes 3 and 4), Kzc (lanes 
5 and 6), V84 (lanes 7 and 8), and VG 
(lanes 9 and 10), RP patients B169 
(lanes 11 and 12), F12 (lanes 13 and 
14), H111 (lanes 15 and 16), H198 
(lanes 17 and 18), and W55 (lanes 19 
and 20), and PM/Scl patients Day5 
(lanes 21 and 22) and Ven 121 (lanes 
23 and 24). Protein bands that are 
specifically detected in oxidatively 
modified cell extract are marked 
with a solid arrow head, and protein 
bands that are present in the control 
cell extract, which could no longer 
be detected in oxidatively modified 
cell extract, are marked with an 
open arrow head. Molecular weight 
markers are at the left of each blot. 
In lanes 7 and 8, the position of DNA 
Topoisomerase I (Topo) is indicated 
on the left.
represent proteins that are only recognized in 
the oxidatively modified cell extract through 
recognition of a neo-epitope. In addition, also 
sera displaying reactivities preferentially or 
exclusively targeting molecules in the control 
extract were observed. In these cases, either 
the oxidative fragments of these proteins were 
too small to be detected on these western blots, 
or the oxidative modification had changed the 
protein in such a way that the patient serum no 
longer recognized it in the oxidatively modified 
cell extract. The results, of which an overview 
is presented in Table 1, were replicated in at 
least two independent experiments (sera that 
did not differentially react with the treated 
and non-treated extract were not included in 
was chosen. Oxidative modification can be 
introduced in vitro by incubation with Fe(II) 
or Cu(II), either alone or in combination with 
H2O2 or ascorbic acid (25). Cell extracts were 
prepared by sonication and removal of debris 
by centrifugation, and were used immediately 
for oxidative treatment. Since EDTA binds 
divalent ions, EDTA was omitted from the lysis 
buffer, and an EDTA-free cocktail of protease 
inhibitors was used to reduce proteolytic 
degradation. Various conditions (0.1 mM 
Fe(II)SO4, either alone or in the presence 
of 1.7 mM ascorbic acid or 1 mM H2O2; and 
0.1 mM Cu(II)SO4 in combination with 
1 mM H2O2) (25) were used to introduce 
oxidative modifications. Modification was 
monitored by the detection of the oxidation-
specific 33-38 kDa smear derived from the 
U1-70K protein (25,27). Consistent with 
previous reports the most efficient production 
of the U1-70K-derived fragments (Figure 1) 
was observed with 0.1 mM Fe2+ and 1.7 mM 
ascorbic acid at room temperature for 30 
minutes (25,27). As a negative control, cell 
extract was incubated in parallel, but in the 
absence of Fe2+ and ascorbic acid. Polypeptides 
were visualized by patient serum B16, which 
was known to react with several components 
of the U1 snRNP, including U1-70K, U1A, and 
Sm-B/B’ (18).
Screening patient sera 
In order to identify autoantigen modifi-
cations by oxidative treatment, sera from 
patients suffering from SSc (n=72), RP 
(n=129), PM/Scl (n=24), SLE (n=5), RA (n=4), 
UCTD (n=5), and MCTD (n=1) were analyzed 
for autoantibody reactivity towards specific 
polypeptides on immunoblots containing 
oxidatively modified cell extract. Figure 2 
demonstrates autoantibody reactivity of the 
patient sera that recognized proteins that were 
only or preferentially detected in the oxidatively 
modified material, but not in the control 
cell extracts. The oxidation-specific protein 
bands could either be degradation products 
of proteins with higher molecular weights that 
are present in the control cell extract, or could 
Figure 1. Detection of the oxidative fragmentation 
of the U1-70K protein (70 kDa), leading to the 
formation of a smear with a molecular weight of 
33 to 38 kDa. Jurkat cells were lysed by sonication, 
centrifuged and clear lysates were incubated with 
0.1 mM Fe2+ and 1.7 mM ascorbic acid for 30 minutes 
at room temperature. As a control, cell lysates were 
incubated for 30 minutes at room temperature in the 
same buffer but without the addition of Fe2+ and ascorbic 
acid. EDTA was added to a final concentration of 10 mM 
to stop the reactions, followed by the addition of SDS-
PAGE loading buffer and heating for 5 minutes at 95oC. 
Per lane, cell extract of 5x105 cells were loaded. The 
control cell extract (-) is run in lane 1, and the oxidatively 
fragmented cell extract (+) is run in lane 2. Polypeptides 
are detected with patient serum B16, 20,000-fold diluted, 
in combination with HRP-labelled rabbit anti-human 
IgA,IgG,IgM antibodies and ECL. The U1-70K protein is 
marked with an arrow, and is detected in both lanes. The 
33 to 38 oxidation-specific smear is marked with a solid 
arrow head and a vertical bar. Molecular weight markers 
are at the left.
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H111 (Figure 2, lanes 15 and 16) reacted with 
proteins of approximately 100, 44, 32, 25, 24, 
and 21 kDa in the control cell extract. In the 
oxidatively modified cell extract all proteins 
were detected, except for the 21 kDa protein. 
RP patient serum H198 (Figure 2, lanes 17 and 
18) reacted with proteins of 80, 30, 22, 20, 
18 and 15 kDa in the control cell extract. In 
the oxidatively modified extract an additional 
protein of 29 kDa was recognized as well. RP 
patient serum W55 (Figure 2, lanes 19 and 
20) demonstrated autoantibody reactivity to 
proteins of approximately 120, 55, and 35 kDa 
in the control cell extract. In the oxidatively 
modified extract, the 55 kDa protein was no 
longer detected, whereas a polypeptide of 
22 kDa was additionally recognized. This 
finding might indicate that the 55 kDa protein 
is fragmented to the 22 kDa protein. The 
22 kDa oxidation-specific protein seemed 
to be recognized somewhat more efficiently 
than the 55 kDa protein, which might result 
from autoantibodies to neo-epitopes on the 
oxidation-specific fragment. 
Serum of PM/Scl patient Day5 (Figure 2, 
lanes 21 and 22) reacted weakly with proteins 
of 80, 34, 30, and 22 kDa, and strongly with 
protein(s) of 37-43 kDa in both the control and 
the oxidatively modified cell extract. In the 
oxidatively modified cell extract, Day5 reacted 
with an additional protein of approximately 25 
kDa. PM/Scl patient serum Ven121 (Figure 2, 
lanes 23 and 24) reacted with 80, 70 kDa and 
35 kDa proteins in control cell extract. In the 
oxidatively modified cell extract the 35 kDa 
protein was no longer detected after oxidation, 
whereas a protein of 37 kDa was additionally 
present. Possibly, the 37 kDa protein could 
represent a modified form of the 35 kDa 
(Figure 2, lanes 7 and 8) reacted with proteins 
of approximately 150 and 100 kDa in the 
control and the oxidatively modified cell 
extracts. The 100 kDa protein is thought to 
represent DNA topoisomerase I (Topo), since 
V84 tested positive for autoantibodies directed 
to this 100 kDa protein in routine laboratory 
assays. V84 reacted with proteins of 95, 65 
and 45 kDa that were specifically present 
in the oxidatively modified cell extract. The 
95 kDa protein might result from oxidative 
fragmentation of Topo, as described previously 
(25), although we were unable to detect this 
polypeptide with other anti-Topo positive 
patient sera. It is unclear whether the proteins 
of 65 and 45 kDa derive from the 150 or the 
100 kDa protein that is present in the control 
cell extract, since autoantibody reactivity with 
neither of these proteins were reduced in the 
oxidatively modified extract. Autoantibodies 
in the serum of SSc patient VG (Figure 2, 
lanes 9 and 10) recognized proteins of 80 and 
17 kDa in control cell extract. The protein of 
17 kDa was no longer detected in the oxidatively 
modified cell extract.
RP patient serum B169 (Figure 2, lanes 
11 and 12) recognized proteins of 150, 45 and 
35 kDa in the control cell extract, the latter 
of which was not detected anymore in the 
oxidatively modified cell extract. Furthermore, 
proteins of approximately 63 and 65 kDa 
were stronger recognized in oxidatively 
modified cell extract compared to the control 
cell extract. Autoantibodies in serum of 
RP patient F12 (Figure 2, lanes 13 and 14) 
reacted with proteins of 100, 94, 80 and 
70 kDa in the control cell extract, but the 
80 and 70 kDa proteins were no longer detected 
in the oxidatively modified extract. RP patient 
the table). Differential reactivity was observed 
with five SSc patients, five RP patients, and 
two PM/Scl patients. It should be noted that 
such reactivities were not seen in any of the 15 
control sera.
SSc patient F14 (Figure 2, lanes 1 and 2) 
reacted with proteins of approximately 200, 
170, 100 and 55 kDa in both cell extracts, and 
with three additional proteins of around 150, 
140 and 130 kDa in the oxidatively modified 
extract. In case these three oxidation-specific 
proteins result from oxidative fragmentation, 
it is unclear whether they derive from the 
200 kDa or from the 170 kDa proteins, since no 
reduction in signals from these proteins in the 
oxidatively modified cell extract was observed, 
as would be expected upon protein degradation. 
However, detection of these oxidation-specific 
56K = annexin XI; CENP-B = centromere protein B; PM/Scl = polymyositis/scleroderma overlap syndrome; 
RP = Raynaud’s phenomenon; SSc = systemic sclerosis; Th/To = Th/To autoantigen (RNase MRP/RNase P); 
Topo = DNA topoisomerase I.
       Result immunoblotting  
           
Patient Diagnosis    Known autoantibody   Shared   Bands specific in   Bands specific  
      reactivities  bands  oxidatively  in control extract  
     (kDa)  modified extract (kDa)  
       (kDa)
F14 SSc     Topo, Th/To, 56K  ~200, 170, 100, 55 150, 140, 130  - 
Ks SSc     Topo   Multiple (weak) -   35-37
Kzc SSc     -     36   35
V84 SSc     Topo   150, 100  95, 65, 45   -
VG SSc     -   80  -   17
Table 1 Overview of patient sera with differential reactivity between oxidatively modified and control cell extracts
proteins could also result from recognition 
of neo-epitopes that are only present on the 
oxidatively modified protein. In this case, this 
patient serum would contain autoantibodies 
to the oxidatively modified form of these 
proteins with no detectable autoantibodies 
to their non-modified counterparts. Serum of 
SSc patient Ks (Figure 2, lanes 3 and 4) reacted 
with a protein smear of 35 to 37 kDa, which 
was not detected in the oxidatively modified 
cell extract. SSc patient serum Kzc (Figure 2, 
lanes 5 and 6) demonstrated unusual differ-
ential reactivities with oxidatively modified 
and control cell extracts, since the oxidation-
specific target protein (36 kDa) migrated 
slower in SDS-PAGE gels than the putatively 
corresponding .proteins in the control cell 
extract (35 kDa). Serum of SSc patient V84 
B169 RP     -   150, 45  65, 63 (stronger)  35
F12 RP     -   100, 94  -   80, 70
H111 RP     -   100, 44, 32, 25, 24 -   21
H198 RP     CENP-B  80, 30, 22, 20, 18, 15 29   -
W55 RP     Th/To   120, 35  22   55
Day5 PM/Scl     Ro52, La, Jo-1  80, 37-43, 34, 30, 22 25   -
Ven121 PM/Scl     Ro52, PM/Scl75, PM/Scl100 80, 70  37   35
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by a trypan blue assay (data not shown). 
Figure 3 shows the autoantibody reactivities of 
patient sera V84 and F14 with antigens present 
in apoptotic, necrotic and oxidative cell 
extracts. The oxidation-specific polypeptides 
of 95, 65 and 45 kDa recognized by V84 were 
clearly recognized in the oxidatively modified 
cell extract, but not in the control, the apoptotic 
and the necrotic cell extracts. A fragment of 
approximately 70 kDa was specifically detected 
in apoptotic cell extracts, both induced by the 
drug anisomycin and by Fas ligand, and was 
believed to result from cleavage of Topo (10). 
Also the oxidation-specific polypeptides of 
around 150, 140 and 130 kDa recognized by 
F14 were clearly detected in the lane with 
oxidatively modified cell extract. These protein 
bands were neither present in the control cell 
extract, nor in the lanes containing apoptotic or 
necrotic cell extract. In addition, patient serum 
F14 recognized a polypeptide of approximately 
70 kDa in the apoptotic material, both after 
induction of apoptosis by anisomycin and by 
Fas ligand. This protein fragment was believed 
to derive from apoptotic cleavage of Topo, 
which is supported by the fact that patient F14 
was known to possess autoreactivity with this 
autoantigen (see Table 1). No differences were 
detected between the necrotic and the control 
cell extracts. These results demonstrate that the 
neo-epitopes on the polypeptides recognized 
by these sera after oxidative modification are 
unique for this process, and are not created 
during apoptosis and necrosis. 
Discussion
To date, experimental data on oxidative 
modifications of autoantigens are sparse. 
Here we report novel patterns of oxidatively 
modified proteins that are recognized by 
autoantibodies in sera from patients suffering 
from scleroderma, or from scleroderma-
associated conditions such as Raynaud’s 
phenomenon and polymyositis/scleroderma 
overlap syndrome. The fact that the oxidative 
fragments are not generated during apoptosis 
and necrosis indicates that neo-epitopes on 
oxidatively modified proteins exist and that 
they are different from apoptotic and necrotic 
neo-epitopes on these autoantigens. Since we 
did not find antibody activities to oxidatively 
modified protein (fragments) in control sera, 
our results support the idea that modifications 
during oxidative stress are linked to 
autoantibody formation in scleroderma and 
scleroderma-related conditions.
The appearance of specific autoantibody 
reactivities with the oxidatively modified 
material may be explained in two ways. First, 
the electrophoretic mobility of proteins that 
are also targeted in the non-modified extract 
might be changed, e.g. by fragmentation, 
which can be expected to occur in the presence 
of radicals (25,27). Second, the modification of 
polypeptides may lead to the generation of neo-
epitopes, which are targeted by the antibodies 
in these sera. Finally, also a combination 
of these phenomena may occur when the 
modification that affects the electrophoretic 
mobility also generates a neo-epitope. The 
finding that autoantibodies in several patient 
sera (for example F14 and V84) reacted 
protein in control cell extract, indicating that 
its molecular weight was slightly increased by 
other modifications than cleavage. It is also 
feasible that the 35 kDa protein was degraded 
to smaller fragments that were not detected on 
this western blot, and that the 37 kDa protein 
results from fragmentation of the 80 or the 
70 kDa proteins.
We also analyzed a set of monoclonal 
antibodies (mAb) directed to well-charac-
terized autoantigens, including anti-La mAb 
SW5, anti-Ro52 mAb 4C6, anti-Sm mAb 
Y12, anti-Sm-B/B’ mAb ANA125, and anti-
U1A/U2B” mAb 9A9, and a polyclonal rabbit 
antibody directed to poly-(ADP-ribose) poly-
merase (PARP). None of these antibodies 
demonstrated differential reactivities (data 
not shown), indicating that their target 
autoantigens are not detectably altered in 
the oxidatively modified cell extract.  
Autoantibody targets generated by oxidative 
modification are not generated during cell 
death
Two patient sera with strong reactivity 
against oxidation-specific polypeptides, V84 
and F14, were analyzed on immunoblots 
containing apoptotic, necrotic and oxidatively 
modified cell extracts. Apoptosis was induced 
by Fas ligand (29) or anisomycin (18) for 
8 hours at 37oC. After 8 hours, the 70 kDa 
U1-70K protein was completely cleaved to 
the apoptosis-specific 40 kDa fragment (data 
not shown), which was detected by western 
blotting using a recombinant anti-U1-70K 
monoclonal antibody (17). The U1-70K 
cleavage is regarded as a biochemical marker 
for apoptosis (30). Necrosis was induced by 
incubation with 200 µM mercury acetate for 
7 hours at 37oC (9). After 7 hours, approximately 
80% of the cells were necrotic, as determined 
Figure 3. Autoantibody reactivities of 
patient sera with proteins in oxidatively 
modified, apoptotic and necrotic cell 
extract on immunoblot. Control cell 
extract was run in lanes 1 and 6, and 
oxidatively modified cell extract, which was 
prepared by incubation with 0.1 mM Fe2+ 
and 1.7 mM ascorbic acid for 30 minutes at 
room temperature, was run in lanes 2 and 7. 
To induce apoptosis, Jurkat cells were 
incubated with anisomycin (lanes 3 and 8) or 
Fas ligand (lanes 4 and 9) for 8 hours. Necrosis 
was induced by incubation with Hg2+ for seven 
hours (lanes 5 and 10). Patient sera were 
incubated with the blotting membrane at a 
1,000-fold dilution and bound antibodies were 
detected by HRP-labelled rabbit anti-human 
IgA,IgG,IgM antibodies and ECL. On the right, 
oxidation-specific fragments are marked with a 
solid arrow head, and apoptosis- and necrosis-
specific fragments are marked with an open 
arrow head. Molecular weight markers are at 
the left of each blot.
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slower in polyacrylamide gels compared to the 
putative corresponding protein in control cell 
extracts.
Differential reactivity with oxidized pro-
teins (or fragments thereof) was observed 
in a relatively low number of patient sera. 
Out of a total of 225 sera only 12 sera were 
selected based upon their differential reactivity 
patterns. This raises the question whether 
the immune response against the modified 
proteins is relevant for the pathophysiology 
of the disease. In addition, it is puzzling why 
the same reactivities were not observed with 
different patient sera, in particular within one 
disease group. An important point to consider 
in this regard is that the serum samples used 
in general were withdrawn from the patients at 
relatively late stages of the disease process. The 
reactivity to the modified antigens is likely to 
be associated with the (very) early phases of the 
disease and it is known that such reactivities 
may become less prominent during further 
development of the disease. Furthermore, 
it has been shown that other processes of 
cell death, or other phenomena, may play a 
role as well. Differences between individual 
patients may cause differences in reactivity 
patterns. For example, a set of scleroderma 
autoantigens has been described to be 
uniquely cleaved by granzyme B, and a 60 kDa 
fragment, generated by granzyme B cleavage 
(and presumably derived from centromere 
protein C) correlated with ischemic digital loss 
in scleroderma patients (32). These findings 
implicate CTL-induced cell death as the 
underlying mechanism in breaking tolerance 
to self-antigens in these specific patients. The 
molecular characterization of the antigens 
Materials and Methods
Patient sera 
Patient sera were obtained from the serum 
collection of the Department of Biochemistry, 
Radboud University Nijmegen (The Netherlands). 
These patients had been seen at the Department 
of Rheumatology of the University Medical Centre 
Nijmegen or the St. Maartenskliniek Nijmegen (The 
Netherlands), and had been classified in accordance 
with standard criteria for each disease. Patient sera 
were present from SSc (n=72), RP (n=129), PM/Scl 
and epitopes that are responsible for the 
differential reactivities observed will, besides 
improving the sensitivity and specificity of 
the assay, facilitate a more systematic and 
more widespread analysis of the occurrence 
of these autoreactivities in autoimmune sera. 
Because only low numbers of SLE, RA, UCTD 
and MCTD sera were analysed in parallel 
in our study and only low frequencies of 
differentially reactive sera were observed for 
the other patient groups, the absence of such 
sera in the SLE, RA, UCTD and MCTD groups 
does not allow conclusions on the recognition 
of oxidatively modified antigens by these 
patients.
In conclusion, we have shown that sera from 
patients with scleroderma or scleroderma-
related conditions contain autoantibodies 
to antigens that are uniquely generated in 
cell extracts after treatment with oxidative 
reagents. Our results thus support the concept 
that modifications generated during oxidative 
stress are linked to autoantibody formation in 
these diseases.
strongly with polypeptides in an oxidative 
modification-dependent manner, which did 
not coincide with an apparent reduction in 
other autoantibody reactivities of these sera, 
suggests that the generation of neo-epitopes is 
the most important process. Clearly, our study 
does not provide insight into the molecular 
identity of the polypeptides that contain 
neo-epitopes created during the oxidative 
treatment. Immunoaffinity purifications of the 
proteins from oxidatively modified cell extracts 
will be required to shed more light on this. Also 
further studies are necessary to elucidate the 
exact nature of these neo-epitopes.
When the polypeptides that are specifically 
targeted by the autoantibodies in the 
oxidatively modified extract are related to 
autoantibody targets in the non-modified 
extract, part of the reactivity may be due to 
antibodies recognizing also the non-modified 
proteins. Competition experiments, in which 
serum is pre-incubated with control cell 
extract in order to compete for binding of 
autoantibodies to common epitopes, might 
provide more insight into this issue. 
Although several distinct patterns of 
oxidative modification could be identified, 
the fragmentation pattern described for the 
scleroderma autoantigen DNA topoisomerase 
I (from a 100 kDa intact protein to 95 kDa 
oxidative fragment), could only be detected 
with one patient serum (V84), and not with 
at least 12 other sera with strong anti-Topo 
reactivity. This observation suggests that the 
oxidation-specific protein of 95 kDa detected 
by serum V84 is probably not generated via 
fragmentation of DNA topoisomerase I, but 
corresponds to another protein instead. The 
fact that Topo fragmentation, as described 
by Casciola-Rosen et al. (25), was not de-
tected in our experiments might be due 
to the difference in cell lines used: Topo 
fragmentation was previously demonstrated 
in HeLa cells (25,27), whereas Jurkat cells 
were used in the study presented here. 
Tissue- or cell-type specific modifications have 
indeed been described before. For example, 
Ulanet et al. published that the scleroderma 
autoantigen B23 was very efficiently cleaved 
in differentiated vascular smooth muscle cells 
upon incubation of the cells with granules 
containing granzyme B, whereas it was not 
cleaved in undifferentiated vascular smooth 
muscle cells and fibroblasts that were treated 
in the same way (31). We used Jurkat cells in 
this study, because apoptotic pathways are 
well-characterized in these cells, and because 
Jurkat cells have been extensively used for 
characterization of autoantigen modifications 
during apoptosis and necrosis. This would also 
allow a comparison of oxidative modifications 
with apoptotic and necrotic modifications. On 
the other hand, it might be important to study 
such modifications in cells that are exposed to 
oxidative stress in vivo. In the case of SSc and 
RP patients, such processes may occur in the 
endothelial cells that form the inner lining of 
blood vessels, and in fibroblasts, which are 
present in the underlying connective tissue. 
As stated above, besides radical-mediated 
polypeptide fragmentation other modifications 
may occur under oxidative stress conditions, 
in particular modifications of amino acid side 
chains. This possibility is indeed supported 
by the finding of serum reactivities with 
oxidation-specific proteins that migrate 
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which contained soluble protein (fragments) that 
had leaked out of the cells. Samples were heated for 
5 minutes at 95oC prior to gel electrophoresis.
SDS-PAGE and immunoblotting
Proteins from cell extracts were separated by 
SDS-PAGE, and were subsequently transferred to 
nitrocellulose membranes (Schleicher&Schuell) 
by semi-dry electroblotting. Protein transfer was 
checked by Ponceau S staining. Per lane proteins 
from approximately 5x105 cells were loaded. 
All incubation steps were carried out at room 
temperature on a shaking table. The blots were 
blocked with 5% non-fat dried milk powder in PBS, 
containing 0.05% Tween-20 (MPBST), for one hour. 
Patient sera were incubated with the blot membrane 
at a 1,000-20,000-fold dilution in MPBST, for 
one hour. Bound antibodies were detected with 
horseradish peroxidase (HRP)-labelled goat-anti-
human IgA,IgG,IgM antibodies (DAKO), 1,000-
fold diluted in MPBST, followed by enhanced 
chemiluminescence (ECL) detection. After antibody 
incubations, membranes were washed extensively 
with MPBST to reduce background signals.
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Since its initial discovery in 1985, the antibody phage display technology has gone through major developments, and a number of sophisticated applications 
have been designed. The first part of this chapter intends to discuss our antibody 
phage display results and to put them in perspective of other developments in 
the field of antibody phage display technology. The data presented in the second 
part of this thesis support the hypothesis that cell death-specific epitopes are 
involved in breaking tolerance to self-antigens. The implications of these results 
are discussed in relation to recent findings in other studies.
Part 1: Antibody phage 
display technology
Formats and applications of recombinant 
antibody fragments
Since single chain variable fragments 
(scFvs), and Fabs, are easily cloned and 
expressed in bacteria and mammalian cells, it 
is relatively simple to fuse them with various 
peptide tags and proteins. If the activity of the 
resulting recombinant antibody is unaltered 
and the fusion protein can be functionally 
expressed, the possible applications of such 
constructs are almost unlimited.
In general, therapeutic antibodies, directed 
to specific cell types or cells in a certain 
pathological condition (for example tumour 
cells), are labelled with specific chemicals, or 
conjugated or fused to proteins that affect (e.g. 
kill) the target cell. Such fusion proteins are 
for example cytokines (1), enzymes that can 
convert pro-drugs (with no cytotoxicity) into 
active drugs (with cytotoxicity) in antibody-
directed enzyme pro-drug therapy (2,3), 
Fas ligand (4), granzyme B (5), and tumour 
necrosis factor-alpha (TNF-alpha) (6). 
For research purposes, many tags are 
available with a variety of applications. The 
vesicular stomatitis virus glycoprotein (VSV-
G)- (7), c-myc- (8,9), and Flag-tags (10) are 
examples of small peptide sequences that are 
widely used for this purpose. In combination 
with anti-VSV-G, anti-c-myc and anti-Flag 
antibodies, tagged scFvs are easily detected in 
various immunological assays. 
Examples of tags that can be used for 
purification of scFvs (and proteins in general) are 
the hexahistidine-tag (11), maltose binding protein 
(12), the streptavidin-binding-tag (13), glutathione-
S-transferase (14), and different domains of the 
Staphylococcus aureus protein A (15). Furthermore, 
fusion of recombinant antibodies to such tags 
allows immunoaffinity purification of their antigens 
from complex protein mixtures. For example, in 
Chapter 4, scFvs directed to unknown targets were 
C-terminally fused to the hexahistidine-tag for 
immobilization on Ni2+-NTA agarose beads. After 
incubation with cell extract, the bound antigens 
were eluted from the beads, separated on 
polyacrylamide gels, and identified by mass 
spectrometry. 
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complex libraries have been made only by a 
few companies, such as Cambridge Antibody 
Technology (library with more than 1011 
different antibodies), MorphoSys (HuCAL 
library, which contains more than 1010 
different antibodies), and Dyax (libraries with 
more than 1010 different antibodies), and thus 
protected from use by others. Alternatively, 
moderate affinities of isolated antibodies can 
be increased by mutagenesis, although this is 
a time-consuming step that has to be carried 
out for each individual antibody (25). If an 
antibody with relatively high affinity is not 
readily isolated from a synthetic library, or if 
a range of antibodies to one particular antigen 
is needed, immunization and preparation of 
an immune library might be a better approach 
(25). This option also offers a suitable alter-
native when high affinity antibodies are 
needed. In Chapter 2, we demonstrated that 
antibodies could be isolated from chickens that 
were simultaneously immunized with mixtures 
of antigens. A similar approach had also been 
used in rabbits (27), but chicken offers two 
additional advantages. First, chickens are, 
compared to rabbits, phylogenetically more 
distant from human, and thus more likely 
to evoke an immune response to conserved 
epitopes on human molecules. Second, 
although preparation of libraries from rabbits 
already involves less primer sets compared 
to the preparation of libraries from mice or 
humans, chicken libraries need only two 
primer sets, which significantly decreases the 
time for library preparation. In conclusion, 
multiple antigen immunization reduces the 
number of animals needed, where chickens are 
an attractive source for antibody generation.
Target discovery by antibody phage display
As described in Chapter 1, several methods 
have been designed for the identification of 
proteome-specific targets. The great advantage 
of such methods is that at the same time that the 
targets are discovered, monoclonal antibodies 
directed to these targets are generated, 
and both the antigen and the antibody are 
potential therapeutic or diagnostic tools. 
The novel subtractive approach described in 
Chapter 4 can be regarded as a combination 
of three existing approaches: selection in 
solution on biotinylated antigens (28,29), 
subtractive selection, and selection on 
antigens immobilized on blotting membranes, 
(30-33). After selection to biotinylated 
antigens in solution, monoclonal phages 
had to be individually analyzed for binding 
reactivity on immunoblot strips containing 
normal and apoptotic cell extract in a rather 
laborious screening procedure. Therefore, 
the last part of the selection procedure, the 
enrichment step on blot, was included to 
reduce the number of phages that needed to 
be analyzed. The combination of subtractive 
selection, selection in solution and selection 
on blotting membranes might result in 
recombinant antibodies that recognize an 
epitope that is available in solution as well as 
on blot, and such antibodies are thus expected 
to be applicable in a wide range of assays. A 
disadvantage might be that some phages that 
do bind differential epitopes during selection 
in solution might not be selected in the second 
part of the procedure, for example when they 
are directed to a conformational epitope that 
is not available anymore on the blot after the 
blotting procedure.
For the use of scFvs in localization studies, 
peptide tags like the VSV-G-tag can be used, 
but several other approaches have been 
described as well. For example, scFvs have 
been fused to the green fluorescent protein 
(GFP) (16), and scFvs can equally well be fused 
to red, yellow and blue fluorescent proteins 
(17,18)  in order to perform double- or triple-
staining studies. Another method for direct 
localization of target antigens is fusion of 
scFvs to alkaline phosphatase (19). Similarly, it 
should be possible to fuse scFvs to horseradish 
peroxidase, although such a format has not 
been described so far.
The approach described in Chapter 3 is an 
attractive additional format for localization 
studies. Here, scFvs were fused to constant 
domains from immunoglobulin light chains 
from different species (human, mouse and 
chicken), and detected with commercially 
available, fluorescently labelled secondary 
antibodies directed to human, mouse 
and chicken immunoglobulins. The main 
advantage of this method compared to the 
approaches described above is that a large 
number of combinations are possible (one is 
not dependent on the animal the antibody is 
derived from), since the secondary antibodies 
with different fluorescent labels are readily 
available. The diversity of combinations that 
is generated by using the light chain constant 
domains from human, mouse and chicken, can 
be further expanded by fusing scFvs to light 
chain constant domains from other species. 
In such systems rabbit and goat are attractive 
alternatives, since secondary antibody conjuga-
tes to rabbit and goat immunoglobulins are 
commercially available. Furthermore, next to 
their use in localization studies, the constant 
domains can also be used for detection of 
the scFvs in ELISA or immunoblotting. A 
disadvantage of recombinant antibodies is that 
they are, in general, less stable compared to 
complete immunoglobulins like monoclonal 
hybridoma antibodies. However, the stability 
can be improved by, for example, mutagenesis 
(20) or loop grafting (21). One can also use 
single domain antibodies, which can be 
isolated from camelid or shark libraries, and 
which have proven to be highly stable (22).
Chapter 3 also demonstrated that fusion of 
scFvs with constant light chain domains leads 
to partial scFv dimerization, although the level 
of dimerization is not as high as with Jun 
domains, which are leucine zipper domains 
that can mediate dimer formation (23,24). The 
fusion of constant light chain domains may 
also increase scFv avidity (24), although this 
still has to be confirmed by experimental data.
Antibody phage display systems
For ethical and economic reasons, it is 
valuable to reduce the number of test animals 
needed in antibody phage display. This can 
be achieved (1) by using naïve or synthetic 
libraries (no animals needed), or (2) by 
preparing immune libraries from animals that 
have been simultaneously immunized with 
multiple antigens (fewer animals needed). 
Although high affinity recombinant antibodies 
can be isolated from naïve or synthetic 
libraries, this is only possible if the libraries 
are very large (i.e. a complexity of 1011 or 
higher) (25). The preparation of such large 
antibody libraries is difficult and laborious 
(see review by (26)), and nowadays such 
    Chapter 9146 General discussion 147
apoptotic structures supports (though not 
proves) the postulation that these proteins can 
trigger an autoimmune reaction.
After the selection steps, three monoclonal 
phages were chosen that strongly react with 
proteins that are differentially present in 
normal and apoptotic cell extracts. These 
three monoclonal phages were used to 
further set-up the identification procedure, 
which included isolation of the target antigen 
from cell extracts by immunoprecipitation, 
and identification of the target by mass 
spectrometry. Of course, it would be of much 
interest to isolate other monoclonal phages 
from the pool of phages that eluted from the 
individual spots, since these might target other 
(disease) markers of interest. It would also 
be valuable to study other cell death-specific 
epitopes on autoantigens, for example those 
created during necrosis or oxidative damage, 
by a similar approach.
Concluding remarks part 1
In short, the methods developed and 
described in this thesis extend the range of 
current methods using antibody phage display 
and recombinant antibodies, and provide 
new means to detect specific (apoptotic) 
autoantigens in autoimmune diseases. The 
differential proteomic selection method may 
be more widely applicable in the identification 
of antigens that are uniquely expressed in one 
proteome but not in another. 
Part 2: The role of cell death-
specific epitopes in breaking 
tolerance to self-antigens
How can tolerance to self-antigens be 
broken?
One model for breaking immunological 
tolerance to ‘self’-antigens that is gaining a lot 
of attention is the molecular mimicry model. 
In this model, which has been mainly linked 
to SLE, the production of autoantibodies in 
patients is believed to be initiated through 
cross-reactivity with epitopes on bacteria or 
viruses. Autoantibodies directed to the SLE 
autoantigens Sm-B/B’, Sm-D and Ro60 have 
been found to cross-react with the Epstein-
Barr virus nuclear antigen-1 (EBNA-1) (see 
reviews by (38-40)), and this virus has been 
found significantly more frequently in SLE 
patients as compared to controls (41,42). 
Recently, McClain et al. identified an epitope 
on Ro60, which was recognized by serum 
samples from SLE patients before they were 
diagnosed (43). It was demonstrated that 
autoantibodies to this early autoepitope cross-
reacted with a peptide contained in EBNA-1. 
Immunization of rabbits with peptides based 
on either the initial epitope on Ro60 or the 
cross-reactive EBNA-1 epitope, resulted in 
autoantibodies to multiple epitopes on Ro60, 
with subsequent epitope spreading to epitopes 
on Sm-B’, RNP and dsDNA. Furthermore, the 
immunized rabbits developed some symptoms 
that are also found in SLE patients. A similar 
cross-reactivity has also been suggested to 
exist between Ro60, which is next to SLE 
also associated with Sjögren’s syndrome, and 
Coxsackie virus 2B protein (44). This finding is 
The extra enrichment step on immuno-
blot is especially suitable when no robotic 
equipment is available. When robotic equip-
ment can be used, it seems preferable to 
perform one selection round on (biotinylated) 
antigens in cell extracts, which keeps 
the diversity relatively high compared to 
performing more selection rounds, and 
subsequently screen as many monoclonal 
phages as possible. Nevertheless, it will still be 
difficult to analyze many monoclonal phages 
individually on blotting strips, but a capture 
ELISA with both extracts could be developed. 
A drawback of the blotting approach is that 
differences in molecular weight, for example 
those of apoptosis-specific epitopes generated 
after specific cleavage of certain proteins, 
might be missed in this way. 
Although the method described in 
Chapter 4 is designed for the identification 
of intracellular targets, it can be used for 
extracellular and cell surface proteins as well. 
In this case, cell surface proteins are isolated 
and, after biotinylation, used for the selection. 
Furthermore, the method should be applicable 
using non-biased naïve of synthetic libraries, 
although chances of isolating a specific target 
are believed to be higher when immune 
libraries with higher affinity reactivities to-
wards the antigen of interest are used.
The three targets (U1-70K, p54nrb/PSF 
and hnRNP C) that were isolated were all 
differentially present between apoptotic and 
non-apoptotic cell extracts, as demonstrated 
in Chapters 4, 6 and 7. U1-70K is a well-known 
marker for systemic lupus erythematosus 
(SLE) overlap disease (also referred to as 
MCTD, mixed connective tissue disease). The 
fact that the epitope on U1-70K recognized by 
scFv R3A4 was apoptosis-specific (Chapter 
4), and that the 40 kDa apoptotic fragment of 
U1-70K was often better recognized by patient 
sera compared to intact U1-70K (Chapter 6), 
supports the hypothesis that such epitopes are 
involved in breaking tolerance to self-antigens. 
These results furthermore demonstrate that 
the subtractive antibody phage display method 
is a valuable tool for the identification of such 
markers.
HnRNP C has been described as an auto-
antigen in only a few patients so far (34,35). 
Due to difficulties with the generation of an 
expression construct for hnNRP C, we were 
not able to measure autoantibody reactivities 
towards this protein. It would be valuable to 
determine whether autoantibodies in patient 
sera to hnRNP C react stronger with the 
apoptotic variant of these proteins, as was 
demonstrated for the U1-70K protein (Chapter 
6). In Chapter 7, we showed that PSF/p54nrb 
is a minor autoantigen as well. Reactivity to 
recombinant p54nrb, though with low titres, 
was found in one patient serum used for the 
screening of the libraries (Chapter 4), and in 
two patients suffering from PM/Scl overlap 
syndrome. In addition, the experiments 
described in Chapter 7 demonstrate that 
p54nrb/PSF and hnRNP C translocate from 
their nuclear localization in normal HeLa 
cells to apoptotic bodies or apoptotic blebs at 
the cell surface. This phenomenon has been 
described for many autoantigens, including 
U1-70K (36,37). Since proteins are believed to 
be more easily exposed to the immune system 
when they are present in apoptotic blebs, the 
presence of p54nrb/PSF and hnRNP C in such 
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to self-antigens is the finding that the U1-70K 
protein displays apoptosis-specific epitopes, 
and that such epitopes are recognized by 
specific autoantibodies in anti-U1-70K patient 
sera (48,49). The experiments described in Chapter 
6, which demonstrate that the majority of anti-
U1 small nuclear ribonucleoprotein (snRNP) 
sera preferentially recognize apoptotically 
cleaved U1-70K as compared to intact U1-70K 
on immunoblot, confirm these data. Moreover, 
the immunoprecipitation experiments shown 
in Chapter 4 demonstrate that apoptosis-
specific epitopes on the U1-70K protein are 
also recognized by the recombinant antibody 
obtained via the subtractive phage display 
approach described in this chapter, as well as 
by recombinant antibodies isolated from SLE-
derived antibody phage display libraries as 
described in a previous study by Degen et al. 
(50). The additional finding that early patient 
sera are relatively enriched for autoantibodies 
directed to the apoptotic fragment of U1-70K 
(Chapter 6) further supports the assumption 
that epitopes that are specifically present on 
apoptotic U1-70K are involved in breaking 
tolerance to U1-70K and the U1 snRNP complex.
The La protein, a protein binding to many 
different RNAs, is an important autoantigen 
associated with Sjögren’s syndrome (see review 
by (51)). Recently, a neo-epitope was found to 
ACPA = anti-citrullinated protein/peptide antibodies; CCP = cyclic citrullinated peptide; dsDNA = double stranded 
DNA; Jo-1 = histidyl tRNA synthetase; MCTD = mixed connective tissue disease (SLE overlap disease); PM/DM = 
polymyositis/dermatomyositis; PM/Scl = polymyositis/scleroderma overlap syndrome; RA = rheumatoid arthritis; 
SLE = systemic lupus erythematosus; SSc = systemic sclerosis (scleroderma); U1 snRNP = U1 small nuclear 
ribonucleoprotein
Table I  Association of autoantibody reactivities and HLA haplotypes with systemic autoimmune diseases
Autoimmune  Examples of   HLA haplotype associated with References 
disorder  serological markers disease or autoantibody reactivity
SLE  anti-dsDNA, anti-Sm  DRB1*0301,0801,1501;       (109)  
     DQB1*0201,0402,0602
SSc (diffuse) anti-DNA Toposiomerase I DR5/11 (DRB1*1101,1104; DQB1*0301;       (110)  
  (Topo)   DPB1*1301)     
     DR2 (DRB1*1502; DQB1*0601; DPB1*0901)  
     DR2 (DRB1*1602; DQB1*0301; DPB1*1301)
SSc (limited) anti-centromere proteins DR1 (DRB1*0101; DQB1*0501)      (110)  
RA  anti-CCP (ACPA)  DR4 (DRB1*0401)         (92) 
PM/DM  anti-Jo-1   A*01; B*08; Cw*0701; DRB1*0301;        (94)  
     DQA1*0501     
PM/DM  anti-Mi2   DRB*0701; DQA1*0201       (94)  
PM/Scl  anti-PM/Scl-100; anti-PM/Scl-75 DR3 (DRB1*0301; DQB1*0501)      (110)  
MCTD  anti-U1 snRNP (anti-RNP) DR4 (DRB1*04; DQB1*0302)       (110)
in accordance with the detection of Coxsackie 
virus RNA in biopsies of salivary glands from 
patients suffering from Sjögren’s syndrome 
(39). Also in the molecular mimicry model, the 
genetic background is believed to contribute 
to an individual’s susceptibility to develop 
an autoimmune response, since many people 
have been infected with Epstein-Barr virus 
(42), though only a small percentage develops 
SLE. 
Another model involves anti-idiotype 
antibodies. Idiotypes are the antigenic 
constitutions of the variable region of an 
antibody, and they are recognized by anti-
idiotypic antibodies, which are known to 
occur in patients suffering from autoimmune 
diseases (see review by (45)). It is believed 
that antibodies carrying idiotypes can induce 
production of anti-idiotype antibodies, which 
subsequently may trigger the production of 
anti-anti-idiotype antibodies. Consequently, 
a network is created of interacting antibodies 
in which the idiotypic determinants of each 
antibody are complemented by those of 
another. Recently, Pendergraft et al. launched 
a theory, which they named the autoantigen 
complementarity theory (46). In this theory 
it is hypothesized that a (microbial) protein 
whose amino acid sequence is (in part) 
structurally the complement of that of a self-
antigen will generate an immune response. 
The idiotypic antibody that is produced elicits a 
second immune response to the first antibody, 
resulting in an anti-idiotypic antibody. Due to 
the complementarity of the initial triggering 
antigen, the idiotypic antibody mimics the 
complementary autoantigen, and as a con-
sequence the anti-idiotypic antibody is directed 
to the autoantigen. By performing homology 
searches of complementary protein sequences, 
these authors found many microbial and 
fungal proteins with complementing abilities, 
supporting the idea that invading micro-
organisms indeed can deliver the initiating 
immunogen.
In a third model it is hypothesized that 
modified self-antigens are released from dying 
cells and that these modifications can break 
immunological tolerance to these self-antigens. 
This model will be discussed extensively in the 
following paragraphs.
Do autoantigens display cell death-specific 
epitopes?
More and more experimental data support 
the hypothesis that neo-epitopes, resulting 
from post-translational modifications of 
autoantigens during cell death, can trigger 
an autoimmune reaction. For example, 
peptidylarginine can be converted into 
peptidylcitrulline, which is catalyzed by 
peptidylarginine deiminases, enzymes that 
are known to be particularly active in dying 
cells. Anti-citrullinated protein antibodies 
(ACPA) are tightly associated with rheumatoid 
arthritis (RA) (see Table 1). Recently, 
Lundberg et al. demonstrated in a rat model 
that citrullinated proteins can break tolerance 
to self-antigens (47). Immunization of rats 
with citrullinated rat serum albumin (RSA) led 
to the production of antibodies to citrullinated 
(and non-citrullinated) RSA, whereas 
immunization with non-modified RSA did 
not. As described in Chapter 5, important 
additional support for the hypothesis that 
neo-epitopes play a role in breaking tolerance 
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The typical molecular responses occurring 
in the various types of cell death differ 
as well. Apoptosis can be divided into an 
intrinsic pathway (characterized by release 
of cytochrome C from the mitochondria 
upon induction by a variety of stimuli) and 
an extrinsic pathway (induced when death 
receptors, such as Fas or the TNF receptor, are 
activated through binding with their ligands). 
In both apoptotic pathways, caspases (cysteine 
proteases that cleave after aspartic acid) are 
key players (60,61). After activation, these 
caspases cleave substrate proteins (62), and 
thereby activate, either directly or indirectly, 
enzymes that subsequently modify other 
molecules in the dying cell. Examples of 
such modifications are (de)phosphorylation, 
transglutamination and citrullination of 
proteins (63), cleavage of chromosomal DNA 
into nucleosomal units (64), and cleavage of 
RNA (see review by (65)).
In addition, cells can be stimulated to go 
into apoptosis by cytotoxic T lymphocytes 
(CTLs), which serve to eliminate virus-
infected cells and tumour cells (see reviews 
by (66,67)). After recognition of a target cell, 
cytotoxic granules containing perforin and 
granzymes are released from the CTLs. The 
granzymes enter the target cell through pores 
that are formed by the perforin molecules, and 
activate caspase-dependent and -independent 
apoptotic pathways (see reviews by (68,69)). 
Granzyme B is a serine protease that is able to 
cleave proteins at the same sites as caspases, 
i.e. at aspartic acid residues (see review by 
(70)), but it can also cleave proteins at other 
sites which are not susceptible to caspase 
cleavage (71). 
For necrosis, only cleavage has been 
described as a possible source of protein 
modifications (72). Here, cathepsins and 
calpains are described as the main cleaving 
enzymes (73,74), although these enzymes can 
also be activated during apoptosis (75,76). 
An additional source of protein modification 
is oxidative fragmentation by radicals, which 
has been linked to SSc autoantigens (77,78). 
Such radicals are believed to be formed during 
ischemia-reperfusion, a process that is known 
to occur in the skin of patients with SSc and 
Raynaud’s phenomenon (see review by (79)).
As summarized in Table 2, the various 
proteolytic enzymes (and radicals) that are 
activated during the different processes 
of cell death cleave their target proteins at 
different recognition motifs, which implies 
that they create different neo-epitopes on 
these proteins. An example of a protein that 
is differentially cleaved during the different 
processes of cell death is the U1-70K protein. 
U1-70K is cleaved by caspase-3 resulting in 
the appearance of a 40 kDa fragment, whereas 
cleavage by granzyme B leads to a fragment of 
60 kDa. During necrosis, U1-70K is degraded 
to untraceable fragments, and oxidative 
fragmentation of U1-70K results in a smear of 
33 – 38 kDa fragments. In conclusion, a cell 
can die in many ways, and specialized enzymes 
are activated in the different pathways. As 
a consequence, the creation of neo-epitopes 
directly depends on the type of cell death.
be created on the La protein upon cleavage by 
granzyme B. Autoantibodies reactive with this 
cell death-specific epitope were detected in a 
number of sera from patients with Sjögren’s 
syndrome (52), indicating that this epitope 
might be  involved in breaking tolerance to 
La in these patients. Furthermore, Schachna 
et al. demonstrated a preferential recognition 
of protein fragments derived from systemic 
sclerosis (SSc, also referred to as scleroderma) 
autoantigens after treatment with granzyme B, 
which suggests that granzyme B cleavage also 
might create novel epitopes on SSc autoantigens 
(53). 
In Chapter 8, it was demonstrated that 
autoantibodies in sera from patients suffering 
from SSc, Raynaud’s phenomenon (RP) and 
polymyositis/scleroderma overlap syndrome 
(PM/Scl) recognize proteins that are modified 
upon oxidative damage. This finding further 
supports the hypothesis that autoantibody 
production in these patients may be triggered 
by a neo-epitope, created on these antigens 
during tissue damage by reactive oxygen 
species. Nevertheless, more experimental data 
are needed to demonstrate the existence of such 
neo-epitopes and the presence of autoantibodies 
directed to them in patient sera.
In conclusion, to date a small though 
increasing number of autoantigens has been 
described to display neo-epitopes that are 
generated only during cell death. The need for 
the identification and characterization of cell 
death-specific epitopes on other autoantigens 
remains, to further substantiate the hypothesis 
that such epitopes are involved in breaking 
tolerance to self-antigens in autoimmune 
diseases.
Can the type of cell death predict disease 
outcome?
Table 1 provides examples of autoantibodies 
that are regarded as markers for disease, 
because of their tight association with a 
certain disease, as for instance autoantibodies 
to cyclic citrullinated peptides (CCP) (99% 
specificity for RA (54)) or DNA topoisomerase 
I (highly specific for SSc, see review by (55)). 
The question why autoantibodies arise in 
autoimmune patients, and why certain 
autoantibody specificities are associated with 
particular autoimmune diseases remains 
intriguing and as yet unanswered. It can be 
assumed that several factors play a role; the 
most important of these will be addressed in 
the following sections.
Protein modifications may depend on cell 
death processes
Cell death is part of the normal develop-
ment and life cycles of cells, and the most 
common (and most extensively studied) types 
of cell death are apoptosis and necrosis. For an 
overview of apoptotic and necrotic processes 
and pathways, the reader is referred to a 
selection of reviews (56-59). In short, the main 
phenotypical differences between the two major 
forms of cell death are cell membrane blebbing, 
chromatin condensation, cell shrinkage, and 
DNA fragmentation during apoptosis, whereas 
necrosis is characterized by cell swelling, loss 
of cell membrane integrity, and disruption 
of the cell. In contrast to the situation during 
apoptosis, the content of necrotic cells is 
released into the cell’s environment, resulting 
in damage to the surrounding cells and a local 
inflammatory response.
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pathways have been well characterized, and 
second, Jurkat cells can grow in suspension, 
and thus can be cultured easily in relatively 
large quantities. Since standard cell lines 
are used instead of the cells that are actually 
affected in the patient, it should be kept in 
mind that the creation of neo-epitopes on 
autoantigens in vitro may differ from the 
in vivo situation. On the one hand, it would 
therefore be preferable to use the cells that are 
present in the inflamed tissue, as for example 
fibroblasts in connective tissue diseases. On 
the other hand, the tissue that is inflamed in 
the patient does not necessarily have to be 
the original source of the neo-epitopes. Given 
the fact that it is still unclear how and where 
a particular autoimmune disease is initiated, 
it will be very difficult, if not impossible, to 
choose the most relevant type of cell.
Genetic background
Normally, apoptotic cells are efficiently 
removed by, for example, macrophages, but 
accumulating evidence indicates that there is an 
impaired clearance of dying cells in some SLE 
patients. In these patients, apoptotic cells have 
been found to circulate in the blood (82) and 
in the germinal centres of lymph nodes (83), 
but apoptotic cells have also been described 
to accumulate in the skin after UV irradiation 
(84). An explanation for these findings could 
be that genetic defects are underlying the 
impaired removal of dying cells, certainly in 
cases when massive cell death (e.g. during 
an infection) occurs. Several mouse studies 
have pointed to genes that might play a role in 
this process. Indeed, mice deficient of factors 
involved in the removal of apoptotic cells, such 
as for example C1q, DNase I, phosphatidylserine 
receptor, C-reactive protein or secreted IgM, 
showed defects in clearance of apoptotic 
cells, developed SLE-like symptoms, and 
demonstrated production of SLE-associated 
antibodies (see reviews by (85-87)). Reduced 
levels or activities of such factors have also 
been observed in SLE patients (see reviews by 
(85-87)). Mutations in cell death-associated 
genes, such as Fas, Fas ligand and Bcl-2, have 
been associated with defective clearance as 
well, both in animal models (see review by 
(88)) and in patients (89,90).
Autoimmune diseases are genetically 
associated with several human leukocyte 
antigen (HLA) alleles (see Table 1). The HLA 
system is the general name of a group of genes 
in the major histocompatibility complex region 
on human chromosome 6 that are expressed 
on antigen-presenting cells, such as dendritic 
cells. They are involved in presenting antigens 
to T cells, which can subsequently activate 
B cells. Approximately 70% of RA patients 
produce detectable levels of autoantibodies 
to citrullinated antigens. Since HLA-DR4 
is known to be associated with RA, it was 
postulated that HLA-DR4 could be involved 
in the presentation of citrulline-containing 
peptides. Indeed, Hill et al. demonstrated, 
using mice that were transgenic for human 
HLA-DR4, that a citrulline-containing peptide 
bound 100-fold stronger to the peptide-
anchoring pocket of HLA-DR4, compared to 
the arginine variant of the same peptide (91). 
It is thought that, as a result, the modified 
(i.e. citrulline containing) peptides are presen-
ted in a higher density on the surface of 
antigen-presenting cells, which may exceed 
Susceptibility to modification may depend 
on the type of tissue
Most autoantigens, in particular those 
targeted in systemic autoimmune diseases, 
are evolutionarily conserved molecules with 
key functions in the cell, and can therefore 
be expected to be present in almost every 
cell. Consequently, one could imagine all 
autoantigens to be modified in dying cells and 
to be exposed to the immune system when a 
dying cell is not efficiently removed. But are all 
neo-epitopes present on these autoantigens? 
Ulanet et al. demonstrated that cleavage of the 
SSc autoantigen B23 (80) by granzyme B is cell 
type dependent (81). B23 was very efficiently 
cleaved in differentiated vascular smooth 
muscle cells upon incubation of the cells with 
granules containing granzyme B, whereas it 
was not cleaved in undifferentiated vascular 
smooth muscle cells or in fibroblasts that were 
treated in the same way. The SSc autoantigen 
DNA topoisomerase I, on the other hand, was 
susceptible to granzyme B cleavage in all of 
these cell types. These findings suggest that, 
although autoantigens might be released 
from dying cells, not all autoantigens will be 
modified in all cell types in the same way. 
Consequently, the generation of a neo-epitope 
on an autoantigen may not only depend on the 
cell death pathway that is entered, but also on 
the type of the dying cell.
Most experiments on cell death are performed 
in vitro using standard cell lines. In our studies 
initially HeLa cells and later Jurkat cells were 
used (Chapters 4, 6, 7 and 8). Jurkat cells were 
chosen for two reasons. First, their apoptotic 
Non-enzymatic Oxidative fragmentation Near metal    (115)  
(radicals)     binding sites
Calpains  Necrosis    X(L/V/I)    (114)  
  (and to a lesser extent apoptosis)
Cathepsins Necrosis    A/L)XHXX   (113)  
  (and to a lesser extent apoptosis)
Granzyme B CTL-induced apoptosis IEPD    (112)
     WEHD  Caspase-1   
     (W/L)EHD Caspase-4, -5   
     DEHD  Caspase-2   
     DEVD  Caspase-3, -7   
Caspases  Apoptosis,   VEHD  Caspase-6 (111,112)  
  CTL-induced apoptosis LETD  Caspase-8   
     LEHD  Caspase-9   
     LEXD  Caspase-10
Proteolytic  Cell death pathways Recognition    References 
enzymes     motifs
X = several amino acids are tolerated at this position
XH = several hydrophobic amino acids are tolerated at this position
Table 2 Overview of proteolytic enzymes that are activated during different types of cell death
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lupus skin disease (in these patients the skin 
becomes irritated and inflamed upon exposure 
to sun light) preferentially recognized the 
40 kDa fragment of U1-70K that is generated 
upon cleavage by caspase-3. When cells are 
exposed to UV light in vitro, apoptosis is 
induced and U1-70K is cleaved by caspase-3 
to this 40 kDa apoptotic fragment. Another 
subset of SLE patients, namely patients that 
also suffered from Raynaud’s phenomenon, 
preferentially recognized the 33-38 kDa 
smear of fragments derived from U1-70K 
upon treatment with radicals (78). These 
findings strongly suggested for the first time 
that the type of cell death, and thus the neo-
epitopes that are created and exposed, not 
only is associated with specific autoantibody 
production but also with particular clinical 
symptoms.
In 2002, Schachna et al. (53) demonstrated 
that the majority of SSc patients suffering 
from ischemic digital loss (84%) preferentially 
recognized granzyme B-cleaved fragments 
of SSc autoantigens, as compared to their 
non-cleaved counterparts. In SSc patients 
without ischemic digital loss this preferential 
recognition occurred in only 40% of the 
patients. Five of 16 patients with ischemic 
digital loss demonstrated a stronger reactivity 
with a granzyme B-generated 60 kDa protein 
fragment, compared to reactivity with protein 
bands with higher molecular weights observed 
in the other patients. Although the identity of 
the 60 kDa fragment was not determined, it 
was suggested to be derived from centromere 
protein C (140 kDa). These findings also 
suggest that granzyme B cleavage generates 
novel epitopes on SSc autoantigens, and 
that the presence of autoantibodies directed 
to these epitopes correlates with clinical 
symptoms.
In conclusion, and as summarized in 
Figure 1, it is feasible that a combination of 
factors and events during (massive) cell death, 
including the enzymes that are activated, the 
type of tissue that is affected, the neo-epitopes 
that are formed and exposed, and the genetic 
background of the individual, determine 
whether an autoimmune reaction is triggered 
or not. To further study these mechanisms 
it will be important to identify additional 
cell death-associated neo-epitopes. Besides 
correlating the recognition of specific epitopes 
with clinical symptoms as was done in the 
study by Greidinger et al. (78), it would be 
of much value to correlate the recognition of 
specific epitopes with HLA alleles as well.
How to gain more insight into the role of 
neo-epitopes?
As a result of epitope spreading, auto-
immune patient sera are in general highly 
polyclonal, i.e. directed to multiple epitopes, 
on one or more autoantigens (99,100). From 
the moment a patient enters the rheumatology 
clinic with first symptoms indicative of an 
autoimmune disorder, generally several 
months to years pass by before a final 
diagnosis is established. It is not difficult to 
imagine that, up to that moment, extensive 
epitope spreading may have taken place in 
these patients. It has been shown in several 
publications that autoantibodies can be 
detected in patient sera years before the actual 
onset of disease. In a large study, using the 
collection of the USA Department of Defense 
the biochemical margin for T cell activation 
(92).
In SSc, HLA genes are also correlated 
to the occurrence of specific autoantibodies 
and/or disease subsets. For example, anti-
centromere antibodies have been associated 
with HLA-DQB1 alleles, and anti-DNA 
topoisomerase I autoantibodies with HLA-
DRB1 alleles, the HLA-DRw11 allele and with a 
particular HLA-DQB1 sequence (see review by 
(93)). A recent study on immunogenetic risk 
and protective factors for polymyositis (PM) 
and dermatomyositis (DM) revealed that also 
in these diseases, HLA haplotypes are linked 
to autoantibody production (94). For example, 
the DRB1*0301 haplotype is correlated to 
the production of autoantibodies directed to 
the Jo-1 autoantigen. The DRB1*0701 and 
DQA1*0201, on the other hand, appeared to 
be protective for the development of anti-
Jo-1 autoantibodies, but have been described 
to be a risk factor for the development of 
anti-Mi2 autoantibodies. It thus appears 
that autoantibody production in systemic 
autoimmune diseases is very much linked to 
particular HLA genes.
Can recognition of specific fragments cor-
relate with clinical symptoms?
In 1997, Casciola-Rosen et al. postulated 
that susceptibility to cleavage by granzyme B 
was unique to SLE autoantigens (71). The 
authors demonstrated that several SLE 
autoantigens were cleaved by granzyme 
B, in contrast to non-SLE autoantigens, 
and that granzyme B cleavage resulted in 
fragments of different molecular weight 
compared to cleavage by caspases. In another 
study, the same authors hypothesized that 
oxidative fragmentation was specific for SSc 
autoantigens (77). They showed that SSc 
autoantigens are more readily fragmented 
by radicals than other autoantigens, and also 
oxidative fragmentation generated fragments 
of molecular weights that differed from 
cleavage by caspases or granzyme B. Simply 
taken, these findings suggested that granzyme 
B-initiated cell death processes would underlie 
autoantibody production in SLE, and that 
tissue damage by oxidative radicals would 
trigger autoantibody production in SSc. This 
hypothesis was supported by the idea that 
radical-mediated tissue injury specifically 
occurs after ischemia-reperfusion in the skin 
of patients suffering from SSc and Raynaud’s 
phenomenon (95,96). However, later studies 
demonstrated that granzyme B cleavage is not 
restricted to SLE autoantigens. For example, 
the SSc autoantigens centromere protein B, 
fibrillarin and DNA topoisomerase I are efficiently 
cleaved by granzyme B as well, whereas 
these proteins are much less susceptible to 
cleavage by caspases (53). Moreover, oxidative 
fragmentation appeared not to be restricted 
to SSc autoantigens, since also Ro60, an 
autoantigen in Sjögren’s syndrome and 
SLE, was shown to be antigenically altered 
upon oxidation (97). It was also shown that 
oxidatively modified nucleosomes exert 
enhanced binding to SLE autoantibodies 
(98). Al these studies suggest that cell death 
processes create neo-epitopes that are involved 
in the production of autoantibodies.
Several years ago, Greidinger et al. 
demonstrated in a very interesting series of 
experiments that sera from SLE patients with 
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wait and see which patients develop SSc. It 
might be necessary to collect serum once or 
twice a year, as was performed in the study of 
anti-U1-70K reactivity described in Chapter 6. 
The disadvantage of such an approach is that 
collecting sufficient sera will take many years.
Helpful experimental systems to study the 
presence autoantibodies to cell death-specific 
epitopes are antibody phage display libraries 
from autoimmune patients, as demonstrated 
by the isolation of recombinant autoantibodies 
directed to apoptosis-specific epitopes on the 
U1-70K protein (Chapter 4). Another example 
is the isolation of autoantibodies to an early 
epitope on the SmB/B’ protein from SLE 
libraries (105). The patient-derived antibody 
libraries used in the experiments described 
in this thesis were prepared from B cells 
harvested from peripheral blood and bone 
marrow tissue. As demonstrated in Chapter 6, 
the majority of anti-U1 snRNP positive patient 
sera contained autoantibodies to the apoptotic 
fragment of U1-70K, which is believed to be an 
early antigen in the anti-U1 snRNP response. 
These findings indicate that plasma cells 
secreting antibodies to early autoantigens 
might still be present in later stages of the 
disease, and such antibodies thus are present 
in the antibody repertoire of the libraries. 
Additionally, memory B cells are present 
in the bone marrow and as a consequence 
their repertoire is included in the libraries as 
well. The subtractive antibody phage display 
method described in Chapter 4 provides an 
attractive alternative approach to identify and 
study cell death-specific epitopes targeted in 
autoimmune diseases (see Figure 2c).
Figure 2 provides a schematic overview 
of possible approaches to identify novel 
neo-epitopes. Since it is rather difficult to 
obtain early sera, it is almost inevitable to 
use relatively late sera for most studies. To 
increase the chance of finding autoantibodies 
directed to cell death-specific epitopes among 
the majority of autoantibodies directed to 
“common” epitopes in a patient serum, com-
petition experiments can be designed, in 
which autoantibodies directed to common 
epitopes are blocked with common epitopes. A 
straightforward method to study autoantibody 
reactivities is by immunoblotting using apop-
totic (induced in various ways, including 
extrinsic and intrinsic pathways and granzyme 
B), necrotic, and oxidatively fragmented cell 
extracts (Figure 2a). Patient sera are pre-
incubated with normal cell extract in solution, 
prior to the immunoblotting procedure, to 
compete for binding to common epitopes. 
The polypeptides that after the competition/
selection procedure still are recognized by 
these sera are most likely detected via neo-
epitope-specific autoantibodies. Alternatively, 
as depicted in Figure 2b, recombinant auto-
antigens can be expressed and treated with 
different cell death-specific enzymes, such as 
the enzymes listed in Table 2. After purification 
of the different cleavage fragments, analysis 
of autoantibody reactivities towards these 
fragments might directly provide insight into 
which enzymes are responsible for the creation 
of neo-epitopes on these autoantigens. Here, it 
would be advantageous to block autoantibody 
reactivity to common epitopes in a competition 
experiment as well.
Repository, Arbuckle et al. analyzed serum 
samples of 130 individuals before they were 
diagnosed with SLE. In 115 patients (88%) at 
least one autoantibody activity was detectably 
present years before the time point of diagnosis 
(up to 9.4 years earlier with a mean of 3.3 
years) (101). Also anti-CCP autoantibodies can 
be detected in RA patients many years before 
the first clinical symptoms appear. This was 
demonstrated in two independent studies 
with samples from patients that had donated 
blood in the years before diagnosis (102,103). 
These findings illustrate that, when one wants 
to study the role of cell death-specific epitopes, 
it is crucial to obtain sera as early as possible, 
preferably before the first clinical symptoms.
Since it is difficult to obtain early serum 
samples, one approach to obtain such sera 
would be to start collecting serum samples 
from the moment the patient enters the clinic 
with the first symptoms, and to repeat this each 
time the patient visits the clinic. For example, 
approximately 9% of patients with primary 
Raynaud’s phenomenon will eventually develop 
SSc (104), and sera from these patients could 
thus be regarded as early SSc sera. A workable 
approach would be to collect samples from 
patients with Raynaud’s phenomenon, and to 
Figure 1. Schematic representation of the hypothesis on the role of cell death-specific neo-epitopes in 
breaking tolerance to self-antigens. (1) Antigens reside at the normal locations in the cell. (2) During cell death 
or tissue damage, antigens are modified by activated enzymes or by radicals, and neo-epitopes are created. The type 
of autoantigen modification depends amongst others on the cell death pathway and the modifying enzymes that are 
activated. During apoptosis, antigens translocate from their normal location in the cell to apoptotic blebs and apoptotic 
bodies at the cell surface, and it is thought that they are more easily exposed to the immune system in this way. During 
necrosis, the cell membrane integrity is lost and the modified antigens may leak out of the cell. It is unclear how antigens 
are exposed to the immune system after tissue damage due to radicals generated after (repeated) events of ischemia-
reperfusion. (3) In case of massive cell death, and when the genetic background of the individual is such that the dying 
cells are not efficiently removed, (4) the modified epitopes can be taken up by cells of the immune system and presented 
to helper T cells. With the help of an appropriate HLA gene that is able to efficiently present the neo-epitope to other 
cells, (5) the neo-epitope is presented at elevated levels to B cells, and an initial immune response directed to the neo-
epitope is triggered. (6) Due to epitope spreading, autoantibodies to other, non-modified epitopes on the same protein 
or complex are produced.
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How can cell death-specific epitopes be 
used for early diagnosis?
Current diagnostic laboratory tests are 
mainly based on the use of recombinant 
proteins or synthetic peptides as antigens. 
From the results described in Chapter 6, where 
it was demonstrated that apoptotic U1-70K is 
a superior marker compared to intact U1-70K 
because it is preferentially recognized by early 
sera, it is clear that detection of autoantibodies 
directed to cell death-specific epitopes could 
facilitate early diagnosis and consequently 
allow earlier treatment of patients. If a 
correlation between recognition of a specific 
neo-epitope and clinical symptoms can be 
established, (mild) treatment could be started 
to prevent or reduce clinical symptoms.
An emerging technology for autoantibody 
profiling is the autoantigen microarray (see 
review by (106)), which involves immobili-
zation of a large number of different auto-
antigens (each in small amounts) on one 
chip. Microarray profiling enables the high 
throughput analysis of autoimmune patients. 
One of the advantages of this technique is that 
the reactivity of a patient serum can be profiled 
against a much broader range of autoantigens 
compared to conventional laboratory tests. In 
addition, recognition of sets of autoantigens 
can be correlated with subtypes of the disease 
(107,108). One could imagine that existing 
microarray chips are extended with cell 
death-specific epitopes, which would provide 
a more sensitive detection of autoantibodies in 
samples of patients with early disease.
Concluding remarks part 2
The work described in this thesis is mainly 
focussed on the question why autoantibodies 
arise in autoimmune patients, and the data 
obtained in our studies clearly support the 
idea that cell death-specific neo-epitopes play 
a role in breaking tolerance to self-antigens in 
susceptible individuals. Other issues regarding 
autoimmune diseases and autoantibodies 
are intriguing as well. For example, it is still 
poorly understood why women are more often 
affected than men. Although hormonal and 
genetic factors are known to play an important 
role in the development of autoimmune 
diseases, more experimental data are needed 
to provide further insight into these issues. 
It is also unclear whether autoantibodies 
can actually cause autoimmune diseases, or 
whether they are just an epiphenomenon 
(a side effect). It is known that autoantibodies 
can have pathogenic effects, as for example 
the precipitation of immune complexes in the 
kidneys of SLE patients, eventually leading to 
kidney failure. Also the RA-specific anti-CCP 
autoantibodies have been shown to enhance 
arthritis in a mouse model (84). The arthritis 
caused by these autoantibodies demonstrates 
their possible pathogenic role, but that does 
not necessarily mean that they actually cause 
autoimmunity.
Figure 2. Possible approaches for the identification of novel cell death-specific epitopes. (a) Competition 
experiment on immunoblots. On the left, immunoblots of cell lysates treated with granzyme B, caspase-3 and radicals, 
and a control lysate, are incubated with patient serum and bound antibodies are detected using a labelled secondary 
antibody (not shown). If a specific protein fragment is stronger recognized than the intact form, this might indicate 
that autoantibodies in the serum are binding to a neo-epitope (depicted by a star in the figure) on this fragment. If the 
signal obtained from the fragment is equal or lower compared to the intact form, it is still possible that the fragment 
contains a neo-epitope and that specific autoantibodies react with it. Since the smaller fragment might lack some of the 
“common” epitopes, autoantibodies directed to these epitopes will not be detected on the fragment. When the patient 
serum is pre-incubated with the control lysate prior to the immunoblotting procedure (as depicted in (a) on the right), 
autoantibodies directed to common epitopes are bound in solution with these epitopes. Since the control lysate does 
not contain neo-epitopes, autoantibodies directed to neo-epitopes are not blocked in solution and will bind to the 
autoantigen fragment on immunoblot. In this example, U1-70K (70 kDa) is treated with granzyme B (resulting in a 60 
kDa fragment), caspase-3 (40 kDa) and radicals (33-38 kDa smear), and all fragments are detected at the left. When 
the patient serum is pre-incubated with common epitopes present in the control lysates, the 70, 40, and 33-38 kDa 
fragments are no longer detected in contrast to the granzyme B-generated fragment of 60 kDa. This indicates that this 
particular patient has generated autoantibodies directed to a neo-epitope on U1-70K that is created upon treatment 
with granzyme B. (b) Competition experiment in ELISA. Autoantigens are recombinantly expressed and treated with 
different cell death-specific enzymes, such as granzyme B and caspase-3, or with radicals. Specific fragments containing 
the neo-epitopes (star) are purified and coated in the ELISA wells. Patient serum is pre-incubated with non-treated 
autoantigen to compete for binding to the common epitopes. After washing, bound antibodies (as depicted in the 
granzyme B well) can be detected with a suitable secondary antibody. (c) Isolation of specific recombinant autoantibody 
fragments by subtractive antibody phage display. Phages displaying recombinant antibody fragments from autoantibodies 
are incubated with non-biotinylated normal cell extract (1), prior to incubation with biotinylated lysates from dying 
cells (2). The biotin group is depicted as a yellow circle, labelled “b“. In this way, phages displaying antibody fragments 
directed to common epitopes are blocked for binding to the same epitopes on biotinylated proteins. After isolation and 
characterization of specific monoclonal antibodies, the protein that displays the specific epitope can be isolated by means 
of immunoaffinity purification, and can subsequently be identified by mass spectrometry.
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Summary
Autoimmune diseases, which affect 
approximately 2-3% of the world population, 
are characterized by the occurrence of 
high titres of autoantibodies. Some of 
these autoantibodies are disease-specific 
and their presence is often a valuable 
diagnostic, and sometimes prognostic, tool 
for clinicians. For example, autoantibodies 
directed to citrullinated proteins are almost 
exclusively present in patients suffering 
from rheumatoid arthritis, and are therefore 
regarded as an excellent serological marker 
for this disease. The question why patients 
produce autoantibodies is still unsolved. 
One model that is more and more supported 
by experimental data, hypothesizes that 
unusual posttranslational modifications, for 
example those occurring during cell death, 
can lead to the generation of neo-epitopes 
that subsequently can lead to the breaking 
of immunological tolerance to self-antigens. 
During the last 15 years the characterization 
of (auto)antibodies was greatly facilitated 
by the antibody phage display technology, a 
sophisticated methodology for the production 
of recombinant monoclonal antibodies. The 
goal of the studies described in this thesis was 
to design and develop novel applications of the 
antibody phage display technology (described 
in Part 1: Chapters 1 to 4) that can be used 
to gain more insight into the occurrence of 
autoantibodies and their antigenic targets 
(elaborated on in Part 2: Chapters 5 to 8). 
Chapter 1 gives an overview of our 
current knowledge on the generation of 
antibodies, with special focus on the antibody 
phage display technology. In addition, it 
introduces the theory of the role of neo-
epitopes in breaking immunological tolerance 
to self-antigens in patients suffering from an 
autoimmune disease. 
Antibody phage display libraries can be 
generated from non-immunized and from 
immunized individuals or laboratory animals. 
In general, antibodies from libraries derived 
from immunized animals have a higher affinity 
compared to antibodies isolated from naïve 
or synthetic (i.e. non-immunized) libraries. 
In addition, the preparation of libraries from 
chicken is less laborious than the generation 
of libraries from human or mouse. In 
Chapter 2 it is demonstrated that chickens 
can be immunized with a mixture of antigens 
to reduce the number of immune libraries 
and consequently to lower the number 
of experimental animals needed for the 
preparation of these libraries. Chickens were 
immunized with two protein mixtures, each 
containing seven distinct autoantigens. From 
the resulting immune libraries, antibodies 
directed to nine of these targets could be 
isolated. These recombinant antibodies can be 
applied in experiments where autoantibodies 
from patient sera are unsuitable, such as 
experiments involving antigen detection in 
human tissues, cells, or sera.
Recombinant antibodies, selected from 
antibody phage display libraries are applicable 
in a wide variety of assays, and are therefore 
valuable research tools. In Chapter 3 
recombinant antibodies were fused with 
human, mouse and chicken immunoglobulin 
constant domains to allow easy double- and 
triple-staining of cells and tissues. This 
approach eliminates problems of co-staining 
with multiple monoclonal and polyclonal 
antibodies.
Chapter 4 describes a novel method to 
use antibody phage display for the discovery 
of disease markers. Phages from antibody 
phage libraries are first subtractively selected 
with biotinylated proteins from two different 
cell extracts, followed by a second selection 
on two-dimensional IEF/SDS-PAGE western 
blots. To demonstrate the feasibility of this 
method, phages from a mixture of antibody 
phage display libraries derived from patients 
with rheumatoid arthritis, systemic lupus 
erythematosus and systemic sclerosis (sclero-
derma), were selected based upon their 
reactivity with epitopes that are exclusively 
present in extracts made from apoptotic cells. 
Epitopes on three nuclear proteins, namely 
hnRNP C, p54nrb/PSF, and U1-70K, could be 
identified as targets for the corresponding 
recombinant antibodies. They may thus 
represent autoantibodies associated with these 
autoimmune diseases. Furthermore, it could 
be shown that the recombinant anti-U1-70K 
antibody obtained from the patient libraries 
specifically interacted with an apoptosis-
specific epitope on this autoantigen. Our 
findings strongly suggest that autoantibodies 
to apoptosis-specific epitopes on U1-70K are 
present in patient sera, which supports the 
hypothesis of neo-epitopes being involved in 
breaking tolerance to self proteins.
Autoantibodies directed to U1-70K, and 
other components of the U1 snRNP complex, 
are specifically associated with SLE and SLE 
overlap syndrome (mixed connective tissue 
disease). Chapter 5 gives an overview of the 
current knowledge on normal and cell death-
specific posttranslational modifications that 
can be present on the U1-70K protein, and 
of the antibodies recognizing neo-epitopes 
generated by such modifications.
In Chapter 6 it is shown that the majority 
of anti-U1 snRNP positive patient sera (54%) 
preferentially recognize apoptotically cleaved 
U1-70K as compared to non-cleaved, intact 
U1-70K. Moreover, in a longitudinal study 
we showed that this preferential recognition 
is especially apparent early in the disease. 
These findings indicate (1) that autoantibodies 
to apoptosis-specific epitopes on U1-70K 
are actually present in patient sera, (2) that 
these antibodies appear before autoantibodies 
directed to the intact form are present, and 
(3) that the apoptosis-specific epitopes are 
involved in breaking immunological tolerance 
to U1-70K and the U1 snRNP complex.
Besides U1-70K, two other potential cell 
death-specific targets for autoantibodies were 
identified in Chapter 4, namely hnRNP C and 
p54nrb/PSF. In the experiments described in 
Chapter 7 the apoptotic modifications on 
hnRNP C and p54nrb/PSF were further studied 
by immunoblotting and immunofluorescence 
assays, using normal and apoptotic cells. The 
results demonstrated that p54nrb is not only 
cleaved, but also undergoes a shift in isoelectric 
point during apoptosis, findings that were not 
described before. In the case of hnRNP C1, 
five isoforms could be detected in normal cell 
extracts, whereas in apoptotic cells only three 
isoforms were detectable. In addition, hnRNP 
C and PSF were shown to translocate from 
the nucleoplasm in healthy cells to apoptotic 
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bodies on the cell surface in apoptotic cells. 
Translocation of these modified proteins to the 
cell surface may enhance their exposure to the 
immune system and facilitate autoantibody 
formation. HnRNP C had been described 
previously as an autoantigen in a few patients. 
In this chapter it is demonstrated that p54nrb is 
an autoantigen as well, because autoantibodies 
directed to p54nrb were found in patients 
suffering from polymyositis/scleroderma 
overlap syndrome.
Oxidative stress and the formation of 
free radicals are believed to play a role in the 
pathology of scleroderma. In Chapter 8 the 
autoantibody reactivity of sera, obtained from 
patients with scleroderma or scleroderma-
associated disease, with neo-epitopes that are 
created by radicals is addressed. Autoantibody 
reactivity was analyzed by immunoblotting 
using either normal cell extracts or cell extracts 
that were treated with Fe2+ and ascorbic 
acid. Twelve patient sera were identified that 
differentially reacted with proteins in the two 
types of extracts. It is hypothesized that the 
oxidatively modified proteins display neo-
epitopes that play a role in breaking tolerance to 
these self-proteins in these patients. Two sera 
were further analyzed and it was demonstrated 
that the neo-epitopes recognized by these sera 
in oxidatively modified cell extracts are not 
created during well-known forms of cell death, 
such as apoptosis or necrosis.
The results of the experiments described in 
this thesis and some remaining questions are 
discussed in Chapter 9.
Samenvatting
Auto-immuunziekten, waar 2-3% van 
de wereldbevolking aan lijdt, worden 
gekenmerkt door de aanwezigheid van hoge 
titers aan auto-antilichamen. Sommige 
van deze auto-antilichamen zijn specifiek 
voor één bepaalde auto-immuunziekte 
en hun aanwezigheid is daardoor vaak 
een waardevol diagnostisch, en soms 
voorspellend, hulpmiddel voor artsen. Auto-
antilichamen gericht tegen gecitrullineerde 
eiwitten komen bijvoorbeeld vrijwel alleen 
voor in patiënten met reumatoïde artritis en 
worden daarom beschouwd als uitstekende 
serologische merkers voor deze ziekte. De 
vraag waaròm patiënten auto-antilichamen 
maken, blijft vooralsnog onbeantwoord. Een 
model dat door steeds meer experimentele 
gegevens wordt ondersteund, veronderstelt 
dat ongebruikelijke post-translationele 
veranderingen van lichaamseigen eiwitten, 
bijvoorbeeld veranderingen die plaatsvinden 
tijdens celdood, kunnen leiden tot de 
vorming van zogenaamde neo-epitopen. 
Zulke neo-epitopen kunnen vervolgens leiden 
tot het doorbreken van immunologische 
tolerantie voor lichaamseigen antigenen. De 
afgelopen vijftien jaar heeft de antilichaam-
faagdisplaytechnologie, een geavanceerde 
methode voor het maken van recombinante 
monoklonale antilichamen, het karakteriseren 
van (auto-)antilichamen makkelijker gemaakt. 
Het doel van de studies die beschreven zijn in 
dit proefschrift was om nieuwe toepassingen 
van de antilichaam-faagdisplaytechniek te 
ontwerpen en te ontwikkelen (beschreven 
in deel 1: Hoofdstukken 1 tot en met 4) om 
meer inzicht te krijgen in de aanwezigheid van 
auto-antilichamen en hun corresponderende 
antigenen (beschreven in deel 2: Hoofdstukken 
5 tot en met 8). 
Hoofdstuk 1 geeft een overzicht van 
onze huidige kennis op het gebied van het 
maken van antilichamen, waarbij de nadruk 
ligt op de antilichaam-faagdisplaytechnologie. 
Daarnaast geeft dit hoofdstuk een inleiding in 
de theorie over de rol die neo-epitopen kunnen 
spelen in het doorbreken van immunologische 
tolerantie voor lichaamseigen antigenen in 
patiënten die lijden aan een auto-immuun-
ziekte.
Antilichaam-faagdisplaybanken kunnen 
gemaakt worden van niet-geïmmuniseerde 
en van geïmmuniseerde individuen of 
proefdieren. Over het algemeen hebben 
antilichamen die geïsoleerd worden uit 
banken van geïmmuniseerde proefdieren een 
hogere affiniteit dan antilichamen uit naïeve 
of synthetische (d.i. niet-geïmmuniseerde) 
banken. Daarnaast is het maken van 
immuunbanken van kippen minder werk dan 
het maken van zulke banken van humaan of 
muizenmateriaal. In Hoofdstuk 2 laten we 
zien dat kippen ook geïmmuniseerd kunnen 
worden met een mengsel van verschillende 
antigenen met als doel het aantal te 
synthetiseren immuunbanken, en daarmee 
ook het aantal kippen dat hiervoor gebruikt 
moet worden, te beperken. Kippen werden 
geïmmuniseerd met twee eiwitmengsels 
die elk zeven verschillende eiwitantigenen 
bevatten. Uit de resulterende immuunbanken 
konden antilichamen tegen negen van deze 
antigenen worden geïsoleerd. De geselecteerde 
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recombinante antilichamen kunnen worden 
toegepast in experimenten waarvoor auto-
antilichamen uit patiëntensera niet geschikt 
zijn, zoals experimenten waarbij auto-
antigenen in humane weefsels, cellen of sera 
geanalyseerd moeten worden.
Recombinante antilichamen uit anti-
lichaam-faagdisplaybanken zijn toepasbaar 
in een breed scala aan assays en zijn daarom 
waardevolle onderzoekshulpmiddelen. In 
Hoofdstuk 3 werden recombinante anti-
lichamen gefuseerd met constante domeinen 
van humane, muizen- en kippen-antilichamen 
om twee- en drievoudige kleuringen van cellen 
en weefsels te vergemakkelijken. Deze aanpak 
omzeilt de problemen die er kunnen zijn bij het 
gelijktijdig kleuren van weefsels met meerdere 
mono- en polyklonale antilichamen.
Hoofdstuk 4 beschrijft een nieuwe 
methode om met behulp van antilichaam-faag-
display ziektemerkers te ontdekken. Fagen 
werden uit antilichaam-faagdisplaybanken 
geïsoleerd door eerst subtractief te selecteren 
op gebiotinyleerde eiwitten in twee verschil-
lende extracten en vervolgens een tweede 
selectie te doen op tweedimensionale IEF/SDS-
PAGE western blots. Om te laten zien dat deze 
methode werkt, werden fagen uit een mengsel 
van banken van patiënten met reumatoïde 
artritis, systemische lupus erythematodes 
en systemische sclerose (sclerodermie) 
geselecteerd op reactiviteit met epitopen die 
uitsluitend aanwezig zijn in extracten van 
apoptotische cellen. Epitopen op drie eiwitten 
uit de celkern, namelijk hnRNP C, p54nrb/
PSF and U1-70K, konden worden geïdenti-
ficeerd als herkenningsplaatsen voor de 
corresponderende recombinante antilichamen. 
Zij zouden dus auto-antilichamen kunnen 
representeren die geassocieerd zijn met 
deze auto-immuunziekten. Bovendien 
werd aangetoond dat het geselecteerde 
recombinante anti-U1-70K antilichaam, dat 
geïsoleerd werd uit de patiëntenbanken, 
exclusief reageerde met een apoptose-
specifiek epitoop op dit auto-antigeen. Onze 
bevindingen geven aan dat auto-antilichamen 
tegen zulke apoptose-specifieke epitopen op 
U1-70K ook in patiëntensera aanwezig zijn. 
Deze resultaten ondersteunen het model, dat 
(apoptotisch gevormde) neo-epitopen een rol 
spelen bij het doorbreken van immunologische 
tolerantie voor lichaamseigen eiwitten. 
Auto-antilichamen tegen U1-70K en tegen 
andere componenten van het U1 snRNP-
complex komen voornamelijk voor bij SLE 
en het SLE-overlap-syndroom. Hoofdstuk 5 
geeft een overzicht van de huidige kennis op 
het gebied van normale en celdood-specifieke 
post-translationele veranderingen die 
aanwezig kunnen zijn op het U1-70K eiwit en 
van de auto-antilichamen die zulke potentiële 
neo-epitopen herkennen.
In Hoofdstuk 6 wordt aangetoond dat 
de meerderheid (54%) van sera met auto-
antilichamen gericht tegen het U1 snRNP 
complex, bij voorkeur het apoptotisch gekliefde 
U1-70K herkennen ten opzichte van het niet-
gekliefde, intacte U1-70K eiwit. Bovendien 
laten we in een longitudinale studie zien dat 
deze preferentiële herkenning voornamelijk 
in een vroeg stadium van de ziekte optreedt. 
Deze bevindingen duiden er sterk op dat 
(1) auto-antilichamen tegen apoptose-
specifieke epitopen op U1-70K daadwerkelijk 
voorkomen in sera van patiënten, (2) dat 
deze auto-antilichamen tegen apoptose-
specifieke epitopen verschijnen vóórdat 
auto-antilichamen tegen de intacte vorm van 
U1-70K aanwezig zijn en (3) dat de apoptose-
specifieke epitopen betrokken zijn bij het 
doorbreken van immunologische tolerantie 
voor U1-70K en het U1 snRNP complex.
Naast U1-70K werden twee andere 
mogelijke merkers voor auto-immuunziekten 
geïdentificeerd in Hoofdstuk 4, namelijk 
de kerneiwitten hnRNP C en p54nrb/PSF. 
In de experimenten die beschreven zijn 
in Hoofdstuk 7 werden de apoptotische 
veranderingen op deze eiwitten bestudeerd 
met behulp van immunoblotting- en immunofl
uorescentietechnieken. Hiervoor werden zowel 
gezonde als apoptotische cellen gebruikt. Er 
werd aangetoond dat p54nrb niet alleen gekliefd 
wordt tijdens apoptose, maar dat tevens het 
isoëlectrische punt verandert. Deze bevinding 
was nog niet eerder beschreven. In het geval 
van hnRNP C1 bleken vijf isovormen aanwezig 
te zijn in het celextract van gezonde cellen, 
terwijl er maar drie isovormen detecteerbaar 
waren in celextracten van apoptotische cellen. 
Daarnaast werd aangetoond dat hnRNP C en 
PSF zich tijdens apoptose van hun normale 
lokalisatie, het nucleoplasma, verplaatsen naar 
apoptotische blaasjes aan het oppervlak van 
de cel. De verplaatsing van deze veranderde 
eiwitten naar het celoppervlak zou hun 
blootstelling aan het immuunsysteem kunnen 
versterken en daardoor de productie van auto-
antilichamen vergemakkelijken. HnRNP C was 
al eerder beschreven als een auto-antigeen in 
een aantal patiënten. Daarnaast konden we 
in dit hoofdstuk aantonen dat ook p54nrb een 
auto-antigeen is, omdat auto-antilichamen 
tegen p54nrb blijken voor te komen in patiënten 
die lijden aan het polymyositis/sclerodermie-
overlap-syndroom.
Er wordt verondersteld dat oxidatieve 
stress en de productie van vrije radicalen een 
rol spelen bij de pathologie van sclerodermie. 
In Hoofdstuk 8 wordt in sera van patiënten 
met sclerodermie of sclerodermie-gerelateerde 
ziekten de reactiviteit bekeken van auto-
antilichamen met neo-epitopen die ontstaan 
door radicalen. Serumreactiviteit werd 
geanalyseerd op western blots, waarbij gebruik 
werd gemaakt van controle-extracten en van 
celextracten die behandeld waren met Fe2+ en 
ascorbinezuur. Twaalf patiëntensera konden 
worden geïdentificeerd die verschillend 
reageerden met eiwitten in de twee extracten. 
Het lijkt er dus op dat ook oxidatief-veranderde 
eiwitten neo-epitopen kunnen bevatten 
die een rol spelen bij het doorbreken van 
tolerantie voor deze lichaamseigen eiwitten 
in deze patiënten. Twee sera werden meer in 
detail geanalyseerd en er werd aangetoond dat 
de neo-epitopen die door deze sera worden 
herkend in het celextract dat behandeld was 
met Fe2+ en ascorbinezuur niet gecreëerd 
worden tijdens de bekende vormen van 
celdood, zoals apoptose en necrose.
De resultaten van de experimenten die in 
dit proefschrift zijn beschreven worden samen 
met een aantal nog onbeantwoorde vragen 
bediscussieerd in Hoofdstuk 9.
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Het proefschrift is af! Ook al staat alleen 
míjn naam op de omslag van dit boekje, het 
was niet tot stand gekomen zonder de hulp van 
vele anderen. Gelukkig is er het veel-gelezen 
Dankwoord om daar even bij stil te staan.
Walther, jou wil ik bedanken voor de kans 
die je mij hebt gegeven om mijn promotie-
onderzoek uit te voeren op jouw afdeling en 
voor de mogelijkheden die je mij hebt geboden 
om mezelf te ontwikkelen. Ik heb veel geleerd 
bij de VRT. Daarnaast zal ik ook altijd terug 
kunnen kijken op een ontzettend leuke tijd. Ik 
heb mooie herinneringen aan de barbecues, de 
labdagjes en de samenwerkingen en de goede 
sfeer binnen de groep!
Jos, bedankt voor je enthousiaste begelei-
ding, ik heb heel veel van je geleerd! Het was 
fijn om een begeleider te hebben die altijd 
boordevol ideeën zit, graag over wetenschap 
en reizen praat, champagne trakteert bij de 
eerste goede resultaten en het organiseren 
van vrijdagmiddag-borrels (natuurlijk met 
Glühwein in de winter) stimuleert. Het was 
ook mooi om te zien hoe je bedrijf gaandeweg 
ontstond, met alles wat daarbij kwam kijken, 
en groeide tot wat het nu is. Veel succes 
toegewenst met ModiQuest! 
Ger, jouw deur stond altijd open om even 
binnen te lopen. Bedankt voor de tijd die je 
altijd vrij maakte om dingen te bespreken. Ik 
ben blij dat je in de loop van de tijd steeds meer 
betrokken raakte bij mijn promotie-onderzoek. 
Ik wens je heel veel succes met jouw nieuwe 
afdeling Biomoleculaire Chemie.
Dankwoord
Kalok, veel van de experimenten die zijn 
beschreven in dit proefschrift hadden er niet 
in gestaan zonder jouw hulp. Onder andere 
jouw massa-producties immunoblots en 
immunoprecipitaties hebben ertoe geleid 
dat je co-auteur bent van drie hoofdstukken. 
Ik wil je bedanken voor je nauwkeurige en 
enthousiaste inzet. Ik heb met heel veel plezier 
met je samengewerkt! 
Ook Hilde wil ik bedanken voor de proefjes 
die ze heeft uitgevoerd voor mijn promotie-
onderzoek.
Natuurlijk wil ik ´mijn´ studenten Bart, 
Dennis, Wieger, Mirjam en Chantal, en ook 
ModiQuest´s studente Annemarie bedanken 
voor hun inzet tijdens hun stages. Van bijna 
elk van jullie is er werk terug te vinden in dit 
boekje. Het was erg gezellig om jullie op het 
lab te hebben en ik heb veel van jullie geleerd. 
Ik wens jullie heel veel succes toe voor jullie 
toekomst!
Vanzelfsprekend wil ik ook alle collega’s 
en oud-collega’s van de VRT, de Eiwitgroep 
en ModiQuest bedanken voor de goede sfeer 
op het lab, de praktische hulp en jullie inbreng 
tijdens werkbesprekingen, brainstormavonden 
of gewoon even tussendoor.
Een aantal collega’s wil ik graag nog even 
apart bedanken. Els, ook jouw deur stond 
altijd open. Bedankt voor je goede raad en 
voor alles wat je voor me hebt geregeld. Oud-
collega´s van lab 2.35 Ben, Maaike en Kelen, 
en alle leden van het voormalige squash-clubje, 
bedankt dat jullie me snel thuis lieten voelen 
op de afdeling. Thanks for making me feel at 
home in the lab! Tim, het was toch wel fijn om 
iemand te hebben die in hetzelfde schuitje zat 
als ik: als HLO-er een promotie-onderzoek 
beginnen. Het is ons gelukt hè? Angélique, 
het was erg leuk dat jij aan een soortgelijk 
onderwerp kwam te werken, waardoor we 
niet alleen in hetzelfde ‘schuitje’ belandden, 
maar ook in hetzelfde ‘U-tje’. Samen met 
onze studenten werd het een gezellig en 
levendig U-tje, met onder andere prachtige 
kerstdecoraties. Bedankt voor jouw inbreng 
en ideeën over mijn onderzoek. Ook een woord 
van dank voor Ilse, faagdisplay-compagnon! 
Reinout, jou wil ik bedanken voor je hulp bij 
de lay-out van dit boekje.
Mijn familie en vrienden wil ik heel graag 
op deze plek bedanken, omdat ze me altijd 
gesteund hebben in de tijden dat dat nodig 
was. Olga wil ik ook graag bedanken voor haar 
hulp bij dit boekje! 
Lieve, lieve Maarten, mijn dankwoord is 
bijna ten einde. Jij sluit de rij. Bedankt voor 
alle liefde en steun die je me hebt gegeven. 
Ik hou van jou!!
 Daniëlle 
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1978 te Zevenaar en groeide op in Didam. 
In 1996 behaalde zij haar VWO diploma aan 
het Liemers College te Zevenaar. Vervolgens 
woonde zij acht maanden als au pair bij een 
Zwitserse familie in Genève. In 1997 begon zij 
aan de Hogere Laboratorium Opleidingen aan 
de Hogeschool van Arnhem en Nijmegen te 
Nijmegen. Tijdens haar laatste studiejaar heeft 
zij haar stage en afstudeeropdracht uitgevoerd 
bij het Instituut voor Biotechnologie aan de 
Eidgenössische Technische Hochschule in 
Zürich, onder begeleiding van Dr. Wouter 
Duetz en Prof. Dr. Bernard Witholt. Het 
diploma hiervoor werd in 2001 behaald.
Van augustus 2001 tot augustus 2002 
was zij werkzaam als analiste op de afdeling 
Biochemie van de Radboud Universiteit 
Nijmegen. Vervolgens voerde zij van augustus 
2002 tot en met april 2006 haar promotie-
onderzoek uit als junior onderzoeker op 
dezelfde afdeling, onder begeleiding van 
Dr. Jos M.H. Raats, Prof. Dr. Ger J.M. Pruijn 
en Prof. Dr. Walther J. van Venrooij. Uit het 
onderzoek dat zij in deze periode uitvoerde, 
vloeide dit proefschrift voort.
Sinds 1 mei 2006 is zij werkzaam als 
postdoc onderzoeker bij het Instituut voor 
Klinische Chemie aan de Universiteit van 
Zürich, onder begeleiding van Prof. Dr. Arnold 
von Eckardstein.
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